Idenix Pharmaceuticals LLC v. Gilead Sciences Inc.
1:13-cv-01987
Overview
Case Number
1:13-cv-01987
Filing Date
2013-12-01
Status
Terminated
Termination Date
2018-09-07
Court
District Court, D. Delaware (ded)
Presiding Judge
Leonard P. Stark
Nature of Suit
830 Patent
Jurisdiction Type
Federal Question
Cause of Action
35:271 Patent Infringement
Jury Demand
Plaintiff
Parties
Respondent
Defendant
Gilead Pharmasset LLC
Represented By
9 Attorneys ListedFish & Richardson, P.C.
Tel: +1 (858) 678-5070
12390 El Camino Real, San Diego, CA 92130
Fish & Richardson, P.C.
Tel: +1 (302) 778-8453
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Fish & Richardson, P.C.
Tel: +1 (302) 778-8477
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Fish & Richardson, P.C.
Tel: +1 (434) 987-4537
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Fish & Richardson, P.C.
Tel: +1 (302) 778-8408
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Fish & Richardson P.C.
Tel: +1 (612) 766-2095
Fax: +1 (612) 288-9696
60 South Sixth Street, # 3200, Minneapolis, MN 55402
Fish & Richardson, P.C.
Tel: +1 (302) 652-5070
Fax: +1 (302) 652-0607
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Fish & Richardson, P.C.
Tel: +1 (302) 778-8471
Fax: +1 (302) 652-0607
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Deep Ellum Search
Tel: +1 (302) 778-8448
Deep Ellum Search, 2703 Canton Street
Gilead Sciences Inc.
Represented By
16 Attorneys ListedFish & Richardson, P.C.
Tel: +1 (858) 678-5070
12390 El Camino Real, San Diego, CA 92130
Fish & Richardson, P.C.
Tel: +1 (302) 778-8453
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Fish & Richardson, P.C.
Tel: +1 (302) 778-8477
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Fish & Richardson, P.C.
Tel: +1 (434) 987-4537
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Fish & Richardson, P.C.
Tel: +1 (302) 778-8408
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Fish & Richardson P.C.
Tel: +1 (612) 766-2095
Fax: +1 (612) 288-9696
60 South Sixth Street, # 3200, Minneapolis, MN 55402
Fish & Richardson, P.C.
Tel: +1 (302) 652-5070
Fax: +1 (302) 652-0607
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Fish & Richardson, P.C.
Tel: +1 (302) 778-8471
Fax: +1 (302) 652-0607
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Deep Ellum Search
Tel: +1 (302) 778-8448
Deep Ellum Search, 2703 Canton Street
Plaintiff
L' Universite de Montpellier
Represented By
4 Attorneys ListedAshby & Geddes
Tel: +1 (302) 654-1888
Fax: +1 (302) 654-2067
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
McCarter & English, LLP
Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399
Renaissance Centre, 405 N. King Street, 8th Floor
Ashby & Geddes
Tel: +1 (302) 654-1888
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Idenix Pharmaceuticals LLC
Represented By
7 Attorneys ListedAshby & Geddes
Tel: +1 (302) 654-1888
Fax: +1 (302) 654-2067
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
McCarter & English, LLP
Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399
Renaissance Centre, 405 N. King Street, 8th Floor
Ashby & Geddes
Tel: +1 (302) 654-1888
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Centre National de la Recherche Scientifique
Represented By
6 Attorneys ListedAshby & Geddes
Tel: +1 (302) 654-1888
Fax: +1 (302) 654-2067
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
McCarter & English, LLP
Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399
Renaissance Centre, 405 N. King Street, 8th Floor
Ashby & Geddes
Tel: +1 (302) 654-1888
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Devlin Law Firm
Tel: +1 (302) 449-9010
Fax: +1 (302) 353-4251
1526 Gilpin Avenue, 19806
Universita Degli Studi di Cagliari
Represented By
6 Attorneys ListedAshby & Geddes
Tel: +1 (302) 654-1888
Fax: +1 (302) 654-2067
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
McCarter & English, LLP
Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399
Renaissance Centre, 405 N. King Street, 8th Floor
Ashby & Geddes
Tel: +1 (302) 654-1888
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Devlin Law Firm
Tel: +1 (302) 449-9010
Fax: +1 (302) 353-4251
1526 Gilpin Avenue, 19806
L' Universite Montpellier II
Represented By
6 Attorneys ListedAshby & Geddes
Tel: +1 (302) 654-1888
Fax: +1 (302) 654-2067
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
McCarter & English, LLP
Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399
Renaissance Centre, 405 N. King Street, 8th Floor
Ashby & Geddes
Tel: +1 (302) 654-1888
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Devlin Law Firm
Tel: +1 (302) 449-9010
Fax: +1 (302) 353-4251
1526 Gilpin Avenue, 19806
Idenix Pharmaceuticals Inc.
Represented By
18 Attorneys ListedAshby & Geddes
Tel: +1 (302) 654-1888
Fax: +1 (302) 654-2067
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
McCarter & English, LLP
Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399
Renaissance Centre, 405 N. King Street, 8th Floor
Ashby & Geddes
Tel: +1 (302) 654-1888
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Devlin Law Firm
Tel: +1 (302) 449-9010
Fax: +1 (302) 353-4251
1526 Gilpin Avenue, 19806
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Leonard P. Stark
Docket Entries
COMPLAINT - filed with Jury Demand against Gilead Pharmasset LLC, Gilead Sciences Inc.. Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1416499.) - filed by Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A pt.1, # 2 Exhibit A pt.2, # 3 Exhibit A pt.3, # 4 Exhibit A pt.4, # 5 Exhibit B, # 6 Civil Cover Sheet)(mdb) (Entered: 12/02/2013)
2013-12-01
1
COMPLAINT - filed with Jury Demand against Gilead Pharmasset LLC, Gilead Sciences Inc.. Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1416499.) - filed by Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A pt.1, # 2 Exhibit A pt.2, # 3 Exhibit A pt.3, # 4 Exhibit A pt.4, # 5 Exhibit B, # 6 Civil Cover Sheet)(mdb) (Entered: 12/02/2013)
2013-12-01
2
COMPLAINT - filed with Jury Demand against Gilead Pharmasset LLC, Gilead Sciences Inc.. Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1416499.) - filed by Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A pt.1, # 2 Exhibit A pt.2, # 3 Exhibit A pt.3, # 4 Exhibit A pt.4, # 5 Exhibit B, # 6 Civil Cover Sheet)(mdb) (Entered: 12/02/2013)
2013-12-01
2
COMPLAINT - filed with Jury Demand against Gilead Pharmasset LLC, Gilead Sciences Inc.. Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1416499.) - filed by Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A pt.1, # 2 Exhibit A pt.2, # 3 Exhibit A pt.3, # 4 Exhibit A pt.4, # 5 Exhibit B, # 6 Civil Cover Sheet)(mdb) (Entered: 12/02/2013)
2013-12-01
2
COMPLAINT - filed with Jury Demand against Gilead Pharmasset LLC, Gilead Sciences Inc.. Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1416499.) - filed by Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A pt.1, # 2 Exhibit A pt.2, # 3 Exhibit A pt.3, # 4 Exhibit A pt.4, # 5 Exhibit B, # 6 Civil Cover Sheet)(mdb) (Entered: 12/02/2013)
2013-12-01
2
COMPLAINT - filed with Jury Demand against Gilead Pharmasset LLC, Gilead Sciences Inc.. Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1416499.) - filed by Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A pt.1, # 2 Exhibit A pt.2, # 3 Exhibit A pt.3, # 4 Exhibit A pt.4, # 5 Exhibit B, # 6 Civil Cover Sheet)(mdb) (Entered: 12/02/2013)
2013-12-01
2
COMPLAINT - filed with Jury Demand against Gilead Pharmasset LLC, Gilead Sciences Inc.. Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1416499.) - filed by Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A pt.1, # 2 Exhibit A pt.2, # 3 Exhibit A pt.3, # 4 Exhibit A pt.4, # 5 Exhibit B, # 6 Civil Cover Sheet)(mdb) (Entered: 12/02/2013)
2013-12-01
2
Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mdb) (Entered: 12/02/2013)
2013-12-01
1
Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,608,600; 8,415,322;. (mdb) (Entered: 12/02/2013)
2013-12-01
1
Disclosure Statement pursuant to Rule 7.1 filed by Idenix Pharmaceuticals Inc. identifying Corporate Parent no parent corporation for Idenix Pharmaceuticals Inc... (Day, John) (Entered: 12/02/2013)
2013-12-02
1
SUMMONS Returned Executed by Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari. Gilead Sciences Inc. served on 12/2/2013, answer due 12/23/2013. (Day, John) (Entered: 12/02/2013)
2013-12-02
1
SUMMONS Returned Executed by Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari. Gilead Pharmasset LLC served on 12/2/2013, answer due 12/23/2013. (Day, John) (Entered: 12/02/2013)
2013-12-02
1
Summons Issued with Magistrate Consent Notice attached as to Gilead Pharmasset LLC on 12/2/2013; Gilead Sciences Inc. on 12/2/2013. (cla, )
2013-12-02
1
No Actions
Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. (rjb)
2013-12-04
1
No Actions
MOTION for Pro Hac Vice Appearance of Attorney Calvin P. Griffith, Anthony M. Insogna, Ryan B. McCrum, John M. Michalik, and Michael S. Weinstein - filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 12/05/2013)
2013-12-05
1
SO ORDERED, re 7 MOTION for Pro Hac Vice Appearance of Attorney Calvin P. Griffith, Anthony M. Insogna, Ryan B. McCrum, John M. Michalik, and Michael S. Weinstein filed by L' Universite Montpellier II, Idenix Pharmaceuticals Inc., Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari. Signed by Judge Leonard P. Stark on 12/6/13. (ntl)
2013-12-06
1
No Actions
Pro Hac Vice Attorney Michael S. Weinstein for Idenix Pharmaceuticals Inc. added for electronic noticing. (els)
2013-12-06
1
No Actions
Pro Hac Vice Attorney Ryan B. McCrum,Anthony M. Insogna for Idenix Pharmaceuticals Inc. added for electronic noticing. (els)
2013-12-09
1
No Actions
Pro Hac Vice Attorney Calvin P. Griffith for Idenix Pharmaceuticals Inc. added for electronic noticing. (dmp, )
2013-12-09
1
No Actions
STIPULATION TO EXTEND TIME to ANSWER Complaint to Feburary 6, 2014 - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 12/18/2013)
2013-12-18
1
SO ORDERED, re 8 STIPULATION TO EXTEND TIME to ANSWER Complaint to Feburary 6, 2014 filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Signed by Judge Leonard P. Stark on 12/20/13. (ntl)
2013-12-20
1
No Actions
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D - Part 1, # 5 Exihbit D - Part 2, # 6 Exhibit D - Part 3, # 7 Exhibit D - Part 4, # 8 Exhibit E, # 9 Exihbit F, # 10 Exhibit G)(Shear, William) (Entered: 02/06/2014)
2014-02-06
1
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D - Part 1, # 5 Exihbit D - Part 2, # 6 Exhibit D - Part 3, # 7 Exhibit D - Part 4, # 8 Exhibit E, # 9 Exihbit F, # 10 Exhibit G)(Shear, William) (Entered: 02/06/2014)
2014-02-06
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D - Part 1, # 5 Exihbit D - Part 2, # 6 Exhibit D - Part 3, # 7 Exhibit D - Part 4, # 8 Exhibit E, # 9 Exihbit F, # 10 Exhibit G)(Shear, William) (Entered: 02/06/2014)
2014-02-06
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D - Part 1, # 5 Exihbit D - Part 2, # 6 Exhibit D - Part 3, # 7 Exhibit D - Part 4, # 8 Exhibit E, # 9 Exihbit F, # 10 Exhibit G)(Shear, William) (Entered: 02/06/2014)
2014-02-06
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D - Part 1, # 5 Exihbit D - Part 2, # 6 Exhibit D - Part 3, # 7 Exhibit D - Part 4, # 8 Exhibit E, # 9 Exihbit F, # 10 Exhibit G)(Shear, William) (Entered: 02/06/2014)
2014-02-06
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D - Part 1, # 5 Exihbit D - Part 2, # 6 Exhibit D - Part 3, # 7 Exhibit D - Part 4, # 8 Exhibit E, # 9 Exihbit F, # 10 Exhibit G)(Shear, William) (Entered: 02/06/2014)
2014-02-06
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D - Part 1, # 5 Exihbit D - Part 2, # 6 Exhibit D - Part 3, # 7 Exhibit D - Part 4, # 8 Exhibit E, # 9 Exihbit F, # 10 Exhibit G)(Shear, William) (Entered: 02/06/2014)
2014-02-06
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D - Part 1, # 5 Exihbit D - Part 2, # 6 Exhibit D - Part 3, # 7 Exhibit D - Part 4, # 8 Exhibit E, # 9 Exihbit F, # 10 Exhibit G)(Shear, William) (Entered: 02/06/2014)
2014-02-06
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D - Part 1, # 5 Exihbit D - Part 2, # 6 Exhibit D - Part 3, # 7 Exhibit D - Part 4, # 8 Exhibit E, # 9 Exihbit F, # 10 Exhibit G)(Shear, William) (Entered: 02/06/2014)
2014-02-06
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D - Part 1, # 5 Exihbit D - Part 2, # 6 Exhibit D - Part 3, # 7 Exhibit D - Part 4, # 8 Exhibit E, # 9 Exihbit F, # 10 Exhibit G)(Shear, William) (Entered: 02/06/2014)
2014-02-06
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D - Part 1, # 5 Exihbit D - Part 2, # 6 Exhibit D - Part 3, # 7 Exhibit D - Part 4, # 8 Exhibit E, # 9 Exihbit F, # 10 Exhibit G)(Shear, William) (Entered: 02/06/2014)
2014-02-06
2
Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Gilead Sciences, Inc. for Gilead Pharmasset LLC filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Shear, William) (Entered: 02/06/2014)
2014-02-06
1
MOTION for Pro Hac Vice Appearance of Attorney John D. Kinton and Thomas E. Friebel - filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 02/14/2014)
2014-02-14
1
SO ORDERED, re 11 MOTION for Pro Hac Vice Appearance of Attorney John D. Kinton and Thomas E. Friebel filed by L' Universite Montpellier II, Idenix Pharmaceuticals Inc., Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari. Signed by Judge Leonard P. Stark on 2/14/14. (ntl)
2014-02-14
1
No Actions
STIPULATION TO EXTEND TIME to respond to Defendants' Counterclaims to April 2, 2014 - filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 02/18/2014)
2014-02-18
1
SO ORDERED, re 12 STIPULATION TO EXTEND TIME to respond to Defendants' Counterclaims to April 2, 2014 filed by L' Universite Montpellier II, Idenix Pharmaceuticals Inc., Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari. Signed by Judge Leonard P. Stark on 2/21/14. (ntl)
2014-02-21
1
No Actions
MOTION to Dismiss for Failure to State a Claim (Motion to Dismiss or Transfer Counterclaims) - filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc.. (Day, John) (Entered: 04/02/2014)
2014-04-02
1
OPENING BRIEF in Support re 13 MOTION to Dismiss for Failure to State a Claim (Motion to Dismiss or Transfer Counterclaims) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc..Answering Brief/Response due date per Local Rules is 4/21/2014. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Day, John) (Entered: 04/02/2014)
2014-04-02
1
MOTION for Pro Hac Vice Appearance of Attorney Lorie Ann Morgan - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Shear, William) (Entered: 04/08/2014)
2014-04-08
1
SO ORDERED, re 15 MOTION for Pro Hac Vice Appearance of Attorney Lorie Ann Morgan filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Signed by Judge Leonard P. Stark on 4/10/14. (ntl)
2014-04-10
1
No Actions
Pro Hac Vice Attorney Lorie Ann Morgan for Gilead Pharmasset LLC,Lorie Ann Morgan for Gilead Sciences Inc. added for electronic noticing. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS(els)
2014-04-17
1
No Actions
STIPULATION TO EXTEND TIME for Defendants to file opposition to Plaintiffs' Motion to Dismiss or Transfer and for Plaintiffs to file their reply to the Motion to Dismiss or Transfer to April 24, 2014 and May 8, 2014, respectively - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Ankenbrand, Michelle) (Entered: 04/21/2014)
2014-04-21
1
SO ORDERED, re 16 STIPULATION TO EXTEND TIME for Defendants to file opposition to Plaintiffs' Motion to Dismiss or Transfer and for Plaintiffs to file their reply to the Motion to Dismiss or Transfer to April 24, 2014 and May 8, 2014, respectively filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Signed by Judge Leonard P. Stark on 4/22/2014. (rpg)
2014-04-22
1
No Actions
ANSWERING BRIEF in Opposition re 13 MOTION to Dismiss for Failure to State a Claim (Motion to Dismiss or Transfer Counterclaims) filed by Gilead Pharmasset LLC, Gilead Sciences Inc..Reply Brief due date per Local Rules is 5/5/2014. (Ankenbrand, Michelle) (Entered: 04/24/2014)
2014-04-24
1
DECLARATION re 17 Answering Brief in Opposition, to Plaintiffs' Motion to Dismiss or Transfer Counterclaims by Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Ankenbrand, Michelle) (Entered: 04/24/2014)
2014-04-24
1
DECLARATION re 17 Answering Brief in Opposition, to Plaintiffs' Motion to Dismiss or Transfer Counterclaims by Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Ankenbrand, Michelle) (Entered: 04/24/2014)
2014-04-24
2
DECLARATION re 17 Answering Brief in Opposition, to Plaintiffs' Motion to Dismiss or Transfer Counterclaims by Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Ankenbrand, Michelle) (Entered: 04/24/2014)
2014-04-24
2
DECLARATION re 17 Answering Brief in Opposition, to Plaintiffs' Motion to Dismiss or Transfer Counterclaims by Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Ankenbrand, Michelle) (Entered: 04/24/2014)
2014-04-24
2
DECLARATION re 17 Answering Brief in Opposition, to Plaintiffs' Motion to Dismiss or Transfer Counterclaims by Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Ankenbrand, Michelle) (Entered: 04/24/2014)
2014-04-24
2
DECLARATION re 17 Answering Brief in Opposition, to Plaintiffs' Motion to Dismiss or Transfer Counterclaims by Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Ankenbrand, Michelle) (Entered: 04/24/2014)
2014-04-24
2
DECLARATION re 17 Answering Brief in Opposition, to Plaintiffs' Motion to Dismiss or Transfer Counterclaims by Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Ankenbrand, Michelle) (Entered: 04/24/2014)
2014-04-24
2
DECLARATION re 17 Answering Brief in Opposition, to Plaintiffs' Motion to Dismiss or Transfer Counterclaims by Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Ankenbrand, Michelle) (Entered: 04/24/2014)
2014-04-24
2
DECLARATION re 17 Answering Brief in Opposition, to Plaintiffs' Motion to Dismiss or Transfer Counterclaims by Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Ankenbrand, Michelle) (Entered: 04/24/2014)
2014-04-24
2
DECLARATION re 17 Answering Brief in Opposition, to Plaintiffs' Motion to Dismiss or Transfer Counterclaims by Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Ankenbrand, Michelle) (Entered: 04/24/2014)
2014-04-24
2
DECLARATION re 17 Answering Brief in Opposition, to Plaintiffs' Motion to Dismiss or Transfer Counterclaims by Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Ankenbrand, Michelle) (Entered: 04/24/2014)
2014-04-24
2
DECLARATION re 17 Answering Brief in Opposition, to Plaintiffs' Motion to Dismiss or Transfer Counterclaims by Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Ankenbrand, Michelle) (Entered: 04/24/2014)
2014-04-24
2
DECLARATION re 17 Answering Brief in Opposition, to Plaintiffs' Motion to Dismiss or Transfer Counterclaims by Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Ankenbrand, Michelle) (Entered: 04/24/2014)
2014-04-24
2
DECLARATION re 17 Answering Brief in Opposition, to Plaintiffs' Motion to Dismiss or Transfer Counterclaims by Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Ankenbrand, Michelle) (Entered: 04/24/2014)
2014-04-24
2
REPLY BRIEF re 13 MOTION to Dismiss for Failure to State a Claim (Motion to Dismiss or Transfer Counterclaims) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 05/08/2014)
2014-05-08
1
NOTICE of Appearance by Santosh Victor Coutinho on behalf of Gilead Pharmasset LLC, Gilead Sciences Inc. (Coutinho, Santosh) (Entered: 05/15/2014)
2014-05-15
1
REQUEST for Oral Argument by Gilead Pharmasset LLC, Gilead Sciences Inc. re 13 MOTION to Dismiss for Failure to State a Claim (Motion to Dismiss or Transfer Counterclaims). (Coutinho, Santosh) (Entered: 05/15/2014)
2014-05-15
1
ORAL ORDER: Pursuant to 28 U.S.C. ยง 636, IT IS HEREBY ORDERED that the following motion is referred to Magistrate Judge Christopher J. Burke: Motion to Dismiss or Transfer Counterclaims (D.I. 13). ORDERED by Judge Leonard P. Stark on 5/20/14. (ntl) (Entered: 05/20/2014)
2014-05-20
1
ORAL ORDER: IT IS HEREBY ORDERED that the parties shall confer regarding proposed dates in the scheduling order and shall submit a proposal, including a proposal for the length and timing of trial, to the Court no later than June 9, 2014. The parties are to review the Court's form scheduling order, which is posted at http://www.ded.uscourts.gov (see Chambers, Judge Stark, Forms). ORDERED by Judge Leonard P. Stark on 5/23/14. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS (ntl) (Entered: 05/23/2014)
2014-05-23
1
Letter to The Honorable Leonard P. Stark from John G. Day regarding Proposed Scheduling Order - re 23 Order,. (Attachments: # 1 Exhibit chart)(Day, John) (Entered: 06/09/2014)
2014-06-09
1
PROPOSED ORDER Scheduling Order re 24 Letter by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 06/09/2014)
2014-06-09
1
MOTION for Pro Hac Vice Appearance of Attorney Barbara R. Rudolph, Michael A. Morin, Robert F. Shaffer, and William B. Raich - filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 06/11/2014)
2014-06-11
1
Pro Hac Vice Attorney William Raich for Idenix Pharmaceuticals Inc. added for electronic noticing. (els)
2014-06-12
1
No Actions
SO ORDERED, re 26 MOTION for Pro Hac Vice Appearance of Attorney Barbara R. Rudolph, Michael A. Morin, Robert F. Shaffer, and William B. Raich filed by L' Universite Montpellier II, Idenix Pharmaceuticals Inc., Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari. Signed by Judge Leonard P. Stark on 6/12/14. (ntl)
2014-06-12
1
No Actions
Pro Hac Vice Attorney Michael A. Morin for Idenix Pharmaceuticals Inc. added for electronic noticing. (els)
2014-06-12
1
No Actions
ORAL ORDER: IT IS HEREBY ORDERED that a Rule 16 scheduling teleconference has been scheduled for July 18, 2014 at 2:45 p.m. Plaintiff's counsel shall initiate the teleconference call to 302-573-4571. No further submissions are needed. ORDERED by Judge Leonard P. Stark on 6/24/14. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS (ntl) (Entered: 06/24/2014)
2014-06-24
1
Pro Hac Vice Attorney Barbara R. Rudolph for Idenix Pharmaceuticals Inc. added for electronic noticing. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS(dmp, )
2014-06-24
1
No Actions
ORAL ORDER: IT IS HEREBY ORDERED that the Rule 16 scheduling teleconference scheduled for July 18, 2014 at 2:45 p.m. is CANCELLED is hereby re-scheduled for August 1, 2014 at 4:00 p.m. ORDERED by Judge Leonard P. Stark on 6/30/14. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS (ntl) (Entered: 06/30/2014)
2014-06-30
1
Letter to Honorable Christopher J. Burke from W. Chad Shear and Andrew Mayo regarding motion to dismiss/transfer. (Attachments: # 1 Exhibit)(Shear, William) (Entered: 07/03/2014)
2014-07-03
1
MOTION for Pro Hac Vice Appearance of Attorney Rebecca Charnas Grant and Tamara Fraizer - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Shear, William) (Entered: 07/16/2014)
2014-07-16
1
SO ORDERED, re 30 MOTION for Pro Hac Vice Appearance of Attorney Rebecca Charnas Grant and Tamara Fraizer filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Signed by Judge Leonard P. Stark on 7/16/14. (ntl)
2014-07-16
1
No Actions
Set/Reset Hearings: A Motion Hearing (re D.I. 13) is set for 8/14/2014 at 02:00 PM in Courtroom 2A before Judge Christopher J. Burke (dlk)
2014-07-28
1
No Actions
Letter to the Honorable Leonard P. Stark from Martina Tyreus Hufnal regarding Joint Request to Add C.A. 14-846 to August 1, 2014 Rule 16 Conference. (Hufnal, AnnaMartina) (Entered: 07/29/2014)
2014-07-29
1
Letter to the Honorable Leonard P. Stark from Martina Tyreus Hufnal regarding Joint Request to Add C.A. 14-846 to August 1, 2014 Rule 16 Conference. (Hufnal, AnnaMartina) (Entered: 07/29/2014)
2014-07-29
1
ORAL ORDER: Having reviewed the parties' letter of July 29 (C.A. No. 13-1987 D.I. 31), IT IS HEREBY ORDERED that: (i) as requested, C.A. No. 14-846 is added to the August 1, 2014 Rule 16 conference; and (ii) the Rule 16 conference on August 1 shall now begin at 1:00 p.m. ORDERED by Judge Leonard P. Stark on 7/30/14. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB (ntl) (Entered: 07/30/2014)
2014-07-30
1
SUBPOENA Returned Executed as to Centerview Partners, LLC on 7/31/14 (Hufnal, AnnaMartina) (Entered: 08/01/2014)
2014-08-01
1
SUBPOENA Returned Executed as to Centerview Partners, LLC on 7/31/14 (Hufnal, AnnaMartina) (Entered: 08/01/2014)
2014-08-01
1
SUBPOENA Returned Executed as to Centerview Partners LLC on 7/31/14 (Hufnal, AnnaMartina) (Entered: 08/01/2014)
2014-08-01
1
SUBPOENA Returned Executed as to Centerview Partners LLC on 7/31/14 (Hufnal, AnnaMartina) (Entered: 08/01/2014)
2014-08-01
1
Minute Entry for proceedings held before Judge Leonard P. Stark - Telephone Scheduling Conference held on 8/1/2014. (Court Reporter Brian Gaffigan.) Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB(rpg)
2014-08-01
1
No Actions
NOTICE OF SERVICE of Defendants' First Set of Requests to Plaintiffs for the Production of Documents and Things (Nos. 1-77) and Defendants' First Set of Interrogatories to Plaintiffs filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 08/04/2014)
2014-08-04
1
SUBPOENA Returned Executed as to subpoena for documents to The Baupost Group, L.L.C. on 7/31/14 (Hufnal, AnnaMartina) (Entered: 08/06/2014)
2014-08-06
1
SUBPOENA Returned Executed as to subpoena for documents to The Baupost Group, L.L.C. on 7/31/14 (Hufnal, AnnaMartina) (Entered: 08/06/2014)
2014-08-06
1
SUBPOENA Returned Executed as to deposition subpoena to The Baupost Group, L.L.C. on 7/31/14 (Hufnal, AnnaMartina) (Entered: 08/06/2014)
2014-08-06
1
SUBPOENA Returned Executed as to deposition subpoena to The Baupost Group, L.L.C. on 7/31/14 (Hufnal, AnnaMartina) (Entered: 08/06/2014)
2014-08-06
1
NOTICE of Appearance by Robert M. Oakes on behalf of Gilead Pharmasset LLC, Gilead Sciences Inc. (Oakes, Robert) (Entered: 08/06/2014)
2014-08-06
1
PROPOSED ORDER (Proposed Scheduling Order) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 08/06/2014)
2014-08-06
1
PROPOSED ORDER (Proposed Scheduling Order) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 08/06/2014)
2014-08-06
1
Joint STIPULATION Stipulation and Order regarding Motion to Disqualify by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 08/07/2014)
2014-08-07
1
Joint STIPULATION Stipulation and Order regarding Motion to Disqualify by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 08/07/2014)
2014-08-07
1
Pro Hac Vice Attorney Robert F. Shaffer for Idenix Pharmaceuticals Inc. added for electronic noticing. (els)
2014-08-07
1
No Actions
SO ORDERED, re Joint STIPULATION Stipulation and Order regarding Motion to Disqualify by Gilead Pharmasset LLC, Gilead Sciences Inc. (28 in 1:14-cv-00109-LPS, 58 in 1:14-cv-00846-LPS-CJB, 40 in 1:13-cv-01987-LPS). Signed by Judge Leonard P. Stark on 8/8/2014. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB(rpg) (Entered: 08/08/2014)
2014-08-08
1
SO ORDERED, re Joint STIPULATION Stipulation and Order regarding Motion to Disqualify by Gilead Pharmasset LLC, Gilead Sciences Inc. (28 in 1:14-cv-00109-LPS, 58 in 1:14-cv-00846-LPS-CJB, 40 in 1:13-cv-01987-LPS). Signed by Judge Leonard P. Stark on 8/8/2014. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB(rpg) (Entered: 08/08/2014)
2014-08-08
1
SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Joinder of Parties due by 7/15/2015. Amended Pleadings due by 7/15/2015. Discovery due by 12/8/2015. A Status Conference is set for 7/26/2016 at 09:00 AM in Courtroom 6B before Judge Leonard P. Stark. Status Report due by 6/15/2015. Tutorial on the technology due by 6/9/2015. Dispositive Motions due by 6/1/2016. A Motion Hearing is set for 7/26/2016 at 09:00 AM in Courtroom 6B before Judge Leonard P. Stark Claim Construction Opening Brief due by 6/9/2015. Claim Construction Answering Brief due by 7/23/2015. A Markman Hearing is set for 10/19/2015 at 09:00 AM in Courtroom 6B before Judge Leonard P. Stark. A Pretrial Conference is set for 9/9/2016 at 09:00 AM in Courtroom 6B before Judge Leonard P. Stark. Proposed Pretrial Order due by 8/29/2014. A Jury Trial is set for 10/11-21/2016 and 12/5-15/2016 at 09:30 AM in Courtroom 6B before Judge Leonard P. Stark. Signed by Judge Leonard P. Stark on 8/8/2014. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB(rpg) (Entered: 08/08/2014)
2014-08-08
1
MOTION to Disqualify Counsel Finnegan, Henderson, Farabow, Garrett & Dunner, LLP as Counsel for Plaintiffs - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Proposed Order)(Shear, William) (Entered: 08/08/2014)
2014-08-08
1
[SEALED] OPENING BRIEF in Support re 43 MOTION to Disqualify Counsel Finnegan, Henderson, Farabow, Garrett & Dunner, LLP as Counsel for Plaintiffs filed by Gilead Pharmasset LLC, Gilead Sciences Inc..Answering Brief/Response due date per Local Rules is 8/25/2014. (Attachments: # 1 Certificate of Service)(Shear, William) (Entered: 08/08/2014)
2014-08-08
1
[SEALED] DECLARATION re 43 MOTION to Disqualify Counsel Finnegan, Henderson, Farabow, Garrett & Dunner, LLP as Counsel for Plaintiffs DECLARATION OF W. CHAD SHEAR by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 SEALED Exhibits A-L, # 2 Certificate of Service)(Shear, William) (Entered: 08/08/2014)
2014-08-08
1
[SEALED] DECLARATION re 43 MOTION to Disqualify Counsel Finnegan, Henderson, Farabow, Garrett & Dunner, LLP as Counsel for Plaintiffs DECLARATION OF JAMISON LYNCH by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Certificate of Service)(Shear, William) (Entered: 08/08/2014)
2014-08-08
1
[SEALED] DECLARATION re 43 MOTION to Disqualify Counsel Finnegan, Henderson, Farabow, Garrett & Dunner, LLP as Counsel for Plaintiffs DECLARATION OF BRYCE ROBERTS by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Certificate of Service)(Shear, William) (Entered: 08/08/2014)
2014-08-08
1
CORRECTING ENTRY: d.i. 41 and 42 deleted per counsel's request. (rpg)
2014-08-08
1
No Actions
CASE REFERRED to Christopher J. Burke for Mediation. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB(dlk)
2014-08-08
1
No Actions
NOTICE of Appearance by James Michael Lennon on behalf of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP (Lennon, James) (Entered: 08/11/2014)
2014-08-11
1
MOTION for Pro Hac Vice Appearance of Attorney Thomas B. Mason - filed by Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. (Lennon, James) (Entered: 08/11/2014)
2014-08-11
1
NOTICE OF SERVICE of Plaintiffs' First Set of Requests for Production to Defendants filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Day, John) (Entered: 08/11/2014)
2014-08-11
1
CORRECTING ENTRY: notice of electronic filing re-generated to all counsel of record re 42 Scheduling Order. (rpg)
2014-08-11
1
No Actions
SO ORDERED, re 49 MOTION for Pro Hac Vice Appearance of Attorney Thomas B. Mason filed by Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. Signed by Judge Leonard P. Stark on 8/12/14. (ntl)
2014-08-12
1
No Actions
Joint STIPULATION TO EXTEND TIME for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to file its Answering Brief in Opposition to Defendants' Motion to Disqualify (D.I. 43) to September 8, 2014 - filed by Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. (Lennon, James) (Entered: 08/14/2014)
2014-08-14
1
REDACTED VERSION of 44 Opening Brief in Support, by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 08/15/2014)
2014-08-15
1
REDACTED VERSION of 47 Declaration, of Roberts by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 08/15/2014)
2014-08-15
1
REDACTED VERSION of 46 Declaration, Lynch by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 08/15/2014)
2014-08-15
1
REDACTED VERSION of 45 Declaration, Shear by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A-L)(Hufnal, AnnaMartina) (Entered: 08/15/2014)
2014-08-15
1
SO ORDERED, re 51 Joint STIPULATION TO EXTEND TIME for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to file its Answering Brief in Opposition to Defendants' Motion to Disqualify (D.I. 43) to September 8, 2014 filed by Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. Signed by Judge Leonard P. Stark on 8/15/14. (ntl)
2014-08-15
1
No Actions
Minute Entry for proceedings held before Judge Christopher J. Burke - Motion Hearing held on 8/14/2014 re 13 MOTION to Dismiss for Failure to State a Claim (Motion to Dismiss or Transfer Counterclaims) filed by Idenix Pharmaceuticals Inc., Centre National de la Recherche Scientifique. The Court took the matter under advisement. If parties wish to expedite mediation they should contact chambers. (Court Reporter Taneha Carroll) (dlk)
2014-08-15
1
No Actions
Official Transcript of Telephone Conference held on August 1, 2014 before Chief Judge Leonard P. Stark. Court Reporter Brian P. Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 9/15/2014. Redacted Transcript Deadline set for 9/25/2014. Release of Transcript Restriction set for 11/24/2014. (bpg) (Entered: 08/25/2014)
2014-08-25
1
Official Transcript of Telephone Conference held on August 1, 2014 before Chief Judge Leonard P. Stark. Court Reporter Brian P. Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 9/15/2014. Redacted Transcript Deadline set for 9/25/2014. Release of Transcript Restriction set for 11/24/2014. (bpg) (Entered: 08/25/2014)
2014-08-25
1
Official Transcript of Motion Hearing held on August 14, 2014 before Magistrate Judge Christopher J. Burke. Court Reporter Taneha Carroll of Hawkins Reporting Service, Telephone number (302) 5658-6697. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 9/15/2014. Redacted Transcript Deadline set for 9/25/2014. Release of Transcript Restriction set for 11/24/2014. (bpg) (Entered: 08/25/2014)
2014-08-25
1
REPORT AND RECOMMENDATIONS recommending GRANTING D.I. 13 MOTION to Dismiss for Failure to State a Claim (Motion to Dismiss or Transfer Counterclaims) filed by Idenix Pharmaceuticals Inc., Centre National de la Recherche Scientifique. Please note that when filing Objections pursuant to Federal Rule of Civil Procedure 72(b)(2), briefing consists solely of the Objections (no longer than ten (10) pages) and the Response to the Objections (no longer than ten (10) pages). No further briefing shall be permitted with respect to objections without leave of the Court. Objections to R&R due by 9/11/2014. Signed by Judge Christopher J. Burke on 08/25/2014. (mlc)
2014-08-25
1
NOTICE OF SERVICE of Plaintiffs' First Set of Interrogatories to Defendants filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 08/28/2014)
2014-08-28
1
NOTICE OF SERVICE of Plaintiffs' First Set of Interrogatories to Defendants filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 08/28/2014)
2014-08-28
1
NOTICE requesting Clerk to remove Michael A. Morin, Barbara R. Rudolph, Robert F. Shaffer, William B. Raich and the law firm of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP as co-counsel. Reason for request: No longer representing plaintiffs due to business decision by Merck & Co., Inc. resulting from its recent acquisition of plaintiff Idenix. (Lennon, James) (Entered: 09/05/2014)
2014-09-05
1
NOTICE requesting Clerk to remove Michael A. Morin, Barbara R. Rudolph, Robert F. Shaffer, William B. Raich and the law firm of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP as co-counsel. Reason for request: No longer representing plaintiffs due to business decision by Merck & Co., Inc. resulting from its recent acquisition of plaintiff Idenix. (Lennon, James) (Entered: 09/05/2014)
2014-09-05
1
NOTICE OF SERVICE of Initial Disclosures filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 09/08/2014)
2014-09-08
1
NOTICE OF SERVICE of Initial Disclosures filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 09/08/2014)
2014-09-08
1
NOTICE OF SERVICE of Plaintiffs' Rule 26(a) Initial Disclosures filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 09/08/2014)
2014-09-08
1
NOTICE OF SERVICE of Plaintiffs' Rule 26(a) Initial Disclosures filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 09/08/2014)
2014-09-08
1
NOTICE requesting Clerk to remove Michelle Nerozzi-Ankenbrand as co-counsel. Reason for request: no longer with the Firm. (Ankenbrand, Michelle) (Entered: 09/10/2014)
2014-09-10
1
NOTICE requesting Clerk to remove Michelle Nerozzi-Ankenbrand as co-counsel. Reason for request: no longer with the Firm. (Ankenbrand, Michelle) (Entered: 09/10/2014)
2014-09-10
1
Letter to The Honorable Leonard P. Stark from Martina Tyreus Hufnal regarding Motion to Disqualify Finnegan, Henderson, Farabow, Garrett & Dunner LLP - re 43 MOTION to Disqualify Counsel Finnegan, Henderson, Farabow, Garrett & Dunner, LLP as Counsel for Plaintiffs, 60 Notice Requesting Removal of Co-Counsel,. (Attachments: # 1 Exhibit A)(Hufnal, AnnaMartina) (Entered: 09/12/2014)
2014-09-12
1
MOTION for Pro Hac Vice Appearance of Attorney John M. Farrell and Rebecca Shult - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 09/15/2014)
2014-09-15
1
ORAL ORDER: Regarding the letter filed at D.I. 64, IT IS HEREBY ORDERED that 43 MOTION to Disqualify Counsel filed by Gilead Sciences Inc., Gilead Pharmasset LLC is DENIED without prejudice as moot. ORDERED by Judge Leonard P. Stark on 9/16/14. (ntl) (Entered: 09/16/2014)
2014-09-16
1
Pro Hac Vice Attorney Rebecca Charnas Grant for Gilead Pharmasset LLC,Rebecca Charnas Grant for Gilead Sciences Inc.,Rebecca Charnas Grant for Gilead Sciences Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB(els)
2014-09-16
1
No Actions
SO ORDERED, re 65 MOTION for Pro Hac Vice Appearance of Attorney John M. Farrell and Rebecca Shult filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Signed by Judge Leonard P. Stark on 9/17/14. (ntl)
2014-09-17
1
No Actions
NOTICE requesting Clerk to remove Thomas B. Mason as co-counsel. Reason for request: No longer representing the law firm of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. (Lennon, James) (Entered: 09/18/2014)
2014-09-18
1
NOTICE of Withdrawal of Appearance of James M. Lennon by Finnegan, Henderson, Farabow, Garrett & Dunner, LLP (Lennon, James) (Entered: 09/18/2014)
2014-09-18
1
MOTION for Pro Hac Vice Appearance of Attorney Corrin N. Drakulich - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 10/01/2014)
2014-10-01
1
NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' First Set of Interrogatories to Plaintiffs and Plaintiffs' Responses and Objections to Defendants' First Set of Requests to Plaintiffs for the Production of Documents and Things (Nos. 1-77) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/02/2014)
2014-10-02
1
NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' First Set of Interrogatories to Plaintiffs and Plaintiffs' Responses and Objections to Defendants' First Set of Requests to Plaintiffs for the Production of Documents and Things (Nos. 1-77) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/02/2014)
2014-10-02
1
STIPULATION TO EXTEND TIME to submit a proposed protective order to October 21, 2014 - filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Mayo, Andrew) (Entered: 10/06/2014)
2014-10-06
1
STIPULATION TO EXTEND TIME to submit a proposed protective order to October 21, 2014 - filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Mayo, Andrew) (Entered: 10/06/2014)
2014-10-06
1
SO ORDERED, re 69 MOTION for Pro Hac Vice Appearance of Attorney Corrin N. Drakulich filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Signed by Judge Leonard P. Stark on 10/7/14. (ntl)
2014-10-07
1
No Actions
SO ORDERED, re (71 in 1:14-cv-00846-LPS-CJB, 71 in 1:13-cv-01987-LPS, 41 in 1:14-cv-00109-LPS) STIPULATION TO EXTEND TIME to submit a proposed protective order to October 21, 2014 filed by L' Universite Montpellier II, Idenix Pharmaceuticals Inc., Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari. Signed by Judge Leonard P. Stark on 10/7/14. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB(ntl)
2014-10-07
1
No Actions
NOTICE OF SERVICE of Defendants' Responses to Plaintiffs' First Set of Requests For Production filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 10/13/2014)
2014-10-13
1
NOTICE OF SERVICE of Defendants' Responses to Plaintiffs' First Set of Requests For Production filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 10/13/2014)
2014-10-13
1
Amended Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Merck & Co., Inc. for Idenix Pharmaceuticals Inc. filed by Idenix Pharmaceuticals Inc.. (Day, John) (Entered: 10/16/2014)
2014-10-16
1
Amended Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Merck & Co., Inc. for Idenix Pharmaceuticals Inc. filed by Idenix Pharmaceuticals Inc.. (Day, John) (Entered: 10/16/2014)
2014-10-16
1
PROPOSED ORDER (Proposed Protective Order) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Mayo, Andrew) (Entered: 10/21/2014)
2014-10-21
1
PROPOSED ORDER (Proposed Protective Order) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Mayo, Andrew) (Entered: 10/21/2014)
2014-10-21
1
SO ORDERED, re (74 in 1:14-cv-00846-LPS-CJB, 74 in 1:13-cv-01987-LPS, 44 in 1:14-cv-00109-LPS) STIPULATED PROTECTIVE ORDER. Signed by Judge Leonard P. Stark on 10/22/14. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB (ntl)
2014-10-22
1
No Actions
NOTICE OF SERVICE of Defendants' Responses to Plaintiffs' First Set of Interrogatories filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 10/28/2014)
2014-10-28
1
NOTICE OF SERVICE of Defendants' Responses to Plaintiffs' First Set of Interrogatories filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 10/28/2014)
2014-10-28
1
ORDER Setting Teleconference: A Telephone Conference is set for 12/1/2014 at 10:15 AM before Judge Christopher J. Burke to discuss ADR. Signed by Judge Christopher J. Burke on 11/6/2014. (dlk) (Main Document 76 replaced on 11/6/2014) (dlk). (Entered: 11/06/2014)
2014-11-06
1
ORAL ORDER Resetting Teleconference: Due to a scheduling conflict, the Telephone Conference set for 12/1/2014 has been moved to 12/8/2014 at 10:15 AM before Judge Christopher J. Burke. Ordered by Judge Christopher J. Burke on 11/7/2014. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB(dlk)
2014-11-07
1
No Actions
ORDER ADOPTING 58 REPORT AND RECOMMENDATION re 13 MOTION to Dismiss is GRANTED. Signed by Judge Leonard P. Stark on 12/2/14. (ntl) (Entered: 12/03/2014)
2014-12-03
1
Minute Entry for proceedings held before Judge Christopher J. Burke - Settlement Teleconference held on 12/8/2014. (dlk)
2014-12-08
1
No Actions
Amended ANSWER to 9 Answer to Complaint,,, Counterclaim,, FIRST AMENDED ANSWER AND COUNTERCLAIMS, COUNTERCLAIM against All Plaintiffs by Gilead Sciences Inc., Gilead Pharmasset LLC.(Hufnal, AnnaMartina) (Entered: 12/22/2014)
2014-12-22
1
ORDER Setting Mediation Conference: A Telephone Conference is set for 12/14/2015 at 11:00 AM before Judge Christopher J. Burke.. Signed by Judge Christopher J. Burke on 12/31/2014. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB(dlk) (Entered: 12/31/2014)
2014-12-31
1
ORDER Setting Mediation Conference: A Telephone Conference is set for 12/14/2015 at 11:00 AM before Judge Christopher J. Burke.. Signed by Judge Christopher J. Burke on 12/31/2014. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB(dlk) (Entered: 12/31/2014)
2014-12-31
1
NOTICE OF SERVICE of Notice of Subpoenas filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 01/06/2015)
2015-01-06
1
NOTICE OF SERVICE of Notice of Subpoenas filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 01/06/2015)
2015-01-06
1
ANSWER to 78 Answer to Counterclaim, by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 01/08/2015)
2015-01-08
1
NOTICE OF SERVICE of Notice of Subpoena filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 01/09/2015)
2015-01-09
1
NOTICE OF SERVICE of Notice of Subpoena filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 01/09/2015)
2015-01-09
1
EMERGENCY MOTION to Stay the January 6, 2015 Discovery Requests - filed by Jeremy Clark. (rwc) (Entered: 01/21/2015)
2015-01-21
1
EMERGENCY MOTION to Stay the January 6, 2015 Discovery Requests - filed by Jeremy Clark. (rwc) (Entered: 01/21/2015)
2015-01-21
1
MOTION to Quash January 6, 2015 Discovery Requests - filed by Jeremy Clark. (rwc) (Entered: 01/21/2015)
2015-01-21
1
MOTION to Quash January 6, 2015 Discovery Requests - filed by Jeremy Clark. (rwc) (Entered: 01/21/2015)
2015-01-21
1
ORAL ORDER by Judge Leonard P. Stark: IT IS HEREBY ORDERED that Plaintiff shall file a Response to Movant Jeremy Clark's Emergency Motion to Stay Discovery Requests by 6:00 PM on Thursday, 1/22/2015, and such Response shall not exceed three (3) pages. re (84 in 1:14-cv-00846-LPS-CJB, 84 in 1:13-cv-01987-LPS, 52 in 1:14-cv-00109-LPS) MOTION to Quash filed by Jeremy Clark, (51 in 1:14-cv-00109-LPS, 83 in 1:14-cv-00846-LPS-CJB, 83 in 1:13-cv-01987-LPS) MOTION to Stay filed by Jeremy Clark Associated Cases: 1:14-cv-00846-LPS-CJB, 1:13-cv-01987-LPS, 1:14-cv-00109-LPS. (rpg) (Entered: 01/21/2015)
2015-01-21
1
NOTICE OF SERVICE of Notice of Subpoena filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 01/21/2015)
2015-01-21
1
NOTICE OF SERVICE of Notice of Subpoena filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 01/21/2015)
2015-01-21
1
Letter to The Honorable Leonard P. Stark from John G. Day regarding plaintiffs' response to Jeremy Clark's Emergency Motion to Stay. (Day, John) (Entered: 01/22/2015)
2015-01-22
1
Letter to The Honorable Leonard P. Stark from John G. Day regarding plaintiffs' response to Jeremy Clark's Emergency Motion to Stay. (Day, John) (Entered: 01/22/2015)
2015-01-22
1
RESPONSE to Motion re 84 MOTION to Quash filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Mayo, Andrew) (Entered: 02/09/2015)
2015-02-09
1
ORAL ORDER: Having reviewed in these three related matters (C.A. Nos. 13-1987, 14-109, 14-846) the Emergency Motion to Stay (see, e.g., C.A. No. 13-1987 D.I. 83), Motion to Quash (13-1987 D.I. 84), letter response (13-1987 D.I. 87), and response (13-1987 D.I. 88), IT IS HEREBY ORDERED that the Motion to Stay and the Motion to Quash are DENIED in all three related actions. There is no indication that the movant properly met and conferred and complied with the Court's other procedures before filing the motions. The movant and any interested parties in these actions are directed to meet and confer and to submit, no later than February 26, a joint status report indicating if there are any remaining disputes relating to the request for production from movant. ORDERED by Judge Leonard P. Stark on 2/18/15. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB (ntl) (Entered: 02/18/2015)
2015-02-18
1
Joint STIPULATION and Protocol Regarding the Format of Document Production by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A)(Hufnal, AnnaMartina) (Entered: 02/24/2015)
2015-02-24
1
Joint STIPULATION and Protocol Regarding the Format of Document Production by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A)(Hufnal, AnnaMartina) (Entered: 02/24/2015)
2015-02-24
1
SO ORDERED D.I. (90 in 1:14-cv-00846-LPS-CJB, 58 in 1:14-cv-00109-LPS, 90 in 1:13-cv-01987-LPS) Stipulation and Protocol Regarding the Format of Document Production filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Ordered by Judge Christopher J. Burke on 2/25/2015. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB(dlk)
2015-02-25
1
No Actions
Joint STATUS REPORT by Centre National de la Recherche Scientifique, L' Universite Montpellier II, Universita Degli Studi di Cagliari, Idenix Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A)(Day, John) (Entered: 02/26/2015)
2015-02-26
1
Joint STATUS REPORT by Centre National de la Recherche Scientifique, L' Universite Montpellier II, Universita Degli Studi di Cagliari, Idenix Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A)(Day, John) (Entered: 02/26/2015)
2015-02-26
1
Letter dated 3/2/15 to Judge Stark from Jeremy Clark regarding subpoenas. (ntl) (Entered: 03/04/2015)
2015-03-03
1
NOTICE to Take Deposition of Audrey Chappe-Dumas on May 20, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 03/09/2015)
2015-03-09
1
NOTICE to Take Deposition of Audrey Chappe-Dumas on May 20, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 03/09/2015)
2015-03-09
1
NOTICE to Take Deposition of Clement Counor on June 3, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 03/09/2015)
2015-03-09
1
NOTICE to Take Deposition of Clement Counor on June 3, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 03/09/2015)
2015-03-09
1
NOTICE to Take Deposition of David Dukhan on June 10, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 03/09/2015)
2015-03-09
1
NOTICE to Take Deposition of David Dukhan on June 10, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 03/09/2015)
2015-03-09
1
NOTICE to Take Deposition of Gilles Gosselin on July 8, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 03/09/2015)
2015-03-09
1
NOTICE to Take Deposition of Gilles Gosselin on July 8, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 03/09/2015)
2015-03-09
1
NOTICE to Take Deposition of Jean Francois Griffon on July 15, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 03/09/2015)
2015-03-09
1
NOTICE to Take Deposition of Jean Francois Griffon on July 15, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 03/09/2015)
2015-03-09
1
NOTICE to Take Deposition of Paulo LaColla on July 22, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 03/09/2015)
2015-03-09
1
NOTICE to Take Deposition of Paulo LaColla on July 22, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 03/09/2015)
2015-03-09
1
NOTICE to Take Deposition of Adel Moussa on May 27, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 03/09/2015)
2015-03-09
1
NOTICE to Take Deposition of Adel Moussa on May 27, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 03/09/2015)
2015-03-09
1
NOTICE to Take Deposition of Jerome Peyronnet on September 2, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 03/09/2015)
2015-03-09
1
NOTICE to Take Deposition of Jerome Peyronnet on September 2, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 03/09/2015)
2015-03-09
1
NOTICE to Take Deposition of Claire Pierra on August 26, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 03/09/2015)
2015-03-09
1
NOTICE to Take Deposition of Claire Pierra on August 26, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 03/09/2015)
2015-03-09
1
NOTICE to Take Deposition of Jingyang Wang on July 29, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 03/09/2015)
2015-03-09
1
NOTICE to Take Deposition of Jingyang Wang on July 29, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 03/09/2015)
2015-03-09
1
NOTICE OF SERVICE of Notice of Subpoenas filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 03/11/2015)
2015-03-11
1
NOTICE OF SERVICE of Notice of Subpoenas filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 03/11/2015)
2015-03-11
1
JOINT STIPULATION AND ORDER re Jeremy Clark. Signed by Judge Leonard P. Stark on 3/17/15. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB (ntl) (Entered: 03/17/2015)
2015-03-17
1
JOINT STIPULATION AND ORDER re Jeremy Clark. Signed by Judge Leonard P. Stark on 3/17/15. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB (ntl) (Entered: 03/17/2015)
2015-03-17
1
NOTICE OF SERVICE of Plaintiffs' First Supplemental Responses to Interrogatory Nos. 1-4 and Plaintiffs' Listing of Claim Terms for Construction filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Day, John) (Entered: 04/01/2015)
2015-04-01
1
NOTICE OF SERVICE of Plaintiffs' First Supplemental Responses to Interrogatory Nos. 1-4 and Plaintiffs' Listing of Claim Terms for Construction filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Day, John) (Entered: 04/01/2015)
2015-04-01
1
NOTICE OF SERVICE of Defendants' First Supplemental Responses to Plaintiffs' Interrogatory Nos. 5, 6 and 8 AND Defendants' Proposed Claim Terms For Construction filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 04/01/2015)
2015-04-01
1
NOTICE OF SERVICE of Defendants' First Supplemental Responses to Plaintiffs' Interrogatory Nos. 5, 6 and 8 AND Defendants' Proposed Claim Terms For Construction filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 04/01/2015)
2015-04-01
1
MOTION for Pro Hac Vice Appearance of Attorney Jenny Shmuel - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 04/03/2015)
2015-04-03
1
MOTION for Pro Hac Vice Appearance of Attorney Jenny Shmuel - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 04/03/2015)
2015-04-03
1
SO ORDERED, re (75 in 1:14-cv-00109-LPS, 107 in 1:13-cv-01987-LPS, 107 in 1:14-cv-00846-LPS-CJB) MOTION for Pro Hac Vice Appearance of Attorney Jenny Shmuel filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Signed by Judge Leonard P. Stark on 4/7/15. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB (ntl)
2015-04-07
1
No Actions
NOTICE OF SERVICE of Notice of Subpoenas filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Day, John) (Entered: 04/17/2015)
2015-04-17
1
NOTICE OF SERVICE of Notice of Subpoenas filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Day, John) (Entered: 04/17/2015)
2015-04-17
1
NOTICE OF SERVICE of Defendants' Proposed Claim Constructions filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 04/21/2015)
2015-04-21
1
NOTICE OF SERVICE of Defendants' Proposed Claim Constructions filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 04/21/2015)
2015-04-21
1
NOTICE OF SERVICE of Plaintiffs' Proposed Claim Constructions filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Day, John) (Entered: 04/21/2015)
2015-04-21
1
NOTICE OF SERVICE of Plaintiffs' Proposed Claim Constructions filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Day, John) (Entered: 04/21/2015)
2015-04-21
1
MOTION for Pro Hac Vice Appearance of Attorney Tasha M. Francis - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Coutinho, Santosh) (Entered: 04/22/2015)
2015-04-22
1
MOTION for Pro Hac Vice Appearance of Attorney Tasha M. Francis - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Coutinho, Santosh) (Entered: 04/22/2015)
2015-04-22
1
SO ORDERED, re (111 in 1:14-cv-00846-LPS-CJB, 111 in 1:13-cv-01987-LPS, 79 in 1:14-cv-00109-LPS) MOTION for Pro Hac Vice Appearance of Attorney Tasha M. Francis filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Signed by Judge Leonard P. Stark on 4/23/15. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB (ntl)
2015-04-23
1
No Actions
SO ORDERED
2015-04-23
1
No Actions
Joint STIPULATION to Amend Claim Construction Submission Deadlines re (60 in 1:14-cv-00846-LPS-CJB, 42 in 1:13-cv-01987-LPS) Scheduling Order,,,, by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 05/04/2015)
2015-05-04
1
SO ORDERED D.I. (112 in 1:13-cv-01987-LPS, 112 in 1:14-cv-00846-LPS-CJB) Stipulation to Amend Claim Construction Submission Deadlines re Scheduling Order (60 in 1:14-cv-00846-LPS-CJB, 42 in 1:13-cv-01987-LPS) filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Ordered by Judge Christopher J. Burke on 5/5/2015. Associated Cases: 1:14-cv-00846-LPS-CJB, 1:13-cv-01987-LPS(dlk)
2015-05-05
1
No Actions
SO ORDERED
2015-05-05
1
No Actions
NOTICE of Withdrawal of Tamara Fraizer as pro hac vice counsel by Gilead Pharmasset LLC, Gilead Sciences Inc. (Hufnal, AnnaMartina) (Entered: 05/11/2015)
2015-05-11
1
NOTICE of Withdrawal of Tamara Fraizer as pro hac vice counsel by Gilead Pharmasset LLC, Gilead Sciences Inc. (Hufnal, AnnaMartina) (Entered: 05/11/2015)
2015-05-11
1
Pro Hac Vice Attorney Tasha M Francis for Gilead Sciences Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB(klc)
2015-05-19
1
No Actions
Add Attorneys - PHV only
2015-05-19
1
No Actions
NOTICE OF SERVICE of Notice of Subpoenas filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
1
NOTICE OF SERVICE of Notice of Subpoenas filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
1
NOTICE OF SERVICE of Gilead's Second Set of Interrogatories to Plaintiffs (Nos. 9-21) filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 05/20/2015)
2015-05-20
1
NOTICE OF SERVICE of Gilead's Second Set of Interrogatories to Plaintiffs (Nos. 9-21) filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 05/20/2015)
2015-05-20
1
CLAIM Construction Chart by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
1
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume I of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 4), # 5 Exhibit D (Part 2 of 4), # 6 Exhibit D (Part 3 of 4), # 7 Exhibit D (Part 4 of 4))(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
1
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume I of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 4), # 5 Exhibit D (Part 2 of 4), # 6 Exhibit D (Part 3 of 4), # 7 Exhibit D (Part 4 of 4))(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume I of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 4), # 5 Exhibit D (Part 2 of 4), # 6 Exhibit D (Part 3 of 4), # 7 Exhibit D (Part 4 of 4))(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume I of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 4), # 5 Exhibit D (Part 2 of 4), # 6 Exhibit D (Part 3 of 4), # 7 Exhibit D (Part 4 of 4))(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume I of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 4), # 5 Exhibit D (Part 2 of 4), # 6 Exhibit D (Part 3 of 4), # 7 Exhibit D (Part 4 of 4))(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume I of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 4), # 5 Exhibit D (Part 2 of 4), # 6 Exhibit D (Part 3 of 4), # 7 Exhibit D (Part 4 of 4))(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume I of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 4), # 5 Exhibit D (Part 2 of 4), # 6 Exhibit D (Part 3 of 4), # 7 Exhibit D (Part 4 of 4))(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume I of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 4), # 5 Exhibit D (Part 2 of 4), # 6 Exhibit D (Part 3 of 4), # 7 Exhibit D (Part 4 of 4))(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
1
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
APPENDIX re (116 in 1:14-cv-00846-LPS-CJB) Claim Construction Chart (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit E1 (Part 1 of 4), # 2 Exhibit E1 (Part 2 of 4), # 3 Exhibit E1 (Part 3 of 4), # 4 Exhibit E1 (Part 4 of 4), # 5 Exhibit E2, # 6 Exhibit E3, # 7 Exhibit E4, # 8 Exhibit E5, # 9 Exhibit E6, # 10 Exhibit E7, # 11 Exhibit F1, # 12 Exhibit F2, # 13 Exhibit F3, # 14 Exhibit F4, # 15 Exhibit F5, # 16 Exhibit F6, # 17 Exhibit F7 (Part 1 of 2), # 18 Exhibit F7 (Part 2 of 2), # 19 Exhibit F8, # 20 Exhibit F9, # 21 Exhibit F10, # 22 Exhibit F11, # 23 Exhibit F12, # 24 Exhibit F13, # 25 Exhibit F14, # 26 Exhibit F15 (Part 1 of 2), # 27 Exhibit F15 (Part 2 of 2), # 28 Exhibit F16, # 29 Exhibit F17, # 30 Exhibit F18, # 31 Exhibit F19)(Mayo, Andrew) (Entered: 05/20/2015)
2015-05-20
2
NOTICE OF SERVICE of Defendants' First Supplemental Response to Plaintiffs' Interrogatory Nos. 4 and 7 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 06/11/2015)
2015-06-11
1
NOTICE OF SERVICE of Defendants' First Supplemental Response to Plaintiffs' Interrogatory Nos. 4 and 7 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 06/11/2015)
2015-06-11
1
NOTICE OF SERVICE of Dennis Liotta's Response and Objections to Plaintiffs' Subpoena to Produce Documents filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 06/11/2015)
2015-06-11
1
NOTICE OF SERVICE of Dennis Liotta's Response and Objections to Plaintiffs' Subpoena to Produce Documents filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 06/11/2015)
2015-06-11
1
NOTICE OF SERVICE of Krzysztof Pankiewicz's Response and Objections to Plaintiffs' Subpoena to Produce Documents filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 06/11/2015)
2015-06-11
1
NOTICE OF SERVICE of Krzysztof Pankiewicz's Response and Objections to Plaintiffs' Subpoena to Produce Documents filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 06/11/2015)
2015-06-11
1
NOTICE OF SERVICE of Bryce Robert's Response and Objections to Plaintiffs' Subpoena to Produce Documents filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 06/11/2015)
2015-06-11
1
NOTICE OF SERVICE of Bryce Robert's Response and Objections to Plaintiffs' Subpoena to Produce Documents filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 06/11/2015)
2015-06-11
1
Interim STATUS REPORT by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 06/15/2015)
2015-06-15
1
Interim STATUS REPORT by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 06/15/2015)
2015-06-15
1
Joint STIPULATION to Extend Page Limitation on Claim Construction Briefs by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 06/18/2015)
2015-06-18
1
SO ORDERED, re (124 in 1:13-cv-01987-LPS, 124 in 1:14-cv-00846-LPS-CJB) Joint Stipulation to Extend Page Limitation on Claim Construction Opening Briefs. Signed by Judge Leonard P. Stark on 6/19/15. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00846-LPS-CJB (ntl)
2015-06-19
1
No Actions
SO ORDERED
2015-06-19
1
No Actions
MOTION for Issuance of Letters Rogatory DEFENDANTS' UNOPPOSED MOTION FOR ISSUANCE OF LETTERS ROGATORY - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Text of Proposed Order)(Coutinho, Santosh) (Entered: 06/22/2015)
2015-06-22
1
MOTION for Issuance of Letters Rogatory DEFENDANTS' UNOPPOSED MOTION FOR ISSUANCE OF LETTERS ROGATORY - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Text of Proposed Order)(Coutinho, Santosh) (Entered: 06/22/2015)
2015-06-22
1
Letter to The Honorable Leonard P. Stark from Andrew C. Mayo regarding Plaintiffs' Technology Tutorial. (Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
1
Letter to The Honorable Leonard P. Stark from Martina Tyreus Hufnal regarding Enclosing DVD of Technology Tutorial. (Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
1
Letter to The Honorable Leonard P. Stark from Martina Tyreus Hufnal regarding Enclosing DVD of Technology Tutorial. (Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
1
CLAIM CONSTRUCTION OPENING BRIEF filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
1
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
1
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
CLAIM CONSTRUCTION OPENING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22)(Mayo, Andrew) (Entered: 06/23/2015)
2015-06-23
2
Claim Construction Opening Brief
2015-06-23
1
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
1
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF JASON MICKLEFIELD, PH.D. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D (Part 1 of 6), # 5 Exhibit D (Part 2 of 6), # 6 Exhibit D (Part 3 of 6), # 7 Exhibit D (Part 4 of 6), # 8 Exhibit D (Part 5 of 6), # 9 Exhibit D (Part 6 of 6), # 10 Exhibit E (Part 1 of 4), # 11 Exhibit E (Part 2 of 4), # 12 Exhibit E (Part 3 of 4), # 13 Exhibit E (Part 4 of 4), # 14 Exhibit F (Part 1 of 2), # 15 Exhibit F (Part 2 of 2), # 16 Exhibit G, # 17 Exhibit H, # 18 Exhibit I, # 19 Exhibit J (Part 1 of 2), # 20 Exhibit J (Part 2 of 2), # 21 Exhibit K, # 22 Exhibit L (Part 1 of 3), # 23 Exhibit L (Part 2 of 3), # 24 Exhibit L (Part 3 of 3), # 25 Exhibit M, # 26 Exhibit N)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
2
DECLARATION re 128 Claim Construction Opening Brief DECLARATION OF TASHA FRANCIS by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14 (Part 1 of 4), # 15 Exhibit 14 (Part 2 of 4), # 16 Exhibit 14 (Part 3 of 4), # 17 Exhibit 14 (Part 4 of 4), # 18 Exhibit 15, # 19 Exhibit 16, # 20 Exhibit 17, # 21 Exhibit 18, # 22 Exhibit 19, # 23 Exhibit 20, # 24 Exhibit 21, # 25 Exhibit 22)(Hufnal, AnnaMartina) (Entered: 06/23/2015)
2015-06-23
1
Letter to The Honorable Leonard P. Stark from Martina Tyreus Hufnal regarding define the counts. (Hufnal, AnnaMartina) (Entered: 06/24/2015)
2015-06-24
1
Letter to The Honorable Leonard P. Stark from Martina Tyreus Hufnal regarding define the counts. (Hufnal, AnnaMartina) (Entered: 06/24/2015)
2015-06-24
1
CORRECTING ENTRY: D.I. 130 was removed from the docket as it was filed by counsel in error. (ntl)
2015-06-24
1
No Actions
- CORRECTING ENTRY
2015-06-24
1
No Actions
ORAL ORDER: IT IS HEREBY ORDERED that Idenix shall repond to the June 24 letter by June 26, 2015 re (93 in 1:14-cv-00109-LPS, 133 in 1:13-cv-01987-LPS) Letter. ORDERED by Judge Leonard P. Stark on 6/25/15. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS (ntl) (Entered: 06/25/2015)
2015-06-25
1
Oral Order
2015-06-25
1
No Actions
Letter to The Honorable Chief Judge Leonard P. Stark from Andrew C. Mayo regarding response to Gilead's June 24, 2015 letter. (Mayo, Andrew) (Entered: 06/26/2015)
2015-06-26
1
Letter to The Honorable Chief Judge Leonard P. Stark from Andrew C. Mayo regarding response to Gilead's June 24, 2015 letter. (Mayo, Andrew) (Entered: 06/26/2015)
2015-06-26
1
Letter to The Honorable Leonard P. Stark from Martina Tyreus Hufnal, counsel for Gilead regarding in response to Idenix letter to the Court of June 26, 2015 - re (93 in 1:14-cv-00109-LPS, 133 in 1:13-cv-01987-LPS) Letter, (95 in 1:14-cv-00109-LPS, 135 in 1:13-cv-01987-LPS) Letter. (Hufnal, AnnaMartina) (Entered: 06/29/2015)
2015-06-29
1
Letter to The Honorable Leonard P. Stark from Martina Tyreus Hufnal, counsel for Gilead regarding in response to Idenix letter to the Court of June 26, 2015 - re (93 in 1:14-cv-00109-LPS, 133 in 1:13-cv-01987-LPS) Letter, (95 in 1:14-cv-00109-LPS, 135 in 1:13-cv-01987-LPS) Letter. (Hufnal, AnnaMartina) (Entered: 06/29/2015)
2015-06-29
1
Letter to The Honorable Chief Judge Leonard P. Stark from John G. Day regarding Idenix's response to Gilead's June 29, 2015 letter. (Day, John) (Entered: 06/30/2015)
2015-06-30
1
Letter to The Honorable Chief Judge Leonard P. Stark from John G. Day regarding Idenix's response to Gilead's June 29, 2015 letter. (Day, John) (Entered: 06/30/2015)
2015-06-30
1
Pro Hac Vice Attorney Jenny Shmuel for Gilead Sciences Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS(klc)
2015-06-30
1
No Actions
Add Attorneys - PHV only
2015-06-30
1
No Actions
ORDER re (125 in 1:14-cv-00846-LPS-CJB, 125 in 1:13-cv-01987-LPS, 88 in 1:14-cv-00109-LPS) DEFENDANTS' UNOPPOSED MOTION FOR ISSUANCE OF LETTERS ROGATORY filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Signed by Judge Leonard P. Stark on 7/6/15. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB (ntl) (Entered: 07/06/2015)
2015-07-06
1
ORDER re (125 in 1:14-cv-00846-LPS-CJB, 125 in 1:13-cv-01987-LPS, 88 in 1:14-cv-00109-LPS) DEFENDANTS' UNOPPOSED MOTION FOR ISSUANCE OF LETTERS ROGATORY filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Signed by Judge Leonard P. Stark on 7/6/15. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB (ntl) (Entered: 07/06/2015)
2015-07-06
1
ORAL ORDER by Judge Leonard P. Stark: Having reviewed the parties' recent letters (D.I. 133, 135, 136, 137), IT IS HEREBY ORDERED that Gilead's request that the Court "define the interference counts" in connection with claim construction -- which the Court construes as a request to modify the scheduling order -- is DENIED. Given the parties' vastly contrasting views as to the best and most efficient manner for the interference portions of these cases to proceed, the Court deems the appropriate exercise of its discretion to be to adhere to the schedule the Court entered at the outset of the cases. Issues relating to the definition of the interference count will be resolved in connection with summary judgment, at trial, or after trial. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS(rpg) (Entered: 07/10/2015)
2015-07-10
1
Oral Order
2015-07-10
1
No Actions
NOTICE to Take Deposition of Suguna Rachakonda on July 24, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Day, John) (Entered: 07/20/2015)
2015-07-20
1
NOTICE to Take Deposition of Suguna Rachakonda on July 24, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Day, John) (Entered: 07/20/2015)
2015-07-20
1
NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' Second Set of Interrogatories filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 07/20/2015)
2015-07-20
1
NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' Second Set of Interrogatories filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 07/20/2015)
2015-07-20
1
NOTICE to Take Deposition of Dr. Jason Micklefield on July 30, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 07/28/2015)
2015-07-28
1
NOTICE to Take Deposition of Dr. Jason Micklefield on July 30, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 07/28/2015)
2015-07-28
1
Joint STIPULATION to Extend Page Limitation on Claim Construction Briefs by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Mayo, Andrew) (Entered: 08/04/2015)
2015-08-04
1
Joint STIPULATION to Extend Page Limitation on Claim Construction Briefs by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Mayo, Andrew) (Entered: 08/04/2015)
2015-08-04
1
SO ORDERED, re (103 in 1:14-cv-00109-LPS, 143 in 1:13-cv-01987-LPS) Joint Stipulation to Extend Page Limitation on Claim Construction Answering Briefs. Signed by Judge Leonard P. Stark on 8/5/15. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS (ntl)
2015-08-05
1
No Actions
SO ORDERED
2015-08-05
1
No Actions
STATEMENT Defendants' Commentary on Plaintiffs' Technology Tutorial by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 08/06/2015)
2015-08-06
1
STATEMENT Defendants' Commentary on Plaintiffs' Technology Tutorial by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 08/06/2015)
2015-08-06
1
DECLARATION re (136 in 1:14-cv-00846-LPS-CJB) Statement Declaration of Martina Tyreus Hufnal in Support of Defendants' Commentary on Plaintiffs' Technology Tutorial by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3)(Hufnal, AnnaMartina) (Entered: 08/06/2015)
2015-08-06
1
DECLARATION re (136 in 1:14-cv-00846-LPS-CJB) Statement Declaration of Martina Tyreus Hufnal in Support of Defendants' Commentary on Plaintiffs' Technology Tutorial by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3)(Hufnal, AnnaMartina) (Entered: 08/06/2015)
2015-08-06
1
DECLARATION re (136 in 1:14-cv-00846-LPS-CJB) Statement Declaration of Martina Tyreus Hufnal in Support of Defendants' Commentary on Plaintiffs' Technology Tutorial by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3)(Hufnal, AnnaMartina) (Entered: 08/06/2015)
2015-08-06
2
DECLARATION re (136 in 1:14-cv-00846-LPS-CJB) Statement Declaration of Martina Tyreus Hufnal in Support of Defendants' Commentary on Plaintiffs' Technology Tutorial by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3)(Hufnal, AnnaMartina) (Entered: 08/06/2015)
2015-08-06
2
DECLARATION re (136 in 1:14-cv-00846-LPS-CJB) Statement Declaration of Martina Tyreus Hufnal in Support of Defendants' Commentary on Plaintiffs' Technology Tutorial by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3)(Hufnal, AnnaMartina) (Entered: 08/06/2015)
2015-08-06
2
CLAIM CONSTRUCTION ANSWERING BRIEF re 128 Claim Construction Opening Brief filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 08/06/2015)
2015-08-06
1
DECLARATION re 146 Claim Construction Answering Brief Declaration of Tasha M. Francis in Support of Defendants' Responsive Claim Construction Brief by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Hufnal, AnnaMartina) (Entered: 08/06/2015)
2015-08-06
1
CLAIM CONSTRUCTION ANSWERING BRIEF filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 23 - 28)(Mayo, Andrew) (Entered: 08/06/2015)
2015-08-06
1
Joint Letter to The Honorable Chief Judge Leonard P. Stark from Andrew C. Mayo regarding Claim Construction Hearing. (Mayo, Andrew) (Entered: 08/06/2015)
2015-08-06
1
NOTICE OF SERVICE of Notice of Subpoenas filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 08/07/2015)
2015-08-07
1
NOTICE OF SERVICE of Notice of Subpoenas filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 08/07/2015)
2015-08-07
1
NOTICE to Take Deposition of Idenix 30(b)(6) Witness on September 18, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 08/07/2015)
2015-08-07
1
NOTICE to Take Deposition of Idenix 30(b)(6) Witness on September 18, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 08/07/2015)
2015-08-07
1
NOTICE to Take Deposition of Bryce Roberts on August 14, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 08/11/2015)
2015-08-11
1
NOTICE to Take Deposition of Bryce Roberts on August 14, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 08/11/2015)
2015-08-11
1
NOTICE OF SERVICE of Subpoenas for Testimony and Subpoenas for Document Production Directed to Adel Moussa and David Standring filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 08/11/2015)
2015-08-11
1
NOTICE OF SERVICE of Subpoenas for Testimony and Subpoenas for Document Production Directed to Adel Moussa and David Standring filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 08/11/2015)
2015-08-11
1
NOTICE to Take Deposition of Centre National De La Recherche Scientifique on September 18, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 08/11/2015)
2015-08-11
1
NOTICE to Take Deposition of Centre National De La Recherche Scientifique on September 18, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 08/11/2015)
2015-08-11
1
NOTICE to Take Deposition of Universita Degli Studi Di Cagliari on September 18, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 08/11/2015)
2015-08-11
1
NOTICE to Take Deposition of Universita Degli Studi Di Cagliari on September 18, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 08/11/2015)
2015-08-11
1
NOTICE to Take Deposition of L'Universite Montpellier II on September 18, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 08/11/2015)
2015-08-11
1
NOTICE to Take Deposition of L'Universite Montpellier II on September 18, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 08/11/2015)
2015-08-11
1
NOTICE to Take Deposition of Gilead Sciences, Inc. and Gilead Pharmasset LLC on September 22, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Day, John) (Entered: 08/12/2015)
2015-08-12
1
NOTICE to Take Deposition of Gilead Sciences, Inc. and Gilead Pharmasset LLC on September 22, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Day, John) (Entered: 08/12/2015)
2015-08-12
1
MOTION for Pro Hac Vice Appearance of Attorney Jonathan E. Singer - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 08/18/2015)
2015-08-18
1
MOTION for Pro Hac Vice Appearance of Attorney Jonathan E. Singer - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 08/18/2015)
2015-08-18
1
NOTICE to Take Deposition of Michael Otto on August 28, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 08/18/2015)
2015-08-18
1
NOTICE to Take Deposition of Michael Otto on August 28, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 08/18/2015)
2015-08-18
1
NOTICE of Appearance by Elizabeth M. Flanagan on behalf of Gilead Pharmasset LLC, Gilead Sciences Inc. (Flanagan, Elizabeth) (Entered: 08/19/2015)
2015-08-19
1
NOTICE of Appearance by Elizabeth M. Flanagan on behalf of Gilead Pharmasset LLC, Gilead Sciences Inc. (Flanagan, Elizabeth) (Entered: 08/19/2015)
2015-08-19
1
SO ORDERED, re (116 in 1:14-cv-00109-LPS, 158 in 1:13-cv-01987-LPS, 150 in 1:14-cv-00846-LPS-CJB) MOTION for Pro Hac Vice Appearance of Attorney Jonathan E. Singer filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Signed by Judge Leonard P. Stark on 8/19/15. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB (ntl)
2015-08-19
1
No Actions
SO ORDERED
2015-08-19
1
No Actions
NOTICE OF SERVICE of Adel Moussa's Responses and Objections to Defendants' Subpoena to Produce Documents filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 08/20/2015)
2015-08-20
1
NOTICE OF SERVICE of Adel Moussa's Responses and Objections to Defendants' Subpoena to Produce Documents filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 08/20/2015)
2015-08-20
1
ORAL ORDER by Judge Leonard P. Stark: Having reviewed the parties' joint letter (D.I. 149 ), IT IS HEREBY ORDERED that each side will be allocated ninety (90) minutes for their presentations at the Markman hearing, to be used as it wishes. The parties shall advise one another and the Court no later than ten (10) days before the hearing whether they will present live testimony. (rpg) (Entered: 08/21/2015)
2015-08-21
1
NOTICE requesting Clerk to remove Rebecca Charnas Grant as co-counsel. Reason for request: no longer with the firm. (Hufnal, AnnaMartina) (Entered: 08/21/2015)
2015-08-21
1
NOTICE requesting Clerk to remove Rebecca Charnas Grant as co-counsel. Reason for request: no longer with the firm. (Hufnal, AnnaMartina) (Entered: 08/21/2015)
2015-08-21
1
Oral Order
2015-08-21
1
No Actions
NOTICE OF SERVICE of Defendants' Objections and Responses to Topics 3, and 38-43 of Plaintiffs' Notice of Rule 30(b)(6) Deposition of Gilead Sciences, Inc. and Gilead Pharmasset LLC filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Flanagan, Elizabeth) (Entered: 08/26/2015)
2015-08-26
1
NOTICE OF SERVICE of Defendants' Objections and Responses to Topics 3, and 38-43 of Plaintiffs' Notice of Rule 30(b)(6) Deposition of Gilead Sciences, Inc. and Gilead Pharmasset LLC filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Flanagan, Elizabeth) (Entered: 08/26/2015)
2015-08-26
1
NOTICE OF SERVICE of David Standring's Responses and Objections to Defendants' Subpoena to Produce Document filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 08/27/2015)
2015-08-27
1
NOTICE OF SERVICE of David Standring's Responses and Objections to Defendants' Subpoena to Produce Document filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 08/27/2015)
2015-08-27
1
NOTICE OF SERVICE of Defendants' Supplemental Initial Disclosures filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 08/28/2015)
2015-08-28
1
NOTICE OF SERVICE of Defendants' Supplemental Initial Disclosures filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 08/28/2015)
2015-08-28
1
NOTICE OF SERVICE of Defendants' Third Set of Interrogatories to Plaintiffs (Nos. 22-26) filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Flanagan, Elizabeth) (Entered: 09/04/2015)
2015-09-04
1
NOTICE OF SERVICE of Defendants' Third Set of Interrogatories to Plaintiffs (Nos. 22-26) filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Flanagan, Elizabeth) (Entered: 09/04/2015)
2015-09-04
1
NOTICE to Take Deposition of Ann Montross on September 17, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 09/10/2015)
2015-09-10
1
NOTICE to Take Deposition of Ann Montross on September 17, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 09/10/2015)
2015-09-10
1
NOTICE OF SERVICE of Notice of Subpoena for Testimony Directed to Raymond Schinazi filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 09/10/2015)
2015-09-10
1
NOTICE OF SERVICE of Notice of Subpoena for Testimony Directed to Raymond Schinazi filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 09/10/2015)
2015-09-10
1
NOTICE OF SERVICE of Plaintiffs' Supplemental Responses to Interrogatory Nos. 3, 5, 6, and 8 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 09/11/2015)
2015-09-11
1
NOTICE OF SERVICE of Plaintiffs' Supplemental Responses to Interrogatory Nos. 3, 5, 6, and 8 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 09/11/2015)
2015-09-11
1
NOTICE OF SERVICE of a subpoena for testimony and a subpoena for document production directed to Jean-Pierre Sommadossi filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 09/17/2015)
2015-09-17
1
NOTICE OF SERVICE of a subpoena for testimony and a subpoena for document production directed to Jean-Pierre Sommadossi filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 09/17/2015)
2015-09-17
1
NOTICE to Take Deposition of Second 30(b)(6) Notice of Centre National De La Recherche Scientifique on October 30, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Flanagan, Elizabeth) (Entered: 09/17/2015)
2015-09-17
1
NOTICE to Take Deposition of Second 30(b)(6) Notice of Centre National De La Recherche Scientifique on October 30, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Flanagan, Elizabeth) (Entered: 09/17/2015)
2015-09-17
1
NOTICE to Take Deposition of Second 30(b)(6) Notice of Idenix Pharmaceuticals, Inc. on October 30, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Flanagan, Elizabeth) (Entered: 09/17/2015)
2015-09-17
1
NOTICE to Take Deposition of Second 30(b)(6) Notice of Idenix Pharmaceuticals, Inc. on October 30, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Flanagan, Elizabeth) (Entered: 09/17/2015)
2015-09-17
1
NOTICE to Take Deposition of Second Notice of 30(b)(6) Deposition of Universita Degli Di Cagliari on October 30, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Flanagan, Elizabeth) (Entered: 09/17/2015)
2015-09-17
1
NOTICE to Take Deposition of Second Notice of 30(b)(6) Deposition of Universita Degli Di Cagliari on October 30, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Flanagan, Elizabeth) (Entered: 09/17/2015)
2015-09-17
1
NOTICE to Take Deposition of Second 30(b)(6) Deposition of L'Universite Montpellier II on October 30, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Flanagan, Elizabeth) (Entered: 09/17/2015)
2015-09-17
1
NOTICE to Take Deposition of Second 30(b)(6) Deposition of L'Universite Montpellier II on October 30, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Flanagan, Elizabeth) (Entered: 09/17/2015)
2015-09-17
1
NOTICE to Take Deposition of Bryce Roberts on September 25, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 09/21/2015)
2015-09-21
1
NOTICE to Take Deposition of Bryce Roberts on September 25, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 09/21/2015)
2015-09-21
1
NOTICE OF SERVICE of Idenix's Objections and Responses to Topics 1-13, 15-17, 20, 22, 26-28, 34-36, and 42 of Defendants' Notice of Deposition of Idenix Pharmaceuticals, Inc. Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 09/24/2015)
2015-09-24
1
NOTICE OF SERVICE of Idenix's Objections and Responses to Topics 1-13, 15-17, 20, 22, 26-28, 34-36, and 42 of Defendants' Notice of Deposition of Idenix Pharmaceuticals, Inc. Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 09/24/2015)
2015-09-24
1
NOTICE OF SERVICE of Defendants' Objections and Responses to Topics 30, and 32-36 of Plaintiffs' Notice of Rule 30(b)(6) Deposition of Gilead Sciences, Inc. and Gilead Pharmasset LLC filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 09/24/2015)
2015-09-24
1
NOTICE OF SERVICE of Defendants' Objections and Responses to Topics 30, and 32-36 of Plaintiffs' Notice of Rule 30(b)(6) Deposition of Gilead Sciences, Inc. and Gilead Pharmasset LLC filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 09/24/2015)
2015-09-24
1
NOTICE OF SERVICE of (i) UMII's Objections and Responses to Defendants' Notice of Deposition of L'Universite Montpellier II Pursuant to Fed. R. Civ. P. 30(b)(b) (ii) UMII's Objections and Responses to Topics 1-13, 15-17, 21, 25-27, and 33-35 of Defendants' Notice of Deposition of L'Universite Montpellier II Pursuant to Fed. R. Civ. P. 30(b)(6) (iii) CNRS's Objections and Responses to Defendants' Second Notice of Deposition of Centre National de la Recherche Scientifique Pursuant to Fed. R. Civ. P. 30(b)(6) (iv) CNRS's Objections and Responses to Topics 1-13, 15-17, 21, 25-27, and 33-35 of Defendants' Notice of Deposition of Centre National de la Recherche Scientifique Pursuant to Fed. R. Civ. P. 30(b)(6) (v) U. Caliari's Objections and Responses to Defendants' Second Notice of Deposition of Universita Degli Studi di Cagliari Pursuant to Fed. R. Civ. P. 30(b)(6) (vi) U. Caliari's Objections and Responses to Topics 1-13, 15-17, 21, 25-27, and 33-35 of Defendants' Notice of Deposition of Universita Degli Studi di Cagliari Pursuant to Fed. R. Civ. P. 30(b)(6) (vii) Idenix's Objections and Responses to Defendants' Second Notice of Deposition of Idenix Pharmaceuticals, Inc. Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Day, John) (Entered: 09/25/2015)
2015-09-25
1
NOTICE OF SERVICE of (i) UMII's Objections and Responses to Defendants' Notice of Deposition of L'Universite Montpellier II Pursuant to Fed. R. Civ. P. 30(b)(b) (ii) UMII's Objections and Responses to Topics 1-13, 15-17, 21, 25-27, and 33-35 of Defendants' Notice of Deposition of L'Universite Montpellier II Pursuant to Fed. R. Civ. P. 30(b)(6) (iii) CNRS's Objections and Responses to Defendants' Second Notice of Deposition of Centre National de la Recherche Scientifique Pursuant to Fed. R. Civ. P. 30(b)(6) (iv) CNRS's Objections and Responses to Topics 1-13, 15-17, 21, 25-27, and 33-35 of Defendants' Notice of Deposition of Centre National de la Recherche Scientifique Pursuant to Fed. R. Civ. P. 30(b)(6) (v) U. Caliari's Objections and Responses to Defendants' Second Notice of Deposition of Universita Degli Studi di Cagliari Pursuant to Fed. R. Civ. P. 30(b)(6) (vi) U. Caliari's Objections and Responses to Topics 1-13, 15-17, 21, 25-27, and 33-35 of Defendants' Notice of Deposition of Universita Degli Studi di Cagliari Pursuant to Fed. R. Civ. P. 30(b)(6) (vii) Idenix's Objections and Responses to Defendants' Second Notice of Deposition of Idenix Pharmaceuticals, Inc. Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Day, John) (Entered: 09/25/2015)
2015-09-25
1
NOTICE OF SERVICE of Plaintiffs' Supplemental Response to Interrogatory No. 7 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Day, John) (Entered: 09/25/2015)
2015-09-25
1
NOTICE OF SERVICE of Plaintiffs' Supplemental Response to Interrogatory No. 7 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Day, John) (Entered: 09/25/2015)
2015-09-25
1
NOTICE OF SERVICE of Plaintiffs' Supplemental Rule 26(a) Initial Disclosures filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 09/29/2015)
2015-09-29
1
NOTICE OF SERVICE of Plaintiffs' Supplemental Rule 26(a) Initial Disclosures filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 09/29/2015)
2015-09-29
1
NOTICE OF SERVICE of Defendants' Fourth Set of Interrogatories to Plaintiffs (Nos. 27-30) filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 09/29/2015)
2015-09-29
1
NOTICE OF SERVICE of Defendants' Fourth Set of Interrogatories to Plaintiffs (Nos. 27-30) filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 09/29/2015)
2015-09-29
1
NOTICE OF SERVICE of Subpoena to Testify at a Deposition directed to Michele Tausek; Subpoena to Produce Documents, Information, or Objects or to Permit Inspection of Premises in a Civil Action directed to Michele Tausek; Subpoena to Testify at a Deposition directed to Ronald C. Renaud, Jr.; and Subponea to Produce Documents, Information, or Objects or to Permit Inspection of Premises in a Civil Action directed to Ronald C. Renaud, Jr. filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 09/30/2015)
2015-09-30
1
NOTICE OF SERVICE of Subpoena to Testify at a Deposition directed to Michele Tausek; Subpoena to Produce Documents, Information, or Objects or to Permit Inspection of Premises in a Civil Action directed to Michele Tausek; Subpoena to Testify at a Deposition directed to Ronald C. Renaud, Jr.; and Subponea to Produce Documents, Information, or Objects or to Permit Inspection of Premises in a Civil Action directed to Ronald C. Renaud, Jr. filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 09/30/2015)
2015-09-30
1
NOTICE OF SERVICE of Defendants' Supplemental Responses to Interrogatory Nos. 1-3, 6, 9 and 10 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 10/02/2015)
2015-10-02
1
NOTICE OF SERVICE of Defendants' Supplemental Responses to Interrogatory Nos. 1-3, 6, 9 and 10 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 10/02/2015)
2015-10-02
1
NOTICE OF SERVICE of Defendants' Second Set of Requests to Plaintiffs For The Production of Documents and Things (Nos. 78-81) filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 10/05/2015)
2015-10-05
1
NOTICE OF SERVICE of Defendants' Second Set of Requests to Plaintiffs For The Production of Documents and Things (Nos. 78-81) filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 10/05/2015)
2015-10-05
1
NOTICE OF SERVICE of Notice of Service regarding subpoena for testimony and subpoena for document production directed to Alistair Stewart filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 10/06/2015)
2015-10-06
1
NOTICE OF SERVICE of Notice of Service regarding subpoena for testimony and subpoena for document production directed to Alistair Stewart filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 10/06/2015)
2015-10-06
1
NOTICE OF SERVICE of Notice of Service re subpoena for testimony and a subpoena for document production directed to Benjamin Mayes filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 10/06/2015)
2015-10-06
1
NOTICE OF SERVICE of Notice of Service re subpoena for testimony and a subpoena for document production directed to Benjamin Mayes filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 10/06/2015)
2015-10-06
1
NOTICE OF SERVICE of subpoenas for testimony and document production directed to Jingyang Wang filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 10/08/2015)
2015-10-08
1
NOTICE OF SERVICE of subpoenas for testimony and document production directed to Jingyang Wang filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 10/08/2015)
2015-10-08
1
NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants Third Set of Interrogatories to Plaintiffs (Nos. 22-27) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/08/2015)
2015-10-08
1
NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants Third Set of Interrogatories to Plaintiffs (Nos. 22-27) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/08/2015)
2015-10-08
1
Letter to The Honorable Leonard P. Stark from John G. Day regarding the request to schedule a discovery teleconference. (Day, John) (Entered: 10/13/2015)
2015-10-13
1
Letter to The Honorable Leonard P. Stark from John G. Day regarding the request to schedule a discovery teleconference. (Day, John) (Entered: 10/13/2015)
2015-10-13
1
NOTICE OF SERVICE of Ronald Renaud, Jr.'s Responses and Objections to Defendants' Subpoena to Produce Documents and Michele Tausek's Responses and Objections to Defendants' Subpoena to Produce Documents filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/14/2015)
2015-10-14
1
NOTICE OF SERVICE of Ronald Renaud, Jr.'s Responses and Objections to Defendants' Subpoena to Produce Documents and Michele Tausek's Responses and Objections to Defendants' Subpoena to Produce Documents filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/14/2015)
2015-10-14
1
NOTICE OF SERVICE of Notice of Subpoena filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/14/2015)
2015-10-14
1
NOTICE OF SERVICE of Notice of Subpoena filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/14/2015)
2015-10-14
1
NOTICE to Take Deposition of Richard Storer on November 10, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 10/15/2015)
2015-10-15
1
NOTICE to Take Deposition of Richard Storer on November 10, 2015 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 10/15/2015)
2015-10-15
1
Minute Entry for proceedings held before Judge Leonard P. Stark - Markman Hearing held on 10/19/2015. (Court Reporter B. Gaffigan.) Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00846-LPS-CJB (ntl)
2015-10-19
1
No Actions
Markman Hearing
2015-10-19
1
No Actions
MOTION for Issuance of Letters Rogatory - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Proposed Order)(Coutinho, Santosh) (Entered: 10/20/2015)
2015-10-20
1
MOTION for Issuance of Letters Rogatory - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Proposed Order)(Coutinho, Santosh) (Entered: 10/20/2015)
2015-10-20
1
NOTICE OF SERVICE of Alistair Stewart's Responses and Objections to Defendants' Subpoena to Produce Documents filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/20/2015)
2015-10-20
1
NOTICE OF SERVICE of Alistair Stewart's Responses and Objections to Defendants' Subpoena to Produce Documents filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/20/2015)
2015-10-20
1
NOTICE OF SERVICE of Jingyang Wang's Responses and Objections to Defendants' Subpoena to Produce Documents filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/22/2015)
2015-10-22
1
NOTICE OF SERVICE of Jingyang Wang's Responses and Objections to Defendants' Subpoena to Produce Documents filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/22/2015)
2015-10-22
1
NOTICE OF SERVICE of Notice of Subpoena filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/23/2015)
2015-10-23
1
NOTICE OF SERVICE of Notice of Subpoena filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/23/2015)
2015-10-23
1
SO ORDERED, re (194 in 1:13-cv-01987-LPS, 151 in 1:14-cv-00109-LPS, 186 in 1:14-cv-00846-LPS-CJB) MOTION for Issuance of Letters Rogatory filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Signed by Judge Leonard P. Stark on 10/23/15. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB (ntl)
2015-10-23
1
No Actions
SO ORDERED
2015-10-23
1
No Actions
ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a teleconference is scheduled for November 23, 2015 at 2:15 p.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than November 16, 2015, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than November 18, 2015, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 10/27/15. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB (ntl) (Entered: 10/27/2015)
2015-10-27
1
NOTICE OF SERVICE of Plaintiffs' Second Set of Interrogatories to Defendants filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/27/2015)
2015-10-27
1
NOTICE OF SERVICE of Plaintiffs' Second Set of Interrogatories to Defendants filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/27/2015)
2015-10-27
1
Order Setting Teleconference
2015-10-27
1
No Actions
NOTICE OF SERVICE of Defendants' Objections and Responses to Plaintiffs' Notice of Rule 30(b)(6) Deposition of Gilead Sciences, Inc. and Gilead Pharmasset LLC filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 10/28/2015)
2015-10-28
1
NOTICE OF SERVICE of Defendants' Objections and Responses to Plaintiffs' Notice of Rule 30(b)(6) Deposition of Gilead Sciences, Inc. and Gilead Pharmasset LLC filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 10/28/2015)
2015-10-28
1
Joint STIPULATION Regarding Access to Documents by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Coutinho, Santosh) (Entered: 10/28/2015)
2015-10-28
1
Joint STIPULATION Regarding Access to Documents by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Coutinho, Santosh) (Entered: 10/28/2015)
2015-10-28
1
NOTICE OF SERVICE of Notice of Subpoenas filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/30/2015)
2015-10-30
1
NOTICE OF SERVICE of Notice of Subpoenas filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/30/2015)
2015-10-30
1
NOTICE OF SERVICE of Plaintiffs' Second Notice of Rule 30(b)(6) Deposition of Defendants Gilead Sciences, Inc. and Gilead Pharmasset LLC filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/30/2015)
2015-10-30
1
NOTICE OF SERVICE of Plaintiffs' Second Notice of Rule 30(b)(6) Deposition of Defendants Gilead Sciences, Inc. and Gilead Pharmasset LLC filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/30/2015)
2015-10-30
1
SO ORDERED, re (201 in 1:13-cv-01987-LPS, 158 in 1:14-cv-00109-LPS, 193 in 1:14-cv-00846-LPS-CJB) Stipulation Regarding Access to Documents. Signed by Judge Leonard P. Stark on 10/30/15. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS-CJB (ntl)
2015-10-30
1
No Actions
SO ORDERED
2015-10-30
1
No Actions
NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' Fourth Set of Interrogatories to Plaintiffs (Nos. 27-30) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 11/02/2015)
2015-11-02
1
NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' Fourth Set of Interrogatories to Plaintiffs (Nos. 27-30) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 11/02/2015)
2015-11-02
1
NOTICE OF SERVICE of Subpoenas for Testimony and Subpoenas for Document Production Directed to (1) Dr. David Weingarten, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP; (2) Albany Molecular Research Inc.; and (3) Alexander Clemens filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 11/03/2015)
2015-11-03
1
NOTICE OF SERVICE of Subpoenas for Testimony and Subpoenas for Document Production Directed to (1) Dr. David Weingarten, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP; (2) Albany Molecular Research Inc.; and (3) Alexander Clemens filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 11/03/2015)
2015-11-03
1
NOTICE OF SERVICE of Subpoena for Testimony Directed to Jeremy Clark filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 11/03/2015)
2015-11-03
1
NOTICE OF SERVICE of Subpoena for Testimony Directed to Jeremy Clark filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 11/03/2015)
2015-11-03
1
NOTICE OF SERVICE of Defendants' Fifth Set of Interrogatories to Plaintiffs (Nos. 31-33) filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 11/03/2015)
2015-11-03
1
NOTICE OF SERVICE of Defendants' Fifth Set of Interrogatories to Plaintiffs (Nos. 31-33) filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 11/03/2015)
2015-11-03
1
NOTICE OF SERVICE of Subpoena to Produce Documents directed to Jeremy Clark filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 11/04/2015)
2015-11-04
1
NOTICE OF SERVICE of Subpoena to Produce Documents directed to Jeremy Clark filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 11/04/2015)
2015-11-04
1
NOTICE OF SERVICE of Defendants' Requests For Admissions (Nos. 1-72) filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 11/04/2015)
2015-11-04
1
NOTICE OF SERVICE of Defendants' Requests For Admissions (Nos. 1-72) filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 11/04/2015)
2015-11-04
1
NOTICE OF SERVICE of U. Cagliari's Objections and Responses to Topic 39 of Defendants' Notice of Deposition of Universita Degli Studi Di Cagliari Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 11/04/2015)
2015-11-04
1
NOTICE OF SERVICE of U. Cagliari's Objections and Responses to Topic 39 of Defendants' Notice of Deposition of Universita Degli Studi Di Cagliari Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 11/04/2015)
2015-11-04
1
NOTICE OF SERVICE of Plaintiffs' First Set of Requests for Admission to Defendants filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 11/05/2015)
2015-11-05
1
NOTICE OF SERVICE of Plaintiffs' First Set of Requests for Admission to Defendants filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 11/05/2015)
2015-11-05
1
NOTICE OF SERVICE of Subpoena for Testimony directed to Merck & Co., Inc. filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 11/05/2015)
2015-11-05
1
NOTICE OF SERVICE of Subpoena for Testimony directed to Merck & Co., Inc. filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 11/05/2015)
2015-11-05
1
NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' Second Set of Requests to Plaintiffs for the Production of Documents and Things (Nos. 78-81) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 11/09/2015)
2015-11-09
1
NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' Second Set of Requests to Plaintiffs for the Production of Documents and Things (Nos. 78-81) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 11/09/2015)
2015-11-09
1
NOTICE OF SERVICE of Subpoenas for Testimony and Document Production directed to Andrea Corcoran filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 11/10/2015)
2015-11-10
1
NOTICE OF SERVICE of Subpoenas for Testimony and Document Production directed to Andrea Corcoran filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 11/10/2015)
2015-11-10
1
NOTICE OF SERVICE of Subpoena for Testimony and Subpoena for Document Production directed to Benjamin Mayes filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 11/10/2015)
2015-11-10
1
NOTICE OF SERVICE of Subpoena for Testimony and Subpoena for Document Production directed to Benjamin Mayes filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 11/10/2015)
2015-11-10
1
NOTICE to Take Deposition of James Meyers on November 11, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 11/10/2015)
2015-11-10
1
NOTICE to Take Deposition of James Meyers on November 11, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 11/10/2015)
2015-11-10
1
NOTICE OF SERVICE of Idenix's Objections and Responses to Topics 14, 21, 23-25, 29-33, and 38-41 of Defendants' Notice of Deposition of Idenix Pharmaceuticals, Inc. Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Idenix Pharmaceuticals Inc..(Mayo, Andrew) (Entered: 11/13/2015)
2015-11-13
1
NOTICE OF SERVICE of Idenix's Objections and Responses to Topics 14, 21, 23-25, 29-33, and 38-41 of Defendants' Notice of Deposition of Idenix Pharmaceuticals, Inc. Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Idenix Pharmaceuticals Inc..(Mayo, Andrew) (Entered: 11/13/2015)
2015-11-13
1
NOTICE to Take Deposition of Michael Sofia on November 19, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 11/16/2015)
2015-11-16
1
NOTICE to Take Deposition of Michael Sofia on November 19, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 11/16/2015)
2015-11-16
1
NOTICE to Take Deposition of Robin L. Washington on December 7, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 11/16/2015)
2015-11-16
1
NOTICE to Take Deposition of Robin L. Washington on December 7, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 11/16/2015)
2015-11-16
1
NOTICE OF SERVICE of (1) CNRS's Objections and Responses to Topics 14, 20, 22-24, 28-32, and 36-38 of Defendants' Notice of Deposition of Centre National De La Recherche Scientifique Pursuant to Fed. R. Civ. P. 30(b)(6); (2) UMII's Objections and Responses to Topics 14, 20, 22-24, 28-32, and 36-38 of Defendants' Notice of Deposition Of LUniversite Montpellier Ii Pursuant to Fed. R. Civ. P. 30(b)(6); and (3) U. Cagliari's Objections and Responses to Topics 14, 20, 22-24, 28-32, and 36-38 Of Defendants' Notice of Deposition of Universita Degli Studi Di Cagliari Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Centre National de la Recherche Scientifique, L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 11/16/2015)
2015-11-16
1
NOTICE OF SERVICE of (1) CNRS's Objections and Responses to Topics 14, 20, 22-24, 28-32, and 36-38 of Defendants' Notice of Deposition of Centre National De La Recherche Scientifique Pursuant to Fed. R. Civ. P. 30(b)(6); (2) UMII's Objections and Responses to Topics 14, 20, 22-24, 28-32, and 36-38 of Defendants' Notice of Deposition Of LUniversite Montpellier Ii Pursuant to Fed. R. Civ. P. 30(b)(6); and (3) U. Cagliari's Objections and Responses to Topics 14, 20, 22-24, 28-32, and 36-38 Of Defendants' Notice of Deposition of Universita Degli Studi Di Cagliari Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Centre National de la Recherche Scientifique, L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 11/16/2015)
2015-11-16
1
[SEALED] Letter to The Honorable Chief Judge Leonard P. Stark from Andrew C. Mayo regarding request that the Court deny Defendants' request to claw back previously produced email. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13 (Part I of II), # 14 Exhibit 13 (Part II of II))(Mayo, Andrew) (Entered: 11/16/2015)
2015-11-16
1
[SEALED] Letter to The Honorable Chief Judge Leonard P. Stark from Andrew C. Mayo regarding request that the Court deny Defendants' request to claw back previously produced email. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13 (Part I of II), # 14 Exhibit 13 (Part II of II))(Mayo, Andrew) (Entered: 11/16/2015)
2015-11-16
1
[SEALED] Letter to The Hon. Leonard P. Stark from Martina Tyreus Hufnal, counsel for Defendants regarding Response to Plaintiffs' Letter Regarding Request to Claw Back Previously Produced E-Mail - re (213 in 1:14-cv-00846-LPS-CJB) Letter,. (Attachments: # 1 Exhibit A, # 2 Attachment 1, # 3 Attachment 2, # 4 Attachment 3, # 5 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 11/18/2015)
2015-11-18
1
[SEALED] Letter to The Hon. Leonard P. Stark from Martina Tyreus Hufnal, counsel for Defendants regarding Response to Plaintiffs' Letter Regarding Request to Claw Back Previously Produced E-Mail - re (213 in 1:14-cv-00846-LPS-CJB) Letter,. (Attachments: # 1 Exhibit A, # 2 Attachment 1, # 3 Attachment 2, # 4 Attachment 3, # 5 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 11/18/2015)
2015-11-18
1
Jeremy L. Clark's Objections and Responses to Gilead Subpoena from Jeremy L. Clark the filing was missing several pages- re 200 Notice of Service, 208 Notice of Service, 165 Notice of Service, -filed by Idenix Pharmaceuticals Inc..(aah) (Entered: 11/19/2015)
2015-11-18
1
Official Transcript of Claim Construction Hearing held on October 19, 2015 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 12/11/2015. Redacted Transcript Deadline set for 12/21/2015. Release of Transcript Restriction set for 2/18/2016. (bpg) (Entered: 11/20/2015)
2015-11-20
1
Minute Entry for proceedings held before Judge Leonard P. Stark - Discovery Teleconference held on 11/23/2015. (Court Reporter B. Gaffigan.) Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl)
2015-11-23
1
No Actions
REDACTED VERSION of (178 in 1:14-cv-00109-LPS, 221 in 1:13-cv-01987-LPS, 213 in 1:14-cv-00846-LPS) Letter, by Idenix Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1-12, # 2 Exhibit 13 part 1, # 3 Exhibit 13 part 2)(Mayo, Andrew) (Entered: 11/24/2015)
2015-11-24
1
REDACTED VERSION of (178 in 1:14-cv-00109-LPS, 221 in 1:13-cv-01987-LPS, 213 in 1:14-cv-00846-LPS) Letter, by Idenix Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1-12, # 2 Exhibit 13 part 1, # 3 Exhibit 13 part 2)(Mayo, Andrew) (Entered: 11/24/2015)
2015-11-24
1
NOTICE to Take Deposition of John McHutchison on December 1, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 11/24/2015)
2015-11-24
1
NOTICE to Take Deposition of John McHutchison on December 1, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 11/24/2015)
2015-11-24
1
NOTICE OF SERVICE of Andrea Corcoran's Responses and Objections to Defendants' Subpoena to Produce Documents and Benjamin Mayes' Responses and Objections to Defendants' Subpoena to Produce Documents filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 11/24/2015)
2015-11-24
1
NOTICE OF SERVICE of Andrea Corcoran's Responses and Objections to Defendants' Subpoena to Produce Documents and Benjamin Mayes' Responses and Objections to Defendants' Subpoena to Produce Documents filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 11/24/2015)
2015-11-24
1
Discovery Conference
2015-11-24
1
No Actions
REDACTED VERSION of (214 in 1:14-cv-00846-LPS, 179 in 1:14-cv-00109-LPS, 222 in 1:13-cv-01987-LPS) Letter, to Hon. Chief Judge Leonard P. Stark in Response to Plaintiffs' Letter Regarding Request to Claw Back Previously Produced E-Mail by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A - REDACTED, # 2 Attachment 1, # 3 Attachment 2, # 4 Attachment 3)(Coutinho, Santosh) (Entered: 11/25/2015)
2015-11-25
1
REDACTED VERSION of (214 in 1:14-cv-00846-LPS, 179 in 1:14-cv-00109-LPS, 222 in 1:13-cv-01987-LPS) Letter, to Hon. Chief Judge Leonard P. Stark in Response to Plaintiffs' Letter Regarding Request to Claw Back Previously Produced E-Mail by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A - REDACTED, # 2 Attachment 1, # 3 Attachment 2, # 4 Attachment 3)(Coutinho, Santosh) (Entered: 11/25/2015)
2015-11-25
1
NOTICE OF SERVICE of Notice of Service of Second Subpoena to Testify at a Deposition directed to Merck & Company, Inc. filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Flanagan, Elizabeth) (Entered: 11/25/2015)
2015-11-25
1
NOTICE OF SERVICE of Notice of Service of Second Subpoena to Testify at a Deposition directed to Merck & Company, Inc. filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Flanagan, Elizabeth) (Entered: 11/25/2015)
2015-11-25
1
Letter to the Hon. Leonard P. Stark from Martina Tyreus Hufnal regarding request for scheduling of a discovery teleconference. (Hufnal, AnnaMartina) (Entered: 11/30/2015)
2015-11-30
1
Letter to the Hon. Leonard P. Stark from Martina Tyreus Hufnal regarding request for scheduling of a discovery teleconference. (Hufnal, AnnaMartina) (Entered: 11/30/2015)
2015-11-30
1
NOTICE OF SERVICE of Defendants' Objections and Responses to Plaintiffs' Second Notice of Rule 30(b)(6) Deposition of Defendants Gilead Sciences, Inc. and Gilead Pharmasset LLC filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 12/01/2015)
2015-12-01
1
NOTICE OF SERVICE of Defendants' Objections and Responses to Plaintiffs' Second Notice of Rule 30(b)(6) Deposition of Defendants Gilead Sciences, Inc. and Gilead Pharmasset LLC filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 12/01/2015)
2015-12-01
1
NOTICE to Take Deposition of Brian Sander on December 3, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Day, John) (Entered: 12/02/2015)
2015-12-02
1
NOTICE to Take Deposition of Brian Sander on December 3, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Day, John) (Entered: 12/02/2015)
2015-12-02
1
NOTICE OF SERVICE of Fox Chase Cancer Center's Responses and Objections to Plaintiffs' Subpoena to Produce Documents, Information, or Objects in a Civil Action and Dr. Christoph Seeger's Responses and Objections to Plaintiffs' Subpoena to Produce Documents, Information, or Objects in a Civil Action filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 12/04/2015)
2015-12-04
1
NOTICE OF SERVICE of Fox Chase Cancer Center's Responses and Objections to Plaintiffs' Subpoena to Produce Documents, Information, or Objects in a Civil Action and Dr. Christoph Seeger's Responses and Objections to Plaintiffs' Subpoena to Produce Documents, Information, or Objects in a Civil Action filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 12/04/2015)
2015-12-04
1
Letter to The Honorable Chief Judge Leonard P. Stark from John G. Day regarding request the scheduling of a discovery teleconference. (Day, John) (Entered: 12/07/2015)
2015-12-07
1
Letter to The Honorable Chief Judge Leonard P. Stark from John G. Day regarding request the scheduling of a discovery teleconference. (Day, John) (Entered: 12/07/2015)
2015-12-07
1
NOTICE OF SERVICE of 1) Plaintiffs' Objections and Responses to Defendants' Fifth Set of Interrogatories; 2) Plaintiffs' Supplemental Responses to Interrogatories 27-30; 3) Plaintiffs' Supplemental Responses to Interrogatory No. 22; 4) Plaintiffs' Supplemental Responses to Interrogatories 5, 7, and 8; and 5) Plaintiffs' Supplemental Responses to Interrogatories 13-15, and 18-21) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 12/07/2015)
2015-12-07
1
NOTICE OF SERVICE of 1) Plaintiffs' Objections and Responses to Defendants' Fifth Set of Interrogatories; 2) Plaintiffs' Supplemental Responses to Interrogatories 27-30; 3) Plaintiffs' Supplemental Responses to Interrogatory No. 22; 4) Plaintiffs' Supplemental Responses to Interrogatories 5, 7, and 8; and 5) Plaintiffs' Supplemental Responses to Interrogatories 13-15, and 18-21) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 12/07/2015)
2015-12-07
1
NOTICE to Take Deposition of Schaefer Price on December 9, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 12/07/2015)
2015-12-07
1
NOTICE to Take Deposition of Schaefer Price on December 9, 2015 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 12/07/2015)
2015-12-07
1
NOTICE OF SERVICE of Defendants' Responses to Plaintiffs' Second Set of Interrogatories and Defendants' Response to Plaintiffs' First Set of Requests For Admission (Nos. 1-73) filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Flanagan, Elizabeth) (Entered: 12/08/2015)
2015-12-08
1
NOTICE OF SERVICE of Defendants' Responses to Plaintiffs' Second Set of Interrogatories and Defendants' Response to Plaintiffs' First Set of Requests For Admission (Nos. 1-73) filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Flanagan, Elizabeth) (Entered: 12/08/2015)
2015-12-08
1
NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' Requests for Admissions (Nos. 1-72) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 12/08/2015)
2015-12-08
1
NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' Requests for Admissions (Nos. 1-72) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 12/08/2015)
2015-12-08
1
ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter (See D.I. 230, 234), IT IS HEREBY ORDERED that a teleconference is scheduled for December 17, 2015 at 10:00 a.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than December 11, 2015, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than December 15, 2015, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 12/9/15. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl) (Entered: 12/09/2015)
2015-12-09
1
Order Setting Teleconference
2015-12-09
1
No Actions
Letter to The Honorable Leonard P. Stark from Santosh V. Coutinho regarding Request to Schedule Discovery Teleconference. (Coutinho, Santosh) (Entered: 12/11/2015)
2015-12-11
1
Letter to The Honorable Leonard P. Stark from Santosh V. Coutinho regarding Request to Schedule Discovery Teleconference. (Coutinho, Santosh) (Entered: 12/11/2015)
2015-12-11
1
[SEALED] Letter to The Honorable Chief Judge Leonard P. Stark from John G. Day regarding Idenix's opening lettter for December 17th discovery dispute teleconference. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K)(Day, John) (Entered: 12/11/2015)
2015-12-11
1
[SEALED] Letter to The Honorable Chief Judge Leonard P. Stark from John G. Day regarding Idenix's opening lettter for December 17th discovery dispute teleconference. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K)(Day, John) (Entered: 12/11/2015)
2015-12-11
1
NOTICE of filing the following Non-Paper material(s) in multi media format: Sealed Exhibits A and B to D.I 241 in C.A. No. 13-1987-LPS, D.I. 198 in C.A. No. 14-109-LPS, and D.I. 231 in C.A. No. 14-846-LPS. Original Non-paper material(s) to be filed with the Clerk's Office. Notice filed by John G. Day on behalf of Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari (Day, John) (Entered: 12/11/2015)
2015-12-11
1
NOTICE of filing the following Non-Paper material(s) in multi media format: Sealed Exhibits A and B to D.I 241 in C.A. No. 13-1987-LPS, D.I. 198 in C.A. No. 14-109-LPS, and D.I. 231 in C.A. No. 14-846-LPS. Original Non-paper material(s) to be filed with the Clerk's Office. Notice filed by John G. Day on behalf of Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari (Day, John) (Entered: 12/11/2015)
2015-12-11
1
[SEALED] Letter to The Honorable Leonard P. Stark from Martina Tyreus Hufnal regarding request to compel Plaintiffs to make witness available for deposition. (Attachments: # 1 Exhibits 1-5, # 2 Exhibits 6-10, # 3 Exhibits 11-15, # 4 Exhibits 16-19)(Hufnal, AnnaMartina) (Entered: 12/11/2015)
2015-12-11
1
[SEALED] Letter to The Honorable Leonard P. Stark from Martina Tyreus Hufnal regarding request to compel Plaintiffs to make witness available for deposition. (Attachments: # 1 Exhibits 1-5, # 2 Exhibits 6-10, # 3 Exhibits 11-15, # 4 Exhibits 16-19)(Hufnal, AnnaMartina) (Entered: 12/11/2015)
2015-12-11
1
[SEALED] MULTI MEDIA DOCUMENT filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari in the form of a CD-ROM. Filing related to 242 Notice of Filing Multi Media Materials. (Media on file in Clerk's Office). (ntl) (Entered: 12/14/2015)
2015-12-14
1
Multi Media Document
2015-12-14
1
No Actions
[SEALED] Official Transcript of Telephone Conference held on November 23, 2015 before Chief Judge Leonard P. Stark. (bpg) (Entered: 12/15/2015)
2015-12-15
1
[SEALED] Official Transcript of Telephone Conference held on November 23, 2015 before Chief Judge Leonard P. Stark. (bpg) (Entered: 12/15/2015)
2015-12-15
1
[SEALED] Letter to The Honorable Leonard P. Stark from John G. Day regarding Plaintiffs' request that the Court deny Defendants' letter application asking to compel the deposition of Dr. Griffon. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4)(Day, John) (Entered: 12/15/2015)
2015-12-15
1
[SEALED] Letter to The Honorable Leonard P. Stark from John G. Day regarding Plaintiffs' request that the Court deny Defendants' letter application asking to compel the deposition of Dr. Griffon. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4)(Day, John) (Entered: 12/15/2015)
2015-12-15
1
[SEALED] Letter to The Hon. Leonard P. Stark from Martina Tyreus Hufnal regarding Discovery Dispute - re (231 in 1:14-cv-00846-LPS) Letter,. (Attachments: # 1 SEALED Exhibits A-J)(Hufnal, AnnaMartina) (Entered: 12/15/2015)
2015-12-15
1
[SEALED] Letter to The Hon. Leonard P. Stark from Martina Tyreus Hufnal regarding Discovery Dispute - re (231 in 1:14-cv-00846-LPS) Letter,. (Attachments: # 1 SEALED Exhibits A-J)(Hufnal, AnnaMartina) (Entered: 12/15/2015)
2015-12-15
1
MEMORANDUM OPINION re claim construction. Signed by Judge Leonard P. Stark on 12/16/15. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl)
2015-12-16
1
MEMORANDUM OPINION re claim construction. Signed by Judge Leonard P. Stark on 12/16/15. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl)
2015-12-16
1
ORDER re (204 in 1:14-cv-00109-LPS, 248 in 1:13-cv-01987-LPS, 237 in 1:14-cv-00846-LPS) Memorandum Opinion re claim construction. Signed by Judge Leonard P. Stark on 12/16/15. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl) (Entered: 12/16/2015)
2015-12-16
1
ORDER re (204 in 1:14-cv-00109-LPS, 248 in 1:13-cv-01987-LPS, 237 in 1:14-cv-00846-LPS) Memorandum Opinion re claim construction. Signed by Judge Leonard P. Stark on 12/16/15. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl) (Entered: 12/16/2015)
2015-12-16
1
ORAL ORDER: IT IS HEREBY ORDERED that the discovery teleconference scheduled for today will begin at 10:15 a.m. ORDERED by Judge Leonard P. Stark on 12/17/15. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl) (Entered: 12/17/2015)
2015-12-17
1
Oral Order
2015-12-17
1
No Actions
Discovery Conference
2015-12-17
1
No Actions
REDACTED VERSION of (231 in 1:14-cv-00846-LPS, 241 in 1:13-cv-01987-LPS, 198 in 1:14-cv-00109-LPS) Letter, by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A-K)(Mayo, Andrew) (Entered: 12/18/2015)
2015-12-18
1
REDACTED VERSION of (231 in 1:14-cv-00846-LPS, 241 in 1:13-cv-01987-LPS, 198 in 1:14-cv-00109-LPS) Letter, by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A-K)(Mayo, Andrew) (Entered: 12/18/2015)
2015-12-18
1
REDACTED VERSION of (233 in 1:14-cv-00846-LPS) Letter, to the Honorable Leonard P. Stark by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibits 1-5, # 2 Exhibits 6-10, # 3 Exhibits 11-15, # 4 REDACTED Exhibits 16-19)(Coutinho, Santosh) (Entered: 12/21/2015)
2015-12-21
1
REDACTED VERSION of (233 in 1:14-cv-00846-LPS) Letter, to the Honorable Leonard P. Stark by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibits 1-5, # 2 Exhibits 6-10, # 3 Exhibits 11-15, # 4 REDACTED Exhibits 16-19)(Coutinho, Santosh) (Entered: 12/21/2015)
2015-12-21
1
REDACTED VERSION of (235 in 1:14-cv-00846-LPS, 246 in 1:13-cv-01987-LPS, 202 in 1:14-cv-00109-LPS) Letter, by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4)(Mayo, Andrew) (Entered: 12/22/2015)
2015-12-22
1
REDACTED VERSION of (235 in 1:14-cv-00846-LPS, 246 in 1:13-cv-01987-LPS, 202 in 1:14-cv-00109-LPS) Letter, by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4)(Mayo, Andrew) (Entered: 12/22/2015)
2015-12-22
1
REDACTED VERSION of (236 in 1:14-cv-00846-LPS) Letter by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Redacted Exhibits A-J)(Coutinho, Santosh) (Entered: 12/30/2015)
2015-12-30
1
REDACTED VERSION of (236 in 1:14-cv-00846-LPS) Letter by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Redacted Exhibits A-J)(Coutinho, Santosh) (Entered: 12/30/2015)
2015-12-30
1
ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a teleconference is scheduled for January 28, 2016 at 12:00 p.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than January 19, 2016, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than January 21, 2016, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 1/6/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl) (Entered: 01/06/2016)
2016-01-06
1
Order Setting Teleconference
2016-01-06
1
No Actions
[SEALED] Official Transcript of Telephone Conference held on December 17, 2015 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone # 302 573-6360. (bpg) Modified on 4/8/2016 (ntl). (Entered: 01/08/2016)
2016-01-08
1
[SEALED] Official Transcript of Telephone Conference held on December 17, 2015 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone # 302 573-6360. (bpg) Modified on 4/8/2016 (ntl). (Entered: 01/08/2016)
2016-01-08
1
MOTION for Pro Hac Vice Appearance of Attorney Alicia A. Russo and Anthony M. Zupic - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 01/15/2016)
2016-01-15
1
MOTION for Pro Hac Vice Appearance of Attorney Alicia A. Russo and Anthony M. Zupic - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 01/15/2016)
2016-01-15
1
Letter to The Honorable Leonard P. Stark from Jeremy D. Anderson regarding discovery dispute - re (244 in 1:14-cv-00846-LPS) Order Setting Teleconference,,,,. (Attachments: # 1 Exhibit A)(Anderson, Jeremy) (Entered: 01/19/2016)
2016-01-19
1
Letter to The Honorable Leonard P. Stark from Jeremy D. Anderson regarding discovery dispute - re (244 in 1:14-cv-00846-LPS) Order Setting Teleconference,,,,. (Attachments: # 1 Exhibit A)(Anderson, Jeremy) (Entered: 01/19/2016)
2016-01-19
1
SO ORDERED
2016-01-19
1
No Actions
Add Attorneys - PHV only
2016-01-20
1
No Actions
Letter to The Honorable Chief Judge Leonard P. Stark from Andrew C. Mayo regarding response to Gilead's January 19, 2016 letter - re (247 in 1:14-cv-00846-LPS, 258 in 1:13-cv-01987-LPS, 214 in 1:14-cv-00109-LPS) Letter. (Attachments: # 1 Exhibit A-E)(Mayo, Andrew) (Entered: 01/21/2016)
2016-01-21
1
Letter to The Honorable Chief Judge Leonard P. Stark from Andrew C. Mayo regarding response to Gilead's January 19, 2016 letter - re (247 in 1:14-cv-00846-LPS, 258 in 1:13-cv-01987-LPS, 214 in 1:14-cv-00109-LPS) Letter. (Attachments: # 1 Exhibit A-E)(Mayo, Andrew) (Entered: 01/21/2016)
2016-01-21
1
Letter to The Honorable Chief Judge Leonard P. Stark from Andrew C. Mayo regarding response to Gilead's January 19, 2016 letter - re (247 in 1:14-cv-00846-LPS, 258 in 1:13-cv-01987-LPS, 214 in 1:14-cv-00109-LPS) Letter. (Attachments: # 1 Exhibit A-E)(Mayo, Andrew) (Entered: 01/21/2016)
2016-01-21
2
Joint STIPULATION TO EXTEND TIME to serve Expert Reports to to February 2, 2016 for Opening Expert Reports; to March 22, 2016 for Supplemental Expert Reports; and to April 22, 2016 for Reply Expert Reports - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Flanagan, Elizabeth) (Entered: 01/26/2016)
2016-01-26
1
Joint STIPULATION TO EXTEND TIME to serve Expert Reports to to February 2, 2016 for Opening Expert Reports; to March 22, 2016 for Supplemental Expert Reports; and to April 22, 2016 for Reply Expert Reports - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Flanagan, Elizabeth) (Entered: 01/26/2016)
2016-01-26
1
SO ORDERED, re (249 in 1:14-cv-00846-LPS, 260 in 1:13-cv-01987-LPS, 216 in 1:14-cv-00109-LPS) Joint STIPULATION TO EXTEND TIME to serve Expert Reports to to February 2, 2016 for Opening Expert Reports; to March 22, 2016 for Supplemental Expert Reports; and to April 22, 2016 for Reply Expert Reports filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Signed by Judge Leonard P. Stark on 1/27/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl)
2016-01-28
1
No Actions
Discovery Conference
2016-01-28
1
No Actions
SO ORDERED
2016-01-28
1
No Actions
STIPULATION to Seal December 17, 2015 Transcript by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Mayo, Andrew) (Entered: 01/29/2016)
2016-01-29
1
STIPULATION to Seal December 17, 2015 Transcript by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Mayo, Andrew) (Entered: 01/29/2016)
2016-01-29
1
NOTICE OF SERVICE of (i) Expert Report of Masad J. Damha, Ph.D.; (ii) Expert Report of Andrew W. Carter; (iii) Expert Report of Dr. Jeffrey S. Glenn Regarding Indirect Infringement of U.S. Patent Nos. 6,914,054 and 7,608,597; (iv) Expert Report of Dr. Jeffrey S. Glenn Regarding Indirect Infringement of U.S. Patent No. 7,608,600; (v) Expert Report of Professor Chris Meier Regarding Infringement of U.S. Patent Nos. 6,914,054 and 7,608,597; and (vi) Expert Report of Professor Chris Meier Regarding Infringement of U.S. Patent No. 7,608,600 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 02/02/2016)
2016-02-02
1
NOTICE OF SERVICE of (i) Expert Report of Masad J. Damha, Ph.D.; (ii) Expert Report of Andrew W. Carter; (iii) Expert Report of Dr. Jeffrey S. Glenn Regarding Indirect Infringement of U.S. Patent Nos. 6,914,054 and 7,608,597; (iv) Expert Report of Dr. Jeffrey S. Glenn Regarding Indirect Infringement of U.S. Patent No. 7,608,600; (v) Expert Report of Professor Chris Meier Regarding Infringement of U.S. Patent Nos. 6,914,054 and 7,608,597; and (vi) Expert Report of Professor Chris Meier Regarding Infringement of U.S. Patent No. 7,608,600 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 02/02/2016)
2016-02-02
1
NOTICE OF SERVICE of (1) Opening Expert Report of John A. Secrist III, Ph.D, with Exhibits A-F - marked Highly Confidential; (2) Opening Expert Report of Christoph Seeger, Ph.D, with Exhibits A-D - marked Highly Confidential; and (3) Opening Expert Report of Dr. Valentino Stella, with Exhibits A-C - marked Confidential filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Flanagan, Elizabeth) (Entered: 02/03/2016)
2016-02-03
1
NOTICE OF SERVICE of (1) Opening Expert Report of John A. Secrist III, Ph.D, with Exhibits A-F - marked Highly Confidential; (2) Opening Expert Report of Christoph Seeger, Ph.D, with Exhibits A-D - marked Highly Confidential; and (3) Opening Expert Report of Dr. Valentino Stella, with Exhibits A-C - marked Confidential filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Flanagan, Elizabeth) (Entered: 02/03/2016)
2016-02-03
1
ORAL ORDER: Having reviewed the parties' Stipulation to Seal December 17, 2015 Transcript (D.I. 261), IT IS HEREBY ORDERED that the parties' request to seal the entirety of the transcript is DENIED. Should the parties continue to request sealing, they must file a motion to that effect, identifying the specific, limited portions they continue to believe warrant sealing, and the basis therefor. ORDERED by Judge Leonard P. Stark on 2/8/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl) (Entered: 02/08/2016)
2016-02-08
1
Oral Order
2016-02-08
1
No Actions
Letter to The Honorable Chief Judge Leonard P. Stark from John G. Day regarding request for discovery dispute teleconference. (Day, John) (Entered: 02/12/2016)
2016-02-12
1
Letter to The Honorable Chief Judge Leonard P. Stark from John G. Day regarding request for discovery dispute teleconference. (Day, John) (Entered: 02/12/2016)
2016-02-12
1
ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a teleconference is scheduled for March 4, 2016 at 2:45 p.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than February 25, 2016, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than February 29, 2016, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 2/23/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl) (Entered: 02/23/2016)
2016-02-23
1
Order Setting Teleconference
2016-02-23
1
No Actions
Official Transcript of Telephone Conference held on January 28, 2016 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 3/16/2016. Redacted Transcript Deadline set for 3/28/2016. Release of Transcript Restriction set for 5/24/2016. (bpg) (Entered: 02/24/2016)
2016-02-24
1
Official Transcript of Telephone Conference held on January 28, 2016 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 3/16/2016. Redacted Transcript Deadline set for 3/28/2016. Release of Transcript Restriction set for 5/24/2016. (bpg) (Entered: 02/24/2016)
2016-02-24
1
NOTICE to Take Deposition of Lieven Stuyver on February 29, 2016 and March 1, 2016 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 02/25/2016)
2016-02-25
1
NOTICE to Take Deposition of Lieven Stuyver on February 29, 2016 and March 1, 2016 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 02/25/2016)
2016-02-25
1
[SEALED] Letter to The Honorable Leonard P. Stark from Andrew C. Mayo regarding March 4, 2016 discovery dispute teleconference. (Attachments: # 1 Exhibit 1-12)(Mayo, Andrew) (Entered: 02/25/2016)
2016-02-25
1
[SEALED] Letter to The Honorable Leonard P. Stark from Andrew C. Mayo regarding March 4, 2016 discovery dispute teleconference. (Attachments: # 1 Exhibit 1-12)(Mayo, Andrew) (Entered: 02/25/2016)
2016-02-25
1
[SEALED] Letter to The Honorable Leonard P. Stark from Martina Tyreus Hufnal regarding Discovery Dispute - re (255 in 1:14-cv-00846-LPS) Order Setting Teleconference,,,, (258 in 1:14-cv-00846-LPS) Letter. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 02/29/2016)
2016-02-29
1
[SEALED] Letter to The Honorable Leonard P. Stark from Martina Tyreus Hufnal regarding Discovery Dispute - re (255 in 1:14-cv-00846-LPS) Order Setting Teleconference,,,, (258 in 1:14-cv-00846-LPS) Letter. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 02/29/2016)
2016-02-29
1
REDACTED VERSION of (225 in 1:14-cv-00109-LPS, 269 in 1:13-cv-01987-LPS, 258 in 1:14-cv-00846-LPS) Letter by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1-12)(Mayo, Andrew) (Entered: 03/03/2016)
2016-03-03
1
Minute Entry for proceedings held before Judge Leonard P. Stark - Discovery Teleconference held on 3/4/2016. (Court Reporter B. Gaffigan.) Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl)
2016-03-04
1
No Actions
Discovery Conference
2016-03-04
1
No Actions
REDACTED VERSION of (259 in 1:14-cv-00846-LPS, 226 in 1:14-cv-00109-LPS, 270 in 1:13-cv-01987-LPS) Letter, to the Honorable Leonard P. Stark by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A)(Coutinho, Santosh) (Entered: 03/16/2016)
2016-03-16
1
STIPULATION TO EXTEND TIME Expert Report Deadlines to Rebuttal Expert Reports extended to March 29, 2016, Reply Expert Reports extended to April 29, 2016, and Close of Expert Discovery extended to May 27, 2016 - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 03/17/2016)
2016-03-17
1
Official Transcript of Telephone Conference held on March 4, 2016 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/7/2016. Redacted Transcript Deadline set for 4/18/2016. Release of Transcript Restriction set for 6/15/2016.(bpg) (Entered: 03/17/2016)
2016-03-17
1
SO ORDERED, re (229 in 1:14-cv-00109-LPS, 273 in 1:13-cv-01987-LPS, 262 in 1:14-cv-00846-LPS) STIPULATION TO EXTEND TIME Expert Report Deadlines to Rebuttal Expert Reports extended to March 29, 2016, Reply Expert Reports extended to April 29, 2016, and Close of Expert Discovery extended to May 27, 2016 filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Signed by Judge Leonard P. Stark on 3/18/2016. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS(rpg)
2016-03-18
1
No Actions
SO ORDERED
2016-03-18
1
No Actions
STIPULATION TO EXTEND TIME to Amend Expert Report Deadlines to Defendants' Rebuttal Damages Expert Report extended to April 5, 2016 and Plaintiffs' Reply Damages Expert Report extended to May 6, 2016 - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 03/29/2016)
2016-03-29
1
NOTICE OF SERVICE of CONFIDENTIAL Expert Report of John McHutchison, M.D., with Exhibits A-B; HIGHLY CONFIDENTIAL Rebuttal Expert Report of John A. Secrist, III, Ph.D., with Exhibit A; HIGHLY CONFIDENTIAL Rebuttal Expert Report of Christoph Seeger, Ph.D, with Exhibit A; and Rebuttal Expert Report of Dr. Valentino Stella with Exhibit A filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 03/30/2016)
2016-03-30
1
NOTICE OF SERVICE of (1) Expert Rebuttal Report of Professor Anthony G.M. Barrett; (2) Rebuttal Expert Report of Robert S. Langer, Sc.D. on Validity of United States Patent No. 7,608,600; (3) Rebuttal Expert Report of Dr. Raffaele De Francesco; and (4) Rebuttal Expert Report of Masad J. Damha, Ph.D. on Validity Of United States Patent No. 7,608,600 filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 03/30/2016)
2016-03-30
1
SO ORDERED, re (231 in 1:14-cv-00109-LPS, 264 in 1:14-cv-00846-LPS, 275 in 1:13-cv-01987-LPS) STIPULATION TO EXTEND TIME to Amend Expert Report Deadlines to Defendants' Rebuttal Damages Expert Report extended to April 5, 2016 and Plaintiffs' Reply Damages Expert Report extended to May 6, 2016 filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Signed by Judge Leonard P. Stark on 3/31/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl)
2016-03-31
1
No Actions
SO ORDERED
2016-03-31
1
No Actions
NOTICE of Appearance by Gregory Robert Booker on behalf of Gilead Pharmasset LLC, Gilead Sciences Inc. (Booker, Gregory) (Entered: 04/01/2016)
2016-04-01
1
Joint STIPULATION TO EXTEND TIME to extend Expert Report Deadlines to Plaintiffs' Supplemental Expert Damages Report extended to April 22, 2016; Defendants' Rebuttal Expert Report exended to May 9, 2016; Plaintiffs' Reply Expert Damages Report extended to May 23, 2016; Close of Expert Discovery for Damages Experts extended to June 1, 2016; and Daubert Motions extended to June 8, 2016 - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 04/05/2016)
2016-04-05
1
SO ORDERED D.I. (268 in 1:14-cv-00846-LPS, 279 in 1:13-cv-01987-LPS, 235 in 1:14-cv-00109-LPS) Joint STIPULATION TO EXTEND TIME to extend Expert Report Deadlines to Plaintiffs' Supplemental Expert Damages Report extended to April 22, 2016; Defendants' Rebuttal Expert Report exended to May 9, 2016; Plaintiffs' Reply Expert Damages filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Ordered by Judge Christopher J. Burke on 4/5/2016. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS(dlk)
2016-04-05
1
No Actions
SO ORDERED
2016-04-05
1
No Actions
[SEALED] MOTION to Redact (212 in 1:14-cv-00109-LPS, 256 in 1:13-cv-01987-LPS, 245 in 1:14-cv-00846-LPS) Transcript,, (Unopposed) - filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Mayo, Andrew) (Entered: 04/06/2016)
2016-04-06
1
ORDER re (236 in 1:14-cv-00109-LPS, 280 in 1:13-cv-01987-LPS, 269 in 1:14-cv-00846-LPS) UNOPPOSED MOTION to Redact the December 17, 2015 Transcript. Signed by Judge Leonard P. Stark on 4/8/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl) (Entered: 04/08/2016)
2016-04-08
1
REDACTED VERSION of (236 in 1:14-cv-00109-LPS, 280 in 1:13-cv-01987-LPS, 269 in 1:14-cv-00846-LPS) MOTION to Redact (212 in 1:14-cv-00109-LPS, 256 in 1:13-cv-01987-LPS, 245 in 1:14-cv-00846-LPS) Transcript,, (Unopposed) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A & B)(Mayo, Andrew) (Entered: 04/14/2016)
2016-04-14
1
STIPULATION and Order Regarding In Camera Submissions by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 04/19/2016)
2016-04-19
1
NOTICE OF SERVICE of Gilead's First Amended Response to Plaintiffs' First Set of Requests For Admission (Nos. 46-49, 51, 55) and Defendants' First Supplemental Responses to Plaintiffs' Second Set of Interrogatories (Nos. 18, 24, 25) filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 04/21/2016)
2016-04-21
1
NOTICE OF SERVICE of Supplemental Expert Report of Andrew W. Carter filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 04/22/2016)
2016-04-22
1
SO ORDERED, re (272 in 1:14-cv-00846-LPS, 239 in 1:14-cv-00109-LPS, 283 in 1:13-cv-01987-LPS) Stipulation and Order Regarding in camera submissions. Signed by Judge Leonard P. Stark on 4/22/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl)
2016-04-22
1
No Actions
SO ORDERED
2016-04-22
1
No Actions
Redaction of Official Transcript of Telephone Conference held on December 17, 2015 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone # 302 573-6360.(212 in 1:14-cv-00109-LPS, 256 in 1:13-cv-01987-LPS, 245 in 1:14-cv-00846-LPS) Transcript. (bpg) (Entered: 04/26/2016)
2016-04-26
1
[SEALED] Letter to The Hon. Leonard P. Stark from Martina Tyreus Hufnal regarding Documents for In-Camera Review - re (272 in 1:14-cv-00846-LPS, 239 in 1:14-cv-00109-LPS, 283 in 1:13-cv-01987-LPS) Stipulation. (Hufnal, AnnaMartina) (Entered: 04/28/2016)
2016-04-28
1
CORRECTING ENTRY: items filed for in camera review deleted per counsel's request on 4/29/16. (rpg)
2016-04-29
1
No Actions
- CORRECTING ENTRY
2016-04-29
1
No Actions
NOTICE OF SERVICE of Expert Report of Dr. Phil S. Baran; Reply Expert Report of John A. Secrist, III, Ph.D.; Reply Expert Report of Christoph Seeger, Ph.D.; and Reply Expert Report of Dr. Valentino Stella filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 05/06/2016)
2016-05-06
1
MOTION for Pro Hac Vice Appearance of Attorney Leozino Agozzino - filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Mayo, Andrew) (Entered: 05/17/2016)
2016-05-17
1
SO ORDERED D.I. (278 in 1:14-cv-00846-LPS, 289 in 1:13-cv-01987-LPS, 244 in 1:14-cv-00109-LPS) MOTION for Pro Hac Vice Appearance of Attorney Leozino Agozzino filed by L' Universite Montpellier II, Idenix Pharmaceuticals Inc., Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari. Ordered by Judge Christopher J. Burke on 5/18/2016. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS(dlk)
2016-05-18
1
No Actions
SO ORDERED
2016-05-18
1
No Actions
NOTICE OF SERVICE of CONFIDENTIAL REBUTTAL EXPERT REPORT OF JONATHAN D. PUTNAM and UPDATED CONFIDENTIAL REBUTTAL EXPERT REPORT OF JONATHAN D. PUTNAM filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 05/19/2016)
2016-05-19
1
MOTION for Pro Hac Vice Appearance of Attorney Michael R. Headley - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (McCann, Douglas) (Entered: 05/23/2016)
2016-05-23
1
MOTION for Pro Hac Vice Appearance of Attorney Lisa L. Furby - filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Mayo, Andrew) (Entered: 05/24/2016)
2016-05-24
1
NOTICE OF SERVICE of Reply Expert Report of Andrew W. Carter filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 05/24/2016)
2016-05-24
1
SO ORDERED, re (246 in 1:14-cv-00109-LPS, 291 in 1:13-cv-01987-LPS, 280 in 1:14-cv-00846-LPS) MOTION for Pro Hac Vice Appearance of Attorney Michael R. Headley filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Signed by Judge Leonard P. Stark on 5/24/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl)
2016-05-24
1
No Actions
SO ORDERED
2016-05-24
1
No Actions
SO ORDERED, re (247 in 1:14-cv-00109-LPS, 281 in 1:14-cv-00846-LPS, 292 in 1:13-cv-01987-LPS) MOTION for Pro Hac Vice Appearance of Attorney Lisa L. Furby filed by L' Universite Montpellier II, Idenix Pharmaceuticals Inc., Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari. Signed by Judge Leonard P. Stark on 5/25/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl)
2016-05-25
1
No Actions
SO ORDERED
2016-05-25
1
No Actions
NOTICE of Appearance by Joseph B. Warden on behalf of Gilead Pharmasset LLC, Gilead Sciences Inc. (Warden, Joseph) (Entered: 05/31/2016)
2016-05-31
1
MOTION to Strike Rebuttal, Reply, and Supplemental Expert Reports of John A. Secrist, III, Ph.D. - filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 05/31/2016)
2016-05-31
1
[SEALED] Letter to The Honorable Chief Judge Leonard P. Stark from John G. Day regarding plaintiffs' opening brief in support of motion to strike - re (295 in 1:13-cv-01987-LPS) MOTION to Strike Rebuttal, Reply, and Supplemental Expert Reports of John A. Secrist, III, Ph.D., (284 in 1:14-cv-00846-LPS) MOTION to Strike Rebuttal, Reply, and Supplemental Expert Reports of John A. Secrist, III, Ph.D., (249 in 1:14-cv-00109-LPS) MOTION to Strike Rebuttal, Reply, and Supplemental Expert Reports of John A. Secrist, III, Ph.D.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H)(Day, John) (Entered: 05/31/2016)
2016-05-31
1
Pro Hac Vice Attorney Lisa L. Furby for Idenix Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:14-cv-00846-LPS, 1:13-cv-01987-LPS, 1:14-cv-00109-LPS(klc)
2016-05-31
1
No Actions
Add Attorneys - PHV only
2016-05-31
1
No Actions
MOTION for Pro Hac Vice Appearance of Attorney Jennifer L. Swize - filed by Idenix Pharmaceuticals LLC, Universite de Montpellier, Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 06/01/2016)
2016-06-01
1
MOTION for Summary Judgment - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Proposed Order)(Hufnal, AnnaMartina) (Entered: 06/01/2016)
2016-06-01
1
[SEALED] OPENING BRIEF in Support re 298 MOTION for Summary Judgment filed by Gilead Pharmasset LLC, Gilead Sciences Inc..Answering Brief/Response due date per Local Rules is 6/20/2016. (Attachments: # 1 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 06/01/2016)
2016-06-01
1
[SEALED] DECLARATION re 299 Opening Brief in Support, 298 MOTION for Summary Judgment Declaration of Martina Tyreus Hufnal - Volume I of III by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 - Part 1, # 3 Exhibit 2 - Part 2, # 4 Exhibit 3 - Part 1, # 5 Exhibit 3 - Part 2, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6, # 9 Exhibit 7, # 10 Exhibit 8, # 11 Exhibit 9, # 12 Exhibit 10, # 13 Exhibit 11, # 14 Exhibit 12, # 15 Exhibit 13, # 16 Exhibit 14, # 17 Exhibit 15 - Part 1, # 18 Exhibit 15 - Part 2, # 19 Exhibit 15 - Part 3, # 20 Exhibit 15 - Part 4, # 21 Exhibit 15 - Part 5, # 22 Exhibit 15 - Part 6, # 23 Exhibit 15 - Part 7, # 24 Exhibit 15 - Part 8, # 25 Exhibit 15 - Part 9, # 26 Exhibit 16, # 27 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 06/01/2016)
2016-06-01
1
[SEALED] DECLARATION re 299 Opening Brief in Support, 300 Declaration,,, 298 MOTION for Summary Judgment Declaration of Martina Tyreus Hufnal - Volume II by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit 17, # 2 Exhibit 18, # 3 Exhibit 19, # 4 Exhibit 20, # 5 Exhibit 21, # 6 Exhibit 22, # 7 Exhibit 23 - Part 1, # 8 Exhibit 23 - Part 2, # 9 Exhibit 23 - Part 3, # 10 Exhibit 23 - Part 4, # 11 Exhibit 24, # 12 Exhibit 25, # 13 Exhibit 26, # 14 Exhibit 27, # 15 Exhibit 28, # 16 Exhibit 29, # 17 Exhibit 30, # 18 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 06/01/2016)
2016-06-01
1
[SEALED] DECLARATION re 299 Opening Brief in Support, 298 MOTION for Summary Judgment, 301 Declaration,, Declaration of Martina Tyreus Hufnal - Volume III by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit 31, # 2 Exhibit 32, # 3 Exhibit 33, # 4 Exhibit 34 - Part 1, # 5 Exhibit 34 - Part 2, # 6 Exhibit 34 - Part 3, # 7 Exhibit 34 - Part 4, # 8 Exhibit 35, # 9 Exhibit 36, # 10 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 06/01/2016)
2016-06-01
1
SO ORDERED, re (297 in 1:13-cv-01987-LPS, 22 in 1:15-cv-00416-LPS-CJB, 286 in 1:14-cv-00846-LPS, 251 in 1:14-cv-00109-LPS) MOTION for Pro Hac Vice Appearance of Attorney Jennifer L. Swize filed by L' Universite Montpellier II, Idenix Pharmaceuticals LLC, Idenix Pharmaceuticals Inc., Universite de Montpellier, Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari. Signed by Judge Leonard P. Stark on 6/3/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS, 1:15-cv-00416-LPS-CJB (ntl)
2016-06-03
1
No Actions
SO ORDERED
2016-06-03
1
No Actions
Pro Hac Vice Attorney Jennifer L. Swize for Idenix Pharmaceuticals LLC,and Idenix Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS, 1:15-cv-00416-LPS-CJB(klc)
2016-06-06
1
No Actions
Add Attorneys - PHV only
2016-06-06
1
No Actions
REDACTED VERSION of (296 in 1:13-cv-01987-LPS, 285 in 1:14-cv-00846-LPS, 250 in 1:14-cv-00109-LPS) Letter,, by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A-H)(Mayo, Andrew) (Entered: 06/07/2016)
2016-06-07
1
[SEALED] Letter to The Honorable Leonard P. Stark from Martina Tyreus Hufnal regarding opposition to motion to strike - re 296 Letter,,. (Attachments: # 1 Exhibit A-V)(Hufnal, AnnaMartina) (Entered: 06/07/2016)
2016-06-07
1
MOTION to Preclude (Idenix's Daubert Motion to Exclude Certain Opinions and Testimony of Jonathan D. Putnam) - filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 06/08/2016)
2016-06-08
1
[SEALED] OPENING BRIEF in Support re 305 MOTION to Preclude (Idenix's Daubert Motion to Exclude Certain Opinions and Testimony of Jonathan D. Putnam) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.Answering Brief/Response due date per Local Rules is 6/27/2016. (Day, John) (Entered: 06/08/2016)
2016-06-08
1
[SEALED] DECLARATION re (295 in 1:14-cv-00846-LPS) Opening Brief in Support, (306 in 1:13-cv-01987-LPS) Opening Brief in Support, (Declaration of Ryan B. McCrum) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F)(Day, John) (Entered: 06/08/2016)
2016-06-08
1
MOTION to Preclude (DAUBERT MOTIONS) - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Text of Proposed Order)(Hufnal, AnnaMartina) (Entered: 06/08/2016)
2016-06-08
1
[SEALED] OPENING BRIEF in Support re 308 MOTION to Preclude (DAUBERT MOTIONS) filed by Gilead Pharmasset LLC, Gilead Sciences Inc..Answering Brief/Response due date per Local Rules is 6/27/2016. (Attachments: # 1 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 06/08/2016)
2016-06-08
1
[SEALED] DECLARATION re 308 MOTION to Preclude (DAUBERT MOTIONS), 309 Opening Brief in Support, by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1-7, # 2 Exhibit 8 - part 1 of 2, # 3 Exhibit 8 - part 2 of 2, # 4 Exhibit 9-12, # 5 Exhibit 13-16, # 6 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 06/08/2016)
2016-06-08
1
REDACTED VERSION of 299 Opening Brief in Support, Motion for Summary Judgment by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 06/08/2016)
2016-06-08
1
REDACTED VERSION of 300 Declaration,,, In Support of Opening Brief - Vol I of III by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 - Part 1, # 3 Exhibit 2 - Part 2, # 4 Exhibit 3 - Part 1, # 5 Exhibit 3 - Part 2, # 6 Exhibit 4, # 7 Exhibit 5-10, # 8 Exhibit 11, # 9 Exhibit 12, # 10 Exhibit 13, # 11 Exhibit 14, # 12 Exhibit 15-16)(Hufnal, AnnaMartina) (Entered: 06/08/2016)
2016-06-08
1
REDACTED VERSION of 301 Declaration,, In Support of Opening Brief - Vol. II of III by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit 17-21, # 2 Exhibit 22, # 3 Exhibit 23 - Part 1, # 4 Exhibit 23 - Part 2, # 5 Exhibit 23 - Part 3, # 6 Exhibit 23 - Part 4, # 7 Exhibit 24-26, # 8 Exhibit 27, # 9 Exhibit 28, # 10 Exhibit 29, # 11 Exhibit 30)(Hufnal, AnnaMartina) (Entered: 06/08/2016)
2016-06-08
1
REDACTED VERSION of 302 Declaration,, In Support of Motion for Summary Judgment Vol. III of III by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit 31-34, # 2 Exhibit 35, # 3 Exhibit 36)(Hufnal, AnnaMartina) (Entered: 06/08/2016)
2016-06-08
1
NOTICE OF SERVICE of SECOND SUPPLEMENTAL INITIAL DISCLOSURES filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 06/09/2016)
2016-06-09
1
[SEALED] Letter to The Honorable Chief Judge Leonard P. Stark from John G. Day regarding plaintiffs' reply brief in support of motion to strike - re (249 in 1:14-cv-00109-LPS) MOTION to Strike Rebuttal, Reply, and Supplemental Expert Reports of John A. Secrist, III, Ph.D., (295 in 1:13-cv-01987-LPS) MOTION to Strike Rebuttal, Reply, and Supplemental Expert Reports of John A. Secrist, III, Ph.D., (284 in 1:14-cv-00846-LPS) MOTION to Strike Rebuttal, Reply, and Supplemental Expert Reports of John A. Secrist, III, Ph.D.. (Attachments: # 1 Exhibit I-O)(Day, John) (Entered: 06/10/2016)
2016-06-10
1
Letter to The Honorable Chief Judge Leonard P. Stark from John G. Day regarding request the scheduling of a teleconference to address Idenix's Motion to Strike. (Day, John) (Entered: 06/10/2016)
2016-06-10
1
REDACTED VERSION of (295 in 1:14-cv-00846-LPS) Opening Brief in Support, (306 in 1:13-cv-01987-LPS) Opening Brief in Support, by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 06/14/2016)
2016-06-14
1
REDACTED VERSION of (307 in 1:13-cv-01987-LPS, 296 in 1:14-cv-00846-LPS) Declaration, (of Ryan B. McCrum) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 06/14/2016)
2016-06-14
1
REDACTED VERSION of 304 Letter to Hon. Leonard P. Stark in support of Motion to Strike by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibits A-V)(Hufnal, AnnaMartina) (Entered: 06/14/2016)
2016-06-14
1
Pro Hac Vice Attorney Leozino Agozzino for Idenix Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (klc)
2016-06-14
1
No Actions
Add Attorneys - PHV only
2016-06-14
1
No Actions
REDACTED VERSION of 309 Opening Brief in Support, of Defendants' Daubert Motions by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 06/15/2016)
2016-06-15
1
REDACTED VERSION of 310 Declaration, of Martina Tyreus Hufnal in Support of Defendants' Daubert Motions and Opening Brief by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 REDACTED Exhibits 1-16)(Hufnal, AnnaMartina) (Entered: 06/15/2016)
2016-06-15
1
REDACTED VERSION of (316 in 1:13-cv-01987-LPS, 267 in 1:14-cv-00109-LPS, 305 in 1:14-cv-00846-LPS) Letter,, by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit I-O)(Mayo, Andrew) (Entered: 06/17/2016)
2016-06-17
1
[SEALED] Letter to The Honorable Leonard P. Stark from Martina Tyreus Hufnal regarding Deposition of Dr. Griffon. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Hufnal, AnnaMartina) (Entered: 06/20/2016)
2016-06-20
1
ORAL ORDER: Having received the letter of June 20 (see, e.g., C.A. No. 13-1987 D.I. 324), IT IS HEREBY ORDERED that the parties' dispute is referred to Magistrate Judge Burke for decision. ORDERED by Judge Leonard P. Stark on 6/20/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl) (Entered: 06/20/2016)
2016-06-20
1
MOTION to Strike Gilead's Good Faith Belief Defense - filed by Centre National de la Recherche Scientifique, L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 06/20/2016)
2016-06-20
1
[SEALED] Letter to The Honorable Chief Judge Leonard P. Stark from John G. Day regarding Indenix's June 20, 2016 Motion to Strike - re (315 in 1:14-cv-00846-LPS) MOTION to Strike Gilead's Good Faith Belief Defense, (275 in 1:14-cv-00109-LPS) MOTION to Strike Gilead's Good Faith Belief Defense, (326 in 1:13-cv-01987-LPS) MOTION to Strike Gilead's Good Faith Belief Defense. (Attachments: # 1 Exhibit 1-4)(Day, John) (Entered: 06/20/2016)
2016-06-20
1
[SEALED] ANSWERING BRIEF in Opposition re 298 MOTION for Summary Judgment filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.Reply Brief due date per Local Rules is 6/30/2016. (Day, John) (Entered: 06/20/2016)
2016-06-20
1
[SEALED] DECLARATION re (277 in 1:14-cv-00109-LPS) Answering Brief in Opposition, (328 in 1:13-cv-01987-LPS) Answering Brief in Opposition, (317 in 1:14-cv-00846-LPS) Answering Brief in Opposition (Declaration of Ryan B. McCrum) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 06/20/2016)
2016-06-20
1
[SEALED] EXHIBIT re (329 in 1:13-cv-01987-LPS, 278 in 1:14-cv-00109-LPS, 318 in 1:14-cv-00846-LPS) Declaration, (Volume I of III) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6-9, # 7 Exhibit 10 (Part I of VI), # 8 Exhibit 10 (Part II of VI), # 9 Exhibit 10 (Part III of VI), # 10 Exhibit 10 (Part IV of VI), # 11 Exhibit 10 (Part V of VI), # 12 Exhibit 10 (Part VI of VI), # 13 Exhibit 11-15, # 14 Exhibit 16, # 15 Exhibit 17, # 16 Exhibit 18, # 17 Exhibit 19, # 18 Exhibit 20, # 19 Exhibit 21)(Day, John) (Entered: 06/20/2016)
2016-06-20
1
[SEALED] EXHIBIT re (329 in 1:13-cv-01987-LPS, 278 in 1:14-cv-00109-LPS, 318 in 1:14-cv-00846-LPS) Declaration, (Volume II of III) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 22, # 2 Exhibit 23, # 3 Exhibit 24, # 4 Exhibit 25, # 5 Exhibit 26-34)(Day, John) (Entered: 06/20/2016)
2016-06-20
1
[SEALED] EXHIBIT re (329 in 1:13-cv-01987-LPS, 278 in 1:14-cv-00109-LPS, 318 in 1:14-cv-00846-LPS) Declaration, (Volume III of III) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 35 (Part I of V), # 2 Exhibit 35 (Part II of V), # 3 Exhibit 35 (Part III of V), # 4 Exhibit 35 (Part IV of V), # 5 Exhibit 35 (Part V of V), # 6 Exhibit 36-47)(Day, John) (Entered: 06/20/2016)
2016-06-20
1
Order
2016-06-20
1
No Actions
[SEALED] Letter to The Honorable Christopher J. Burke from John G. Day regarding response to Gilead's June 20, 2016 letter - re Order Setting Teleconference,,,,. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Day, John) (Entered: 06/21/2016)
2016-06-21
1
Joint MOTION for Discovery Teleconference to Resolve Discovery Dispute - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 06/21/2016)
2016-06-21
1
ORAL ORDER Setting Teleconference: The Court has reviewed Defendants June 20, 2016 letter regarding a discovery dispute. (D.I. 324 in Civil Action No. 13-1987-LPS, D.I. 273 in Civil Action No. 14-109-LPS, D.I. 313 in Civil Action No. 14-846-LPS). It hereby ORDERS that the procedures for resolving a discovery dispute set out in paragraph 3(g) of the Scheduling Order will be altered as follows with regard to this dispute: (1) The parties shall file a joint "Motion for Teleconference to Resolve Discovery Dispute," the text of which can be found in the "Forms" tab of Judge Burke's page on the District Court's website.; (2) A discovery dispute teleconference will be held on Wednesday, 6/22/2016 at 09:30 AM before Judge Christopher J. Burke.; (3) Any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party(s) reasons for its opposition by 5:00 pm today. Ordered by Judge Christopher J. Burke on 6/21/2016. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS(mlc)
2016-06-21
1
No Actions
Pro Hac Vice Attorney Michael R. Headley for Gilead Sciences Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS(cna)
2016-06-21
1
No Actions
Add Attorneys - PHV only
2016-06-21
1
No Actions
Order Setting Teleconference
2016-06-21
1
No Actions
Order on Motion for Discovery AND ~Util - Terminate Motions AND Discovery Conference
2016-06-22
1
No Actions
REDACTED VERSION of (277 in 1:14-cv-00109-LPS) Answering Brief in Opposition, (328 in 1:13-cv-01987-LPS) Answering Brief in Opposition, (317 in 1:14-cv-00846-LPS) Answering Brief in Opposition by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Mayo, Andrew) (Entered: 06/27/2016)
2016-06-27
1
REDACTED VERSION of (329 in 1:13-cv-01987-LPS, 278 in 1:14-cv-00109-LPS, 318 in 1:14-cv-00846-LPS) Declaration, (of Ryan B. McCrum) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Mayo, Andrew) (Entered: 06/27/2016)
2016-06-27
1
REDACTED VERSION of (330 in 1:13-cv-01987-LPS, 319 in 1:14-cv-00846-LPS, 279 in 1:14-cv-00109-LPS) Exhibit to a Document,,, (Volume I of III) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit part 2, # 2 Exhibit part 3, # 3 Exhibit part 4)(Mayo, Andrew) (Entered: 06/27/2016)
2016-06-27
1
REDACTED VERSION of (280 in 1:14-cv-00109-LPS, 320 in 1:14-cv-00846-LPS, 331 in 1:13-cv-01987-LPS) Exhibit to a Document, (Volume II of III) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Mayo, Andrew) (Entered: 06/27/2016)
2016-06-27
1
REDACTED VERSION of (321 in 1:14-cv-00846-LPS, 281 in 1:14-cv-00109-LPS, 332 in 1:13-cv-01987-LPS) Exhibit to a Document,, (Volume III of III) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Mayo, Andrew) (Entered: 06/27/2016)
2016-06-27
1
REDACTED VERSION of (327 in 1:13-cv-01987-LPS, 316 in 1:14-cv-00846-LPS, 276 in 1:14-cv-00109-LPS) Letter, by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1-4)(Mayo, Andrew) (Entered: 06/27/2016)
2016-06-27
1
[SEALED] ANSWERING BRIEF in Opposition re 308 MOTION to Preclude (DAUBERT MOTIONS) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari.Reply Brief due date per Local Rules is 7/8/2016. (Day, John) (Entered: 06/27/2016)
2016-06-27
1
[SEALED] DECLARATION re (330 in 1:14-cv-00846-LPS) Answering Brief in Opposition, (341 in 1:13-cv-01987-LPS) Answering Brief in Opposition, (290 in 1:14-cv-00109-LPS) Answering Brief in Opposition, (Declaration of Ryan B. McCrum) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 06/27/2016)
2016-06-27
1
[SEALED] EXHIBIT re (291 in 1:14-cv-00109-LPS, 331 in 1:14-cv-00846-LPS, 342 in 1:13-cv-01987-LPS) Declaration, (Volume 1 of 2, Exhibits 1-10) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 Part 1, # 3 Exhibit 2 Part 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6 Part 1, # 8 Exhibit 6 Part 2, # 9 Exhibit 6 Part 3, # 10 Exhibit 6 Part 4, # 11 Exhibit 6 Part 5, # 12 Exhibit 7, # 13 Exhibit 8, # 14 Exhibit 9, # 15 Exhibit 10 Part 1, # 16 Exhibit 10 Part 2, # 17 Exhibit 10 Part 3)(Day, John) (Entered: 06/27/2016)
2016-06-27
1
[SEALED] EXHIBIT re (291 in 1:14-cv-00109-LPS, 331 in 1:14-cv-00846-LPS, 342 in 1:13-cv-01987-LPS) Declaration, (Volume 2 of 2, Exhibits 11-23) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 11, # 2 Exhibit 12, # 3 Exhibit 13, # 4 Exhibit 14, # 5 Exhibit 15, # 6 Exhibit 16, # 7 Exhibit 17 Part 1, # 8 Exhibit 17 Part 2, # 9 Exhibit 17 Part 3, # 10 Exhibit 18, # 11 Exhibit 19, # 12 Exhibit 20, # 13 Exhibit 21, # 14 Exhibit 22, # 15 Exhibit 23)(Day, John) (Entered: 06/27/2016)
2016-06-27
1
[SEALED] ANSWERING BRIEF in Opposition re 308 MOTION to Preclude (DAUBERT MOTIONS) filed by Gilead Pharmasset LLC, Gilead Sciences Inc..Reply Brief due date per Local Rules is 7/8/2016. (Attachments: # 1 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 06/27/2016)
2016-06-27
1
[SEALED] DECLARATION re 345 Answering Brief in Opposition, Declaration of Martina Tyreus Hufnal in Support of Defendants' Answering Brief in Opposition to Plaintiff's Daubert Motion by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibits 1-3, # 2 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 06/27/2016)
2016-06-27
1
Letter to The Honorable Leonard P. Stark from Martina Tyreus Hufnal regarding Good-Faith Belief of Noninfringement - re (322 in 1:14-cv-00846-LPS) Letter. (Attachments: # 1 Exhibits A-C)(Hufnal, AnnaMartina) (Entered: 06/27/2016)
2016-06-27
1
REDACTED VERSION of (313 in 1:14-cv-00846-LPS) Letter to the Honorable Leonard P. Stark re Dr. Griffon deposition by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B - redacted in its entirety)(Hufnal, AnnaMartina) (Entered: 06/27/2016)
2016-06-27
1
REDACTED VERSION of (322 in 1:14-cv-00846-LPS, 333 in 1:13-cv-01987-LPS, 282 in 1:14-cv-00109-LPS) Letter by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Mayo, Andrew) (Entered: 06/28/2016)
2016-06-28
1
Official Transcript of Telephone Conference held on June 22, 2016 before Judge Christopher J. Burke. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 7/20/2016. Redacted Transcript Deadline set for 8/1/2016. Release of Transcript Restriction set for 9/27/2016.(bpg) (Entered: 06/29/2016)
2016-06-29
1
[SEALED] REPLY BRIEF re 298 MOTION for Summary Judgment filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 06/30/2016)
2016-06-30
1
[SEALED] DECLARATION re 351 Reply Brief Declaration of Martina Tyreus Hufnal in Support of Summary Judgment Reply Brief by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibits 37-43)(Hufnal, AnnaMartina) (Entered: 06/30/2016)
2016-06-30
1
[SEALED] Letter to The Honorable Chief Judge Leonard P. Stark from John G. Day regarding reply brief in support of Idenix's Motion to Strike Gilead's Undisclosed Defense of Good Faith Belief in Non-Infringement. (Attachments: # 1 Exhibit 5, # 2 Exhibit 6, # 3 Exhibit 7, # 4 Exhibit 8, # 5 Exhibit 9)(Day, John) (Entered: 06/30/2016)
2016-06-30
1
REDACTED VERSION of (330 in 1:14-cv-00846-LPS) Answering Brief in Opposition, (341 in 1:13-cv-01987-LPS) Answering Brief in Opposition, (290 in 1:14-cv-00109-LPS) Answering Brief in Opposition, by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Mayo, Andrew) (Entered: 07/05/2016)
2016-07-05
1
REDACTED VERSION of (291 in 1:14-cv-00109-LPS, 331 in 1:14-cv-00846-LPS, 342 in 1:13-cv-01987-LPS) Declaration, (of Ryan B. McCrum) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Mayo, Andrew) (Entered: 07/05/2016)
2016-07-05
1
REDACTED VERSION of (292 in 1:14-cv-00109-LPS, 343 in 1:13-cv-01987-LPS, 332 in 1:14-cv-00846-LPS) Exhibit to a Document,, (Volume I of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 3-10)(Mayo, Andrew) (Entered: 07/05/2016)
2016-07-05
1
REDACTED VERSION of (344 in 1:13-cv-01987-LPS, 293 in 1:14-cv-00109-LPS, 333 in 1:14-cv-00846-LPS) Exhibit to a Document,, (Volume II of II) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 11-17, # 2 Exhibit 18-23)(Mayo, Andrew) (Entered: 07/05/2016)
2016-07-05
1
REDACTED VERSION of 345 Answering Brief in Opposition, to Plaintiffs' Daubert Motion by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 07/05/2016)
2016-07-05
1
REDACTED VERSION of 346 Declaration, of Martina Tyreus Hufnal in Support of Defendants' Answering Brief in Opposition to Plaintiffs' Daubert Motion by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibits 1-3)(Hufnal, AnnaMartina) (Entered: 07/05/2016)
2016-07-05
1
REDACTED VERSION of (342 in 1:14-cv-00846-LPS, 353 in 1:13-cv-01987-LPS, 302 in 1:14-cv-00109-LPS) Letter, by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 5-9)(Mayo, Andrew) (Entered: 07/07/2016)
2016-07-07
1
[SEALED] REPLY BRIEF re 308 MOTION to Preclude (DAUBERT MOTIONS) Defendant's Reply Brief in Support of Their Daubert Motion filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Certificate of Service)(Flanagan, Elizabeth) (Entered: 07/08/2016)
2016-07-08
1
[SEALED] REPLY BRIEF re 305 MOTION to Preclude (Idenix's Daubert Motion to Exclude Certain Opinions and Testimony of Jonathan D. Putnam) filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 07/08/2016)
2016-07-08
1
[SEALED] DECLARATION re 361 Reply Brief, Declaration of Elizabeth M. Flanagan in Support of Defendants' Reply Brief in Support of Their Daubert Motions by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibits 17-19, # 2 Certificate of Service)(Flanagan, Elizabeth) (Entered: 07/08/2016)
2016-07-08
1
DECLARATION re (362 in 1:13-cv-01987-LPS) Reply Brief, (350 in 1:14-cv-00846-LPS) Reply Brief (Declaration of Ryan B. McCrum) by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit G, # 2 Exhibit H, # 3 Exhibit I)(Day, John) (Entered: 07/08/2016)
2016-07-08
1
REDACTED VERSION of (361 in 1:13-cv-01987-LPS) Reply Brief, (310 in 1:14-cv-00109-LPS) Reply Brief, (351 in 1:14-cv-00846-LPS) Reply Brief Defendants' Reply Brief in Support of Their Daubert Motions by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Flanagan, Elizabeth) (Entered: 07/15/2016)
2016-07-15
1
REDACTED VERSION of (311 in 1:14-cv-00109-LPS) Declaration, (363 in 1:13-cv-01987-LPS) Declaration, (353 in 1:14-cv-00846-LPS) Declaration, of Elizabeth M. Flanagan in Support of Defendants' Reply Brief in Support of Their Daubert Motions by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 REDACTED Exhibits 17-19)(Flanagan, Elizabeth) (Entered: 07/15/2016)
2016-07-15
1
REDACTED VERSION of (362 in 1:13-cv-01987-LPS) Reply Brief, (350 in 1:14-cv-00846-LPS) Reply Brief by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Mayo, Andrew) (Entered: 07/15/2016)
2016-07-15
1
REDACTED VERSION of (340 in 1:14-cv-00846-LPS) Reply Brief, (300 in 1:14-cv-00109-LPS) Reply Brief, (351 in 1:13-cv-01987-LPS) Reply Brief in Support of Summary Judgment Motions by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 07/15/2016)
2016-07-15
1
REDACTED VERSION of (341 in 1:14-cv-00846-LPS) Declaration, (301 in 1:14-cv-00109-LPS) Declaration, (352 in 1:13-cv-01987-LPS) Declaration of Martina Tyreus Hufnal in Support of Defendants' Reply Brief in Support of Summary Judgment Motions by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibits 37-43)(Hufnal, AnnaMartina) (Entered: 07/15/2016)
2016-07-15
1
[SEALED] MEMORANDUM ORDER re in camera review of documents. Signed by Judge Leonard P. Stark on 7/20/16. This order has been emailed to local counsel. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl) (Entered: 07/20/2016)
2016-07-20
1
NOTICE of Subsequent Authority by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari (Attachments: # 1 Exhibit A)(Day, John) (Entered: 07/20/2016)
2016-07-20
1
Joint Letter to The Honorable Chief Judge Leonard P. Stark from John G. Day regarding the parties' proposals for trial schedule. (Day, John) (Entered: 07/21/2016)
2016-07-21
1
Joint STATUS REPORT by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit (Proposed Redactions to the July 20, 2016 Memorandum Opinion)(Mayo, Andrew) (Entered: 07/22/2016)
2016-07-22
1
ORAL ORDER: IT IS HEREBY ORDERED that with respect to the hearing tomorrow, July 26: (i) the parties shall be prepared to address, all pending motions, as well as the issues raised in the recent status letters to the Court; (ii) the order in which matters will be argued is as follows: (1) Idenix motion to strike reports of Dr. Secrist; (2) Idenix motion to strike good faith defense; (3) Gilead motion for summary judgment; (4) Idenix motion to preclude; (5) Gilead motion to preclude; (6) status of attorney-client privilege issues; and (7) trial scheduling; and (iii) each side will be allocated up to ninety (90) minutes for its argument. ORDERED by Judge Leonard P. Stark on 7/25/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl) (Entered: 07/25/2016)
2016-07-25
1
NOTICE of Subsequent Authority by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari (Attachments: # 1 Exhibit A)(Day, John) (Entered: 07/25/2016)
2016-07-25
1
ORAL ORDER: IT IS HEREBY ORDERED that the hearing on July 26 will begin at 9:30 a.m. ORDERED by Judge Leonard P. Stark on 7/25/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl) (Entered: 07/25/2016)
2016-07-25
1
MOTION for Pro Hac Vice Appearance of Attorney Craig Countryman - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 07/25/2016)
2016-07-25
1
Order
2016-07-25
1
No Actions
Order AND 1 - Terminate Hearings AND ~Util - Set Hearings
2016-07-25
1
No Actions
REDACTED PUBLIC VERSION of 370 Memorandum Order. (ntl) (Entered: 07/26/2016)
2016-07-26
1
ORAL ORDER: For the reasons stated by the Court at today's hearing, IT IS HEREBY ORDERED that: (i) Plaintiffs' Motion to Strike (C.A. No. 13-1987 D.I. 295) is DENIED; (ii) Plaintiffs' Motion to Strike (D.I. 326) is GRANTED; (iii) Defendants' Motion for Summary Judgment (D.I. 298) is DENIED WITHOUT PREJUDICE with regard to Defendants' written description invalidity contention and DENIED with regard to the motion's remaining grounds; (iv) Plaintiffs' Motion to Preclude (D.I. 305) is DENIED; (v) Defendants' Motion to Preclude (D.I. 308) is DENIED; (vi) the Scheduling Order (D.I. 42) is AMENDED to remove the October 11 trial date and a jury trial will proceed on December 5, 2016, with a pretrial conference on Wednesday, November 23 beginning at 9:00 a.m.; and (vii) the Parties SHALL submit a joint status report no later than July 29 containing (a) a proposed briefing schedule for supplemental construction of the relevant '054 and '597 patent claim terms, (b) a proposed briefing schedule for a renewed motion for summary judgment for lack of written description, and (c) proposed amendments to the Scheduling Order (D.I. 42) to account for the December trial date and reopening of fact and/or expert discovery related to the denial of Plaintiffs' Motion to Strike (D.I. 295). ORDERED by Judge Leonard P. Stark on 7/26/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl) (Entered: 07/26/2016)
2016-07-26
1
SO ORDERED
2016-07-26
1
No Actions
Oral Argument
2016-07-26
1
No Actions
Order AND 1 - Terminate Deadlines and Hearings AND ~Util - Set Hearings
2016-07-26
1
No Actions
Official Transcript of Motions Hearing held on July 26, 2016 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 8/18/2016. Redacted Transcript Deadline set for 8/29/2016. Release of Transcript Restriction set for 10/26/2016. (bpg) (Entered: 07/28/2016)
2016-07-28
1
MOTION for Pro Hac Vice Appearance of Attorney Tharan G. Lanier - filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 07/29/2016)
2016-07-29
1
Joint STATUS REPORT by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Day, John) (Entered: 07/29/2016)
2016-07-29
1
SO ORDERED
2016-08-02
1
No Actions
ORAL ORDER: Having reviewed the parties' joint status report (C.A. No. 13-1987 D.I. 382), IT IS HEREBY ORDERED that: (i) the parties' joint proposal regarding supplemental claim construction and any renewed motion for summary judgment on written description grounds is ADOPTED, provided neither side files more than a total of twenty-five (25) pages of briefing; (ii) the Court will hear argument on claim construction and summary judgment on written description on Thursday, October 6 at 10:00 a.m., with each side allocated thirty (30) minutes; (iii) the parties' joint proposal to amend the Scheduling Order (D.I. 42; D.I. 382 at 3) is ADOPTED; (iv) fact discovery will close on September 30, 2016; (v) any supplemental report(s) by Plaintiffs' experts are due October 10, 2016; (vi) any supplemental report(s) by Defendants' experts are due October 17, 2016; (vii) expert depositions will be limited to 3.5 hours each; (viii) expert discovery will close on October 28, 2016; (ix) Plaintiffs may, if they have a good faith basis to do so, file a motion for summary judgment regarding Defendants late-disclosed defense, and briefing on such a motion would proceed as follows: motion and opening brief (limited to 20 pages) on October 31, 2016, answering brief (limited to 20 pages) on November 10, 2016, and reply brief (limited to 10 pages) on November 15, 2016, with oral argument (if necessary) to be heard during the pretrial conference on November 23, 2016 at 9:00 am. This schedule, including the Courts resolution of the parties disputes, provides sufficient time for Plaintiffs to obtain relevant fact discovery prior to supplemental expert discovery, which will ameliorate the prior prejudice to Plaintiffs and will facilitate the orderly resolution of Defendants late-disclosed defense, while still permitting trial in December. The Court is not persuaded it would be appropriate or helpful to allow a deposition of Dr. Secrist this month, nor that Defendants ability to serve a supplemental expert report addressing whatever emerges in forthcoming discovery should be dependent on Plaintiffs election to serve an expert report. ORDERED by Judge Leonard P. Stark on 8/3/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl) (Entered: 08/03/2016)
2016-08-03
1
Order AND ~Util - Set Hearings
2016-08-03
1
No Actions
Add Attorneys - PHV only
2016-08-04
1
No Actions
NOTICE OF SERVICE of Defendants' Proposed Supplemental Claim Constructions filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 08/05/2016)
2016-08-05
1
[SEALED] MOTION for Reconsideration - filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1-5)(Day, John) (Entered: 08/05/2016)
2016-08-05
1
REDACTED VERSION of (374 in 1:14-cv-00846-LPS, 385 in 1:13-cv-01987-LPS, 330 in 1:14-cv-00109-LPS) MOTION for Reconsideration by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit 1-5)(Mayo, Andrew) (Entered: 08/12/2016)
2016-08-12
1
MOTION for Summary Judgment Renewed Motion For Summary Judgment - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Proposed Order)(Hufnal, AnnaMartina) (Entered: 08/22/2016)
2016-08-22
1
[SEALED] OPENING BRIEF in Support re 387 MOTION for Summary Judgment Renewed Motion For Summary Judgment filed by Gilead Pharmasset LLC, Gilead Sciences Inc..Answering Brief/Response due date per Local Rules is 9/9/2016. (Attachments: # 1 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 08/22/2016)
2016-08-22
1
[SEALED] DECLARATION re 387 MOTION for Summary Judgment Renewed Motion For Summary Judgment, 388 Opening Brief in Support, Declaration of Martina Tyreus Hufnal in Support of Defendants' Opening Brief in Support of Their Renewed Summary Judgment Motion by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibits 1-7, # 2 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 08/22/2016)
2016-08-22
1
[SEALED] ANSWERING BRIEF in Opposition re 385 MOTION for Reconsideration filed by Gilead Pharmasset LLC, Gilead Sciences Inc..Reply Brief due date per Local Rules is 9/1/2016. (Attachments: # 1 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 08/22/2016)
2016-08-22
1
[SEALED] DECLARATION re 390 Answering Brief in Opposition, Declaration of Martina Tyreus Hufnal in Support of its Answering Brief in Oppositon to Plaintiffs' Motion For Reconsideration by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibits 1-6, # 2 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 08/22/2016)
2016-08-22
1
[SEALED] CLAIM CONSTRUCTION OPENING BRIEF filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 08/22/2016)
2016-08-22
1
[SEALED] DECLARATION re 392 Claim Construction Opening Brief Declaration of Martina Tyreus Hufnal in Support of Opening Claim Construction Brief by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 08/22/2016)
2016-08-22
1
REDACTED VERSION of (337 in 1:14-cv-00109-LPS) Answering Brief in Opposition, (382 in 1:14-cv-00846-LPS) Answering Brief in Opposition, (388 in 1:13-cv-01987-LPS) Opening Brief in Support, by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 08/29/2016)
2016-08-29
1
REDACTED VERSION of (338 in 1:14-cv-00109-LPS) Declaration, (383 in 1:14-cv-00846-LPS) Declaration, of Martina Tyreus Hufnal in support of Opposition to Motion For Reconsideration by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibits 1-6)(Hufnal, AnnaMartina) (Entered: 08/29/2016)
2016-08-29
1
REDACTED VERSION of (378 in 1:14-cv-00846-LPS) Opening Brief in Support, (333 in 1:14-cv-00109-LPS) Opening Brief in Support, (388 in 1:13-cv-01987-LPS) Opening Brief in Support, of Renewed Motion For Summary Judgment by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 08/29/2016)
2016-08-29
1
REDACTED VERSION of (334 in 1:14-cv-00109-LPS) Declaration, (379 in 1:14-cv-00846-LPS) Declaration, (389 in 1:13-cv-01987-LPS) Declaration, of Martina Tyreus Hufnal in Support of Renewed Motion For Summary Judgment by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibits 1-7)(Hufnal, AnnaMartina) (Entered: 08/29/2016)
2016-08-29
1
REDACTED VERSION of (381 in 1:14-cv-00846-LPS) Declaration, (335 in 1:14-cv-00109-LPS) Claim Construction Opening Brief, (392 in 1:13-cv-01987-LPS) Claim Construction Opening Brief by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 08/29/2016)
2016-08-29
1
REDACTED VERSION of (343 in 1:14-cv-00109-LPS) Redacted Document, (381 in 1:14-cv-00846-LPS) Declaration, (393 in 1:13-cv-01987-LPS) Declaration, of Martina Tyreus Hufnal in Support of Supplemental Claim Construction Brief by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibits 4-7, # 5 Exhibit 8, # 6 Exhibit 9)(Hufnal, AnnaMartina) (Entered: 08/29/2016)
2016-08-29
1
Supplemental CLAIM CONSTRUCTION REPLY BRIEF re 392 Claim Construction Opening Brief filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 09/09/2016)
2016-09-09
1
DECLARATION re 400 Claim Construction Reply Brief Declaration of Martina Tyreus Hufnal in Support of Supplemental Claim Construction Reply Brief by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit 10)(Hufnal, AnnaMartina) (Entered: 09/09/2016)
2016-09-09
1
[SEALED] REPLY BRIEF re 387 MOTION for Summary Judgment Renewed Motion For Summary Judgment filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 09/16/2016)
2016-09-16
1
[SEALED] DECLARATION re 402 Reply Brief Declaration of Martina Tyreus Hufnal in Support of Defendants' Reply in Supply of Their Renewed Summary Judgment Motion by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit 8, # 2 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 09/16/2016)
2016-09-16
1
Letter to Honorable Leonard P. Stark from Martina Tyreus Hufnal regarding October 6 hearing date. (Hufnal, AnnaMartina) (Entered: 09/20/2016)
2016-09-20
1
REDACTED VERSION of (398 in 1:14-cv-00846-LPS) Reply Brief, (347 in 1:14-cv-00109-LPS) Reply Brief, (402 in 1:13-cv-01987-LPS) Reply Brief in Support of Their Renewed Summary Judgment Motion by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 09/23/2016)
2016-09-23
1
REDACTED VERSION of (403 in 1:13-cv-01987-LPS) Declaration, (348 in 1:14-cv-00109-LPS) Declaration, (399 in 1:14-cv-00846-LPS) Declaration, of Martina Tyreus Hufnal in Support of Renewed Summary Judgment Motion by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit 8 - redacted in its entirety)(Hufnal, AnnaMartina) (Entered: 09/23/2016)
2016-09-23
1
ORAL ORDER: IT IS HEREBY ORDERED that the Oral Argument scheduled for October 6, 2016 is CANCELLED and is re-scheduled for October 7, 2016 at 8:30 a.m. ORDERED by Judge Leonard P. Stark on 9/23/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl) (Entered: 09/23/2016)
2016-09-23
1
Order AND ~Util - Set Hearings
2016-09-23
1
No Actions
MOTION to Amend Case Caption pursuant to Name Change (Unopposed) - filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., L' Universite Montpellier II, Universita Degli Studi di Cagliari. (Mayo, Andrew) (Entered: 09/27/2016)
2016-09-27
1
ORDER re 408 MOTION to Amend Case Caption pursuant to Name Change (Unopposed) filed by L' Universite Montpellier II, Idenix Pharmaceuticals Inc., Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari. Signed by Judge Leonard P. Stark on 9/28/16. (ntl) (Entered: 09/29/2016)
2016-09-29
1
NOTICE OF SERVICE of Plaintiffs' First Supplemental Response and Objections to Interrogatory No. 9 and Plaintiffs' Second Supplemental Rule 26(a) Initial Disclosures filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., Idenix Pharmaceuticals LLC, L' Universite Montpellier II, L' Universite de Montpellier, Universita Degli Studi di Cagliari.(Day, John) (Entered: 09/30/2016)
2016-09-30
1
Minute Entry for proceedings held before Judge Leonard P. Stark - Oral Argument held on 10/7/2016. (Court Reporter B. Gaffigan.) Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl)
2016-10-07
1
No Actions
NOTICE OF SERVICE of Second Supplemental Expert Report of Andrew W. Carter filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., Idenix Pharmaceuticals LLC, L' Universite Montpellier II, L' Universite de Montpellier, Universita Degli Studi di Cagliari.(Mayo, Andrew) (Entered: 10/12/2016)
2016-10-12
1
Oral Argument
2016-10-12
1
No Actions
NOTICE OF SERVICE of Third Supplemental Expert Report of John A. Secrist, III, Ph.D. and Supplemental Expert Report of Christoph Seeger, Ph.D. filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 10/19/2016)
2016-10-19
1
NOTICE OF SERVICE of Expert Supplemental Rebuttal Report of Jonathan D. Putnam filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Hufnal, AnnaMartina) (Entered: 10/19/2016)
2016-10-19
1
Add Attorneys - PHV only
2016-10-19
1
No Actions
Official Transcript of Oral Argument Hearing held on October 7, 2016 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 11/14/2016. Redacted Transcript Deadline set for 11/25/2016. Release of Transcript Restriction set for 1/23/2017. (bpg) (Entered: 10/24/2016)
2016-10-24
1
MOTION to Quash Motion for a Protective Order and to Quash Trial Subpoena Directed to Peter Schaeffer Price, Jr. - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Proposed Order)(Warden, Joseph) (Entered: 11/03/2016)
2016-11-03
1
[SEALED] OPENING BRIEF in Support re 415 MOTION to Quash Motion for a Protective Order and to Quash Trial Subpoena Directed to Peter Schaeffer Price, Jr. filed by Gilead Pharmasset LLC, Gilead Sciences Inc..Answering Brief/Response due date per Local Rules is 11/21/2016. (Attachments: # 1 Certificate of Service)(Warden, Joseph) (Entered: 11/03/2016)
2016-11-03
1
[SEALED] DECLARATION re (359 in 1:14-cv-00109-LPS, 419 in 1:14-cv-00846-LPS, 415 in 1:13-cv-01987-LPS) MOTION to Quash Motion for a Protective Order and to Quash Trial Subpoena Directed to Peter Schaeffer Price, Jr. Declaration of Martina Tyreus Hufnal in Support of Defendants' and Peter Schaeffer Price, Jr.'s Motion For A Protective Order and to Quash Trial Subpoena Directed to Peter Schaeffer Price, Jr. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Certificate of Service)(Warden, Joseph) (Entered: 11/03/2016)
2016-11-03
1
[SEALED] Letter to The Honorable Leonard P. Stark from Martina Tyreus Hufnal regarding Response re Idenix's Motion to Strike Expert Reports - re (416 in 1:14-cv-00846-LPS) MOTION to Strike Defendant's Late-Disclosed Defenses Based on Merck Work. (Attachments: # 1 Exhibits 1-8, # 2 Certificate of Service)(Hufnal, AnnaMartina) (Entered: 11/07/2016)
2016-11-07
1
MOTION to Continue Trial - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Proposed Order)(Warden, Joseph) (Entered: 11/07/2016)
2016-11-07
1
[SEALED] OPENING BRIEF in Support re 419 MOTION to Continue Trial filed by Gilead Pharmasset LLC, Gilead Sciences Inc..Answering Brief/Response due date per Local Rules is 11/25/2016. (Attachments: # 1 Certificate of Service)(Warden, Joseph) (Entered: 11/07/2016)
2016-11-07
1
[SEALED] DECLARATION re (428 in 1:14-cv-00846-LPS, 363 in 1:14-cv-00109-LPS, 419 in 1:13-cv-01987-LPS) MOTION to Continue Trial Declaration of Martina Tyreus Hufnal in Support of Motion to Continue Trial by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibits 1-3, # 2 Certificate of Service)(Warden, Joseph) (Entered: 11/07/2016)
2016-11-07
1
STIPULATION and [Proposed] Order regarding Juror Questionnaire by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., Idenix Pharmaceuticals LLC, L' Universite Montpellier II, L' Universite de Montpellier, Universita Degli Studi di Cagliari. (Attachments: # 1 Exhibit A)(Mayo, Andrew) (Entered: 11/08/2016)
2016-11-08
1
REDACTED VERSION of (420 in 1:14-cv-00846-LPS) Opening Brief in Support, (416 in 1:13-cv-01987-LPS) Opening Brief in Support, (360 in 1:14-cv-00109-LPS) Opening Brief in Support, of Defendants' Motion For a Protective Order and to Quash Trial Subpoena Directed to Peter Schaeffer Price, Jr. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Warden, Joseph) (Entered: 11/10/2016)
2016-11-10
1
REDACTED VERSION of (417 in 1:13-cv-01987-LPS, 361 in 1:14-cv-00109-LPS, 421 in 1:14-cv-00846-LPS) Declaration,, of Martina Tyreus Hufnal in Support of Defendants' Motion For a Protective Order and to Quash Trial Subpoena Directed to Peter Schaeffer Price, Jr. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibits 1-3)(Warden, Joseph) (Entered: 11/10/2016)
2016-11-10
1
REDACTED VERSION of (420 in 1:13-cv-01987-LPS) Opening Brief in Support, (429 in 1:14-cv-00846-LPS) Opening Brief in Support, (364 in 1:14-cv-00109-LPS) Opening Brief in Support Gilead's Motion to Continue Trial by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Warden, Joseph) (Entered: 11/14/2016)
2016-11-14
1
REDACTED VERSION of (430 in 1:14-cv-00846-LPS, 365 in 1:14-cv-00109-LPS, 421 in 1:13-cv-01987-LPS) Declaration, of Martina Tyreus Hufnal in Support of Gilead's Motion to Continue Trial by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibits 1-3)(Warden, Joseph) (Entered: 11/14/2016)
2016-11-14
1
SO ORDERED, re 422 Stipulated Order re jury questionnaire. Signed by Judge Leonard P. Stark on 11/15/16. (ntl) (Entered: 11/15/2016)
2016-11-15
1
REDACTED VERSION of (418 in 1:13-cv-01987-LPS, 362 in 1:14-cv-00109-LPS, 427 in 1:14-cv-00846-LPS) Letter, to the Hon. Leonard P. Stark re Merck Work by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibits 1-8)(Hufnal, AnnaMartina) (Entered: 11/15/2016)
2016-11-15
1
NOTICE to Take Deposition of David Standring on November 17, 2016 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 11/16/2016)
2016-11-16
1
NOTICE to Take Deposition of Gilles Gosselin on November 18, 2016 filed by Gilead Pharmasset LLC, Gilead Sciences Inc..(Coutinho, Santosh) (Entered: 11/16/2016)
2016-11-16
1
MEMORANDUM OPINION re claim construction of two disputed terms and renewed motion for summary judgment on written description. Signed by Judge Leonard P. Stark on 11/16/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl)
2016-11-16
1
ORDER re (446 in 1:14-cv-00846-LPS, 374 in 1:14-cv-00109-LPS, 431 in 1:13-cv-01987-LPS) Memorandum Opinion -- (387 in 1:13-cv-01987-LPS)(332 in 1:14-cv-00109-LPS) (377 in 1:14-cv-00846-LPS) Renewed Motion For Summary Judgment filed by Gilead Sciences Inc., Gilead Pharmasset LLC is DENIED. Signed by Judge Leonard P. Stark on 11/16/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl) (Entered: 11/16/2016)
2016-11-16
1
MEMORANDUM ORDER re (374 in 1:14-cv-00846-LPS, 385 in 1:13-cv-01987-LPS, 330 in 1:14-cv-00109-LPS) MOTION for Reconsideration filed by L' Universite Montpellier II, Idenix Pharmaceuticals Inc., Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari is DENIED. Signed by Judge Leonard P. Stark on 11/16/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl)
2016-11-16
1
ORAL ORDER: In light of the Court's decisions today resolving various motions and providing supplemental claim constructions, IT IS HEREBY ORDERED that the proposed final pretrial order, which was due to be filed by 6:00 p.m. today, is now due no later than tomorrow, November 17, at 6:00 p.m. ORDERED by Judge Leonard P. Stark on 11/16/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl) (Entered: 11/16/2016)
2016-11-16
1
Order
2016-11-16
1
No Actions
MOTION for Pro Hac Vice Appearance of Attorney Stephanie E. Parker and Bradley W. Harrison - filed by Centre National de la Recherche Scientifique, Idenix Pharmaceuticals LLC, L' Universite de Montpellier, Universita Degli Studi di Cagliari. (Day, John) (Entered: 11/17/2016)
2016-11-17
1
MOTION for Pro Hac Vice Appearance of Attorney Juanita Brooks - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 11/18/2016)
2016-11-18
1
MOTION to Bifurcate Motion to Phase Trial - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Proposed Order)(Warden, Joseph) (Entered: 11/18/2016)
2016-11-18
1
[SEALED] OPENING BRIEF in Support re 437 MOTION to Bifurcate Motion to Phase Trial filed by Gilead Pharmasset LLC, Gilead Sciences Inc..Answering Brief/Response due date per Local Rules is 12/5/2016. (Warden, Joseph) (Entered: 11/18/2016)
2016-11-18
1
[SEALED] DECLARATION re (438 in 1:13-cv-01987-LPS) Opening Brief in Support, (458 in 1:14-cv-00846-LPS) Opening Brief in Support, (457 in 1:14-cv-00846-LPS, 437 in 1:13-cv-01987-LPS) MOTION to Bifurcate Motion to Phase Trial Declaration of Joseph B. Warden in Support of Motion to Phase Trial by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibits 1-4, # 2 Certificate of Service)(Warden, Joseph) (Entered: 11/18/2016)
2016-11-18
1
Proposed Voir Dire by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 11/21/2016)
2016-11-21
1
Proposed Jury Instructions by Gilead Pharmasset LLC, Gilead Sciences Inc. (Preliminary). (Hufnal, AnnaMartina) (Entered: 11/21/2016)
2016-11-21
1
Proposed Jury Instructions by Gilead Pharmasset LLC, Gilead Sciences Inc. (Final). (Hufnal, AnnaMartina) (Entered: 11/21/2016)
2016-11-21
1
VERDICT SHEET by Gilead Pharmasset LLC, Gilead Sciences Inc. . (Hufnal, AnnaMartina) (Entered: 11/21/2016)
2016-11-21
1
SO ORDERED, re (451 in 1:14-cv-00846-LPS, 378 in 1:14-cv-00109-LPS, 435 in 1:13-cv-01987-LPS) MOTION for Pro Hac Vice Appearance of Attorney Stephanie E. Parker and Bradley W. Harrison filed by Idenix Pharmaceuticals LLC, Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari, L' Universite de Montpellier, (436 in 1:13-cv-01987-LPS, 379 in 1:14-cv-00109-LPS, 456 in 1:14-cv-00846-LPS) MOTION for Pro Hac Vice Appearance of Attorney Juanita Brooks filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Signed by Judge Leonard P. Stark on 11/21/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (etg)
2016-11-21
1
No Actions
MEMORANDUM ORDER re (428 in 1:14-cv-00846-LPS, 363 in 1:14-cv-00109-LPS, 419 in 1:13-cv-01987-LPS) MOTION to Continue Trial is DENIED. Rulings on pretrial order and trial issues and on motions in limine. Signed by Judge Leonard P. Stark on 11/22/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl)
2016-11-22
1
NOTICE of Appearance by Michael P. Kelly on behalf of Centre National de la Recherche Scientifique, Idenix Pharmaceuticals Inc., Idenix Pharmaceuticals LLC, L' Universite Montpellier II, L' Universite de Montpellier, Universita Degli Studi di Cagliari (Kelly, Michael) (Entered: 11/22/2016)
2016-11-22
1
STIPULATION Stipulation Regarding Trial Subpoenas to Dr. Duffy and Mr. Price re (419 in 1:14-cv-00846-LPS, 359 in 1:14-cv-00109-LPS, 415 in 1:13-cv-01987-LPS) MOTION to Quash Motion for a Protective Order and to Quash Trial Subpoena Directed to Peter Schaeffer Price, Jr. by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 11/22/2016)
2016-11-22
1
Pro Hac Vice Attorney Bradley W. Harrison and Stephanie E. Parker for Idenix Pharmaceuticals LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (lmm)
2016-11-23
1
No Actions
SO ORDERED, re (389 in 1:14-cv-00109-LPS, 446 in 1:13-cv-01987-LPS, 475 in 1:14-cv-00846-LPS) Joint Stipulation Regarding Trial Subpoenas to Dr. Duffy and Mr. Price. Signed by Judge Leonard P. Stark on 11/28/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl)
2016-11-28
1
No Actions
Official Transcript of Pretrial Conference held on November 23, 2016 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 12/20/2016. Redacted Transcript Deadline set for 12/30/2016. Release of Transcript Restriction set for 2/27/2017.(bpg) (Entered: 11/29/2016)
2016-11-29
1
REDACTED VERSION of (381 in 1:14-cv-00109-LPS) Opening Brief in Support, (438 in 1:13-cv-01987-LPS) Opening Brief in Support, (458 in 1:14-cv-00846-LPS) Opening Brief in Support Motion to Phase Trial by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Warden, Joseph) (Entered: 11/29/2016)
2016-11-29
1
REDACTED VERSION of (459 in 1:14-cv-00846-LPS, 382 in 1:14-cv-00109-LPS, 439 in 1:13-cv-01987-LPS) Declaration, of Joseph Warden in Support of Motion to Phase Trial by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Attachments: # 1 Exhibits 1-4)(Warden, Joseph) (Entered: 11/29/2016)
2016-11-29
1
Letter to The Honorable Leonard P. Stark from Martina Tyreus Hufnal regarding Statements About Infringement at Trial. (Hufnal, AnnaMartina) (Entered: 11/30/2016)
2016-11-30
1
[SEALED] Letter to The Honorable Leonard P. Stark from Martina Tyreus Hufnal regarding Unresolved Disputes Regarding Testimony and Related Documents. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 PX-677, # 6 PX-739, # 7 PX-878, # 8 PX-879, # 9 PX-880, # 10 PX-1280, # 11 PX-1482, # 12 PX-1555 Part 1, # 13 PX-1555 Part 2, # 14 PX-1555 Part 3, # 15 PX-1555 Part 4)(Hufnal, AnnaMartina) (Entered: 12/03/2016)
2016-12-03
1
MEMORANDUM ORDER re Schinazi deposition. Signed by Judge Leonard P. Stark on 12/4/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl)
2016-12-04
1
[SEALED] Letter to The Honorable Leonard P. Stark from Martina Tyreus Hufnal regarding Unresolved Dispute regarding the Deposition Testimony of Dr. Michael Otto. (Attachments: # 1 Exhibit A, # 2 Exhibit PX0498b - Part 1, # 3 Exhibit PX0498b - Part 2, # 4 Exhibit PX2116)(Hufnal, AnnaMartina) (Entered: 12/04/2016)
2016-12-04
1
[SEALED] Letter to The Honorable Leonard P. Stark from Martina Tyreus Hufnal regarding Unresolved Issues regarding Deposition Testimony of Dr. Lieven Stuyver. (Attachments: # 1 Exhibit A, # 2 Exhibit PX0470, # 3 Exhibit PX0647, # 4 Exhibit PX0764)(Hufnal, AnnaMartina) (Entered: 12/04/2016)
2016-12-04
1
[SEALED] Letter to The Honorable Leonard P. Stark from Joseph B. Warden regarding Unresolved Disputes Regarding Deposition Testimony of Peter Schaefer Price. (Attachments: # 1 Exhibit A, # 2 Exhibit PX1135b)(Warden, Joseph) (Entered: 12/04/2016)
2016-12-04
1
ORAL ORDER: For the reasons stated by the Court during the pretrial conference held on November 23, 2016 (see C.A. No. 14-846 D.I. 477 ("Tr.")), IT IS HEREBY ORDERED that: (i) Gilead's motion for a bifurcated trial (D.I. 457) is DENIED; (ii) Plaintiffs' motion to strike Gileads defenses based on Merck prior art (D.I. 416) is DENIED; (iii) Plaintiffs' motion for summary judgment with respect to Gilead's obviousness and anticipation defenses based on Merck prior art (D.I. 411) is DENIED; (iv) Gilead's motion for a protective order and to quash trial subpoena (D.I. 419) is DENIED AS MOOT (see Tr. at 128; D.I. 475); and (v) the parties' proposed pretrial order (D.I. 454) is ADOPTED, subject to the Court's various rulings and clarifications made during the pretrial conference and otherwise (see, e.g., Tr.; D.I. 480; D.I. 485; D.I. 486). ORDERED by Judge Leonard P. Stark on 12/5/16. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl) (Entered: 12/05/2016)
2016-12-05
1
ORAL ORDER: IT IS HEREBY ORDERED that this matter is STAYED pending the U.S. Court of Appeals for the Federal Circuit's decision in appeal no. 15-1802. (See C.A. No. 14-846, D.I. 520 at 2 (stating parties' joint request to stay C.A. Nos. 13-1987 and 14-109)). ORDERED by Judge Leonard P. Stark on 1/23/17. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS (ntl) (Entered: 01/23/2017)
2017-01-23
1
MOTION for Pro Hac Vice Appearance of Attorney David Gindler, Gary Frischling, Jason Sheasby, H. Annita Zhong, Christopher Abernethy and S. Adina Stohl - filed by Gilead Pharmasset LLC, Gilead Sciences Inc.. (Hufnal, AnnaMartina) (Entered: 01/27/2017)
2017-01-27
1
SO ORDERED, re (534 in 1:14-cv-00846-LPS, 402 in 1:14-cv-00109-LPS, 458 in 1:13-cv-01987-LPS) MOTION for Pro Hac Vice Appearance of Attorney David Gindler, Gary Frischling, Jason Sheasby, H. Annita Zhong, Christopher Abernethy and S. Adina Stohl filed by Gilead Sciences Inc., Gilead Pharmasset LLC. Signed by Judge Leonard P. Stark on 1/31/17. Associated Cases: 1:13-cv-01987-LPS, 1:14-cv-00109-LPS, 1:14-cv-00846-LPS (ntl)
2017-01-31
1
No Actions
Official Transcript of Jury Trial - Volume A held on December 5, 2016 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone No. (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 3/20/2017. Redacted Transcript Deadline set for 3/30/2017. Release of Transcript Restriction set for 5/30/2017. (bpg) (Entered: 02/27/2017)
2017-02-27
1
Official Transcript of Jury Trial - Volume B held on December 6, 2016 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone No. (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 3/20/2017. Redacted Transcript Deadline set for 3/30/2017. Release of Transcript Restriction set for 5/30/2017. (bpg) (Entered: 02/27/2017)
2017-02-27
1
Official Transcript of Jury Trial - Volume C held on December 7, 2016 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone No. (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 3/20/2017. Redacted Transcript Deadline set for 3/30/2017. Release of Transcript Restriction set for 5/30/2017. (bpg) (Entered: 02/27/2017)
2017-02-27
1
Official Transcript of Jury Trial - Volume C (Chambers Conference) held on December 7, 2016 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone No. (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 3/20/2017. Redacted Transcript Deadline set for 3/30/2017. Release of Transcript Restriction set for 5/30/2017. (bpg) (Entered: 02/27/2017)
2017-02-27
1
Official Transcript of Jury Trial - Volume D held on December 8, 2016 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone No. (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 3/20/2017. Redacted Transcript Deadline set for 3/30/2017. Release of Transcript Restriction set for 5/30/2017. (bpg) (Entered: 02/27/2017)
2017-02-27
1
Official Transcript of Jury Trial - Volume E held on December 9, 2016 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone No. (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 3/20/2017. Redacted Transcript Deadline set for 3/30/2017. Release of Transcript Restriction set for 5/30/2017. (bpg) (Entered: 02/27/2017)
2017-02-27
1
Official Transcript of Jury Trial - Volume F held on December 12, 2016 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone No. (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 3/20/2017. Redacted Transcript Deadline set for 3/30/2017. Release of Transcript Restriction set for 5/30/2017. (bpg) (Entered: 02/27/2017)
2017-02-27
1
[SEALED] Sealed Transcript of Jury Trial - Volume F held on December 12, 2016 before Chief Judge Leonard P. Stark. (bpg) (Entered: 02/27/2017)
2017-02-27
1
Official Transcript of Jury Trial - Volume G held on December 13, 2016 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone No. (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 3/20/2017. Redacted Transcript Deadline set for 3/30/2017. Release of Transcript Restriction set for 5/30/2017. (bpg) (Entered: 02/27/2017)
2017-02-27
1
[SEALED] Sealed Transcript of Jury Trial - Volume G held on December 13, 2016 before Chief Judge Leonard P. Stark. (bpg) (Entered: 02/27/2017)
2017-02-27
1
Official Transcript of Jury Trial - Volume H held on December 14, 2016 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone No. (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 3/20/2017. Redacted Transcript Deadline set for 3/30/2017. Release of Transcript Restriction set for 5/30/2017. (bpg) (Entered: 02/27/2017)
2017-02-27
1
Official Transcript of Jury Trial - Volume I held on December 15, 2016 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone No. (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 3/20/2017. Redacted Transcript Deadline set for 3/30/2017. Release of Transcript Restriction set for 5/30/2017. (bpg) (Entered: 02/27/2017)
2017-02-27
1
NOTICE of Change of Address by Andrew Colin Mayo (Mayo, Andrew) (Entered: 04/25/2017)
2017-04-25
1
NOTICE requesting Clerk to remove Thomas E. Friebel as co-counsel.. (Mayo, Andrew) (Entered: 12/20/2017)
2017-12-20
1
NOTICE of Withdrawal of Counsel by Gilead Pharmasset LLC, Gilead Sciences Inc. (McCann, Douglas) (Entered: 03/22/2018)
2018-03-22
1
NOTICE requesting Clerk to remove Michael S. Weinstein as co-counsel. Reason for request: no longer with firm. (Mayo, Andrew) (Entered: 06/04/2018)
2018-06-04
1
STIPULATION of Dismissal With Prejudice by Gilead Pharmasset LLC, Gilead Sciences Inc.. (McCann, Douglas) (Entered: 09/04/2018)
2018-09-04
1
SO ORDERED, re 475 Stipulation of Dismissal filed by Gilead Sciences Inc., Gilead Pharmasset LLC, ***Civil Case Terminated. Signed by Judge Leonard P. Stark on 9/6/18. (ntl)
2018-09-07
1
No Actions